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Introduction
4 Chapter 1. Introduction
Adequately utilized, data in the medical field can be an inexhaustible source of know-
ledge to fuel a learning health care system and help clinicians in making the right decision.
The design of data analysis methods in medical studies is changing fundamentally due to
the complexities generated in medical data, such as having too many variables or missing
data and more specifically, having repeated correlated measures in time. Therefore, the
need to develop new methods to address questions that can deal with these complexit-
ies is emerging. However, the issue with newly developed methods may be the lack of
fully-fledged validation of these techniques that does not enable us be certain about the
obtained results and to fully know how to extend the obtained results to future data.
Heart failure (HF) is recognised as a frequent disease in Western countries that causes
increasing public health problems and is the topic of many clinical studies. HF is the
main cause of hospital admission among elderly in developed countries [51, 83] and it is
very likely that prevalence will further increase in most countries [50, 72]. Regardless of
the main causes of hospitalization, these admissions impose enormous health care costs
related to relatively long hospital stays [81, 127]. Therefore, precisely diagnosing and
monitoring progression of disease in HF patients may have a major role in reducing dis-
ease burden and health care costs. Currently, diagnosing HF and monitoring patients are
mainly based on clinical signs and symptoms. However, management of patients based
on clinical signs and symptoms can be challenging as signs and symptoms of HF are not
specific [111]. Moreover, monitoring progression of the disease can be very challenging
and it is often impossible to select individuals who are most likely to need hospitalization,
or to progress to mortality, and thus who are in need of more intensive treatment. There-
fore, new tools are required to better monitor patients and to define the most effective
treatment. Biomarkers are promising in this regard, as ideally, they predict outcome quite
well. Moreover, some, e.g., Brain Natriuretic Peptide (BNP) and N-terminal pro-B-type
Natriuretic Peptide (NT-proBNP), have shown to be of diagnostic value in HF [37, 146].
Due to the fact that biomarkers reflect different aspect of disease and state of body, they
may not only have diagnostic and prognostic usages, but also therapeutic implications. In
order to move towards individualized therapy, implementing biomarkers to guide man-
agement of HF can help select patients in need of more intensive therapy and improve
therapeutic decision making. So far, however, only very few biomarkers are being used
in daily practice due to the lack of direct therapeutic consequences based on biomarker
measurement.
This thesis investigates the diagnostic and prognostic role of biomarkers and their us-
ages in establishing a guidance in medical HF therapy in individual HF patients. The
analyses are based on data feom the Trial of Intensified versus standard Medical therapy
in Elderly patients with Congestive Heart Failure (TIME-CHF) [19, 102] study, as it con-
tains multiple biomarker measurements over time together with detailed information on
medication, allowing one to investigate the interaction between biomarkers and treatment
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effects.
1.1 Conceptual Framework
1.1.1 Definition of Heart Failure
Heart failure (HF), sometimes referred to as Congestive Heart Failure (CHF), occurs when
the heart muscle does not pump sufficient blood to fulfill the requirements of the body
as well as it should. In a clinical definition, HF is a clinical syndrome with according
symptoms and signs, such as edema (accumulation of fluid causing swelling in the leg),
dyspnea (shortness of breath, excessive tiredness), fatigue, together with proof of an un-
derlying functional and/or structural hearth disease [84, 85].
Problems of HF increase with age [116] and is the most important reason for hospit-
alization in patients aged ≥ 65 years [83, 122]. HF has a high prevalence such that 1% to
2% of the population and up to 10% of the population aged ≥ 70 years suffer from CHF
[90, 110]. HF hospitalizations have a great impact on disease burden, particularly quality
of life, and on health care costs [81].
The diagnosis of HF is difficult, especially when relying on signs and symptoms only
[111, 85]. In addition to physical examinations, diagnostic tests support the diagnosis of
HF, e.g., chest X-ray laboratory tests, electrocardiography, and echocardiography. How-
ever, diagnosing HF remains difficult, especially in elderly patients. This is due to the fact
that in older age, HF patients usually have multiple comorbidities such as renal failure,
diabetes, pulmonary disorders, cancer, anemia, cerebrovascular and peripheral arterial
occlusive disease. In addition to comorbidities, in elderly patients various other factors
such as sedentary lifestyle may mitigate the signs of HF. Hence investigating the relation-
ship between other markers, e.g. biomarkers, and the severity and diagnosis of HF seems
necessary and helpful, especially in elderly patients.
1.1.2 Biomarkers in Heart Failure
Biomarkers usually refer to measurable circulating markers in the blood that may indicate
some biological processes in the body. Biomarkers are usually enzymes or proteins that
are in relationship with one or more pathophysiological pathways relevant in HF [5, 115,
120]. Evaluating the diagnostic and prognostic accuracy and effectiveness of biomarkers
in HF has been a topic of great interest in the last decades [58, 115, 137].
Assessing the relationship between biomarkers and disease not only can be of dia-
gnostic and prognostic value, but also may have therapeutic implications [4, 86]. Knowing
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about the prognostic implications of biomarkers might be interesting, but without having
therapeutic consequences, they may not be of clinical use.
Despite the large amount of research related to biomarkers, the use of biomarkers
in the treatment of HF is still very limited. Among the biomarkers investigated, BNP
and NT-proBNP are the only ones that currently are incorporated in the guidelines for
diagnosis of HF [133]. It has been shown that the circulating level of NT-proBNP is nor-
mally very low in healthy individuals and is increased in HF, and correlates well with
ventricular wall stress and severity of HF [58, 80]. Most of the medical HF therapies
significantly reduce NT-proBNP levels [37, 146]. Therefore, NT-proBNP has been also
suggested as a tool to tailor and intensify medical HF therapy. Several trials and meta-
analyses suggested that performing repeated measurements of NT-proBNP may help to
establish guideline recommended medical HF therapy in HF with reduced ejection frac-
tion (HFrEF) patients and to improve outcome [65, 96].
1.1.3 Heart Failure Medications
Monitoring progression of HF is not that a easy task since it is also mainly based on
interpreting the clinical symptoms and signs. Therefore it remains difficult to predict
and prevent HF events accurately and consequently it is very difficult or even sometimes
impossible to find the best drug therapy for individual HF patients.
In the past decades, medical therapy for HFrEF has evolved greatly [88]. Several med-
ication classes – e.g., Renin-Angiotensin System (RAS) blockers encompassing Angiotensin-
Converting-Enzyme (ACE)-inhibitors and Angiotensin-Receptor Blockers (ARBs), β-
blockers and Mineralocorticoid Receptor Antagonists (MRAs) – have proven to improve
prognosis in HFrEF and therefore are recommended in high doses by current guidelines
[145]. In addition, (loop) diuretics are recommended for decongestion to relieve symp-
toms [145]. However, in clinical practice, it is often difficult to implement all medication
classes and to reach guideline recommended dosage, especially in elderly and comorbid
patients [78]. In such cases, it would be crucial to know which drug is most important
to be given in high doses to improve prognosis, and which may be less important. At
present, it is largely impossible to make this decision for an individual patient.
1.2 Objectives of the thesis
This thesis has two main objectives: a medical objective and a methodological objective.
The medical objective of this thesis is to investigate biomarkers in the TIME-CHF
study as markers to monitor progression of HF and to guide HF drug therapy. The meth-
odological objective of the thesis is to develop new methods with the aim to facilitate
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investigation of biomarkers, or other variables, and to develop criteria backing the results
covering the medical objective of the thesis.
We deal with these main objectives by studying the following research questions:
Research Question 1: Does NT-proBNP guided therapy reduce repeated HF hospitaliz-
ations?
HF therapy guided by NT-proBNP may be superior to standard therapy in patients
with chronic HF as shown in various meta-analyses [36, 104, 121]. However, the obtained
results from different individual trials were not uniform [69, 102, 133]. This is most likely
because of limited power of these trials due to a relatively small sample size.
The TIME-CHF study is the largest trial evaluating NT-proBNP-guided therapy so
far in the HF domain. The results have shown that there was no significant effect on the
primary endpoint hospital-free survival, while the disease specific endpoint HF hospital-
free survival was significantly improved [102, 118].
Despite the fact that repeated hospitalizations (both related to HF and other causes
[29, 51]) are very common in HF patients, most intervention trials for treatment of HF
have only evaluated the effect on time-to-first event (hospitalization or death). Since hos-
pitalizations are common (and a very costly problem) [81, 127], it may be clinically more
relevant to see whether any new HF therapy prevents hospitalizations beyond the first
event [17, 113].
Research Question 2: What is the best cutpoint for dichotomization of continuous vari-
ables?
Dichotomizing a continuous variable is a common part of many diagnostic and pro-
gnostic analyses, such as biomarker studies, and is widely used in clinical research. Di-
chotomization of a covariate makes it easier for clinicians to interpret the covariate’s effect
on the outcome variable and guides them in their choice of therapy. By using dichotom-
ized covariates we may have a simpler interpretation of common effect measures from
statistical models such as odds ratios and hazard ratios. They can also help to avoid er-
rors of wrong functionality form assumptions for covariates in regression models, and to
make data summarization more efficient. Therefore, selecting or estimating a cutpoint for
a covariate might be worthwhile in many directions.
Research Question 3: How to measure the goodness-of-fit and the predictive perform-
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ance of a logistic-GEE model?
In many clinical trials such as TIME-CHF, observations for individual patients are of-
ten repeated over time (longitudinal data). The difficulty with any investigation in such a
trial lies within the fact that the outcomes for a single patient, which could be the quality
of life of a patient or the risk of hospitalization at several points of time, are likely to be
correlated. Moreover, repeated measures of biomarkers, medication and other covariates
are typically correlated as well. Therefore, the correlation between outcomes and vari-
ation of covariates in time needs to be taken into account for proper analysis.
Among the methods dealing with correlated observations, logistic Generalized Estim-
ating Equations (logistic-GEE) has become the most popular regression model for analyz-
ing longitudinal data with binary outcomes [47, 73]. However, assessing the goodness-of-
fit and predictive performance of logistic-GEE models is problematic, due to the fact that
the outcomes are correlated within a patient and no likelihood is available. So far, several
criteria and tests have been proposed for assessing the goodness-of-fit of logistic-GEE
models in the literature (see e.g, [31, 32, 107]). However, most of them have shortcom-
ings, making it impossible to have a commonly applicable and accepted criterion or test.
Moreover, to the best of our knowledge there is no criterion reflecting the predictive per-
formance of logistic-GEE models. Therefore, in order to have a better interpretation of
the obtained results, using a logistic-GEE model and its extension to a future data set,
we need a measure that can reflect both goodness-of-fit and predictive performance of the
model.
Research Question 4: Can biomarkers predict treatment effects of medication in patients
with systolic HF?
Repeated measurements of NT-proBNP, as was suggested in several studies, may help
to establish medical therapy as considered by the guidelines in HFrEF patients [65, 96].
However, guiding HF therapy by a single marker is a limited approach because one bio-
marker cannot cover the complex pathophysiological pathways that play a role in HF. In
fact, the NT-proBNP approach is based on the idea that patients at highest risk of poor
outcome are in need of intensified therapy. However, there is no specific tailoring of in-
dividual therapy. In addition, despite a general beneficial effect of HF drugs, not every
drug may have the same benefit in a specific patient, or for a patient subgroup. Further-
more, different medication classes in HF interfere with different pathways. Therefore, a
combination of biomarkers that reflect these pathways may be better to indicate which
medication class is most important to up-titrate or possibly also to down-titrate in a spe-
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cific patient, aiming towards precision medicine in HF. Unfortunately at present, it is still
impossible to make this decision for an individual patient.
1.3 Structure of the Thesis
These four research questions have shaped the structure of this thesis. Chapter 2 provides
the reader with general background information on the TIME-CHF study and the meth-
ods used to address the research questions. In order to address research question 1, in
Chapter 3, we have employed the gap-time method (proposed by Prentice, Williams
and Peterson [10, 106]) to investigate the effect of NT-proBNP-guided therapy on the
recurrence of all-cause hospitalization events (all-cause hospitalization or death) and HF
hospitalization events (HF hospitalization or death) in TIME-CHF. We do this not only
for all patients, but also for different age groups. In Chapter 4, we deal with research
question 2. To this end we propose a Bayesian approach for dichotomizing continuous
covariates when using a regression model. This method can be used both in univariate
and in multivariate settings. We have also applied the proposed Bayesian approach to
estimate the cutpoint for some covariates in TIME-CHF. In Chapter 5, we address re-
search question 3 and propose a new measure for evaluating the quality of logistic-GEE
models, namely Generalized Ranking Accuracy (GRA). GRA can be used for assessing
the goodness-of-fit and the predictive performance of logistic-GEE models depending on
the type of assessment method (e.g. cross-validation). In this chapter we also compare the
GRA with some other existing criteria and assess the performance of GRA in a simulation
study. In Chapter 6, we deal with research question 4 and explore the hypothesis that bio-
markers may be able to predict response to therapy in HF in TIME-CHF. We investigate
the interaction between multiple repeatedly measured biomarkers, and the response to the
four most important classes of HF medication regarding the risk of HF hospitalization or
death. To this end we employ logistic-GEE models and implement the GRA to evaluate
these models and to assess the reliability of the obtained results. Finally, in Chapter 7,
we conclude the thesis by answering the research questions and providing an outlook on
possible directions for future research.

2
Background
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This chapter provides general background information about the Trial of Intensified
versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-
CHF). It also discusses the methods we used to address research questions 1-4. In Section
2.1 we introduce the TIME-CHF study and give information about the characteristics
of the patients, available biomarkers, and medications. In Section 2.2 we present the
Prentice, Williams and Peterson Gap-Time (PWP-GT) model as a method for analysing
repeated events which helps us to deal with research question 1, in Chapter 3. In Section
2.3 we give general information about Bayesian Inference that we use to address research
question 2, in Chapter 4. In Section 2.4 we briefly explain and formalize the bipartite
ranking task for clustered data and the logistic Generalized Estimation Equations (GEE)
model. The latter we use when dealing with research questions 3 and 4, in Chapters 5 and
6, respectively.
2.1 The TIME-CHF Study
The TIME-CHF study was a multicenter trial that involved 15 centers in Switzerland
and Germany [19, 102]. The study included 622 patients aged 60 years or older with
symptomatic Heart Failure (HF), HF hospitalization within the last year, and a N-terminal
pro-B-type Natriuretic Peptide (NT-proBNP) level of 400 pg/mL or higher in patients
younger than 75 years and a level of 800 pg/mL or higher in patients aged 75 years or
older. Patients were randomized to two treatment groups: standard (symptom-guided)
therapy or intensified (NT-proBNP-guided) therapy during the 18 months of the trial.
Both treatment groups were stratified into two age groups of 60 to 74 and 75 years or
older. In this single-blind trial, patients in contrast with treating physicians were blinded
to treatment group allocation.
According to the protocol used, after the baseline assessment, the patients were treated
and followed up for 18 months in pre-specified visits after 1, 3, 6, 12, and 18 months, with
further follow-up up to 5.5 years. For each patient, every hospitalization together with its
cause and eventual mortality were recorded. The median of the overall survival time (time
until death) was 3.96 (range from 0.01 to 5.5) years and 60.3% of patients were alive after
5.5 years follow-up.
Within 5.5 years follow-up, 132 patients (61 NT-proBNP-guided, 71 symptom-guided)
experienced one and 345 patients (167 NT-proBNP-guided, 178 symptom-guided) two or
more all-cause hospitalization events (all-cause hospitalization or death). Regarding HF
hospitalization events (HF hospitalization or death), 166 patients (78 NT-proBNP-guided,
88 symptom-guided) experienced one event and 151 patients (68 NT-proBNP-guided, 83
symptom-guided) two or more events. The median number of all-cause hospitalization
events and HF hospitalization events were 2 and 1, respectively.
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Three main types of covariates were measured per patient in the TIME-CHF study:
Patient characteristics: Table 2.1 presents the baseline characteristics of patients we
used in this thesis, per treatment group as mean ± standard deviation for continuous vari-
ables or as numbers and percentages for binary variables.
Biomarkers: Blood samples were drawn at every visit; samples were stored at -80
degrees Celsius until analysis. At the end of the trial, twenty biomarkers were meas-
ured from these stored samples of all available visits. The selection of biomarkers was
based on the representation of different pathways that are known to reflect important
pathophysiological pathways [120]. The following biomarkers were measured: Sol-
uble FMS-Like Tyrosine kinase-1 (SFLT), Growth Differentiation Factor 15 (GDF15),
CYStatin-C (CYSC), Ferritin, Interleukin-6 (IL6), Placental Like Growth Factor (PLGF),
Sex Hormone-Binding Globulin (SHBG), Soluble TransFerrin Receptor (STFR), High
Sensitivity Troponin T (HSTNT), Type-1 Procollagen N-terminal Peptide (TP1NP), Uric
acid (Uric), Blood Urea Nitrogen (BUN), Soluble ST2 (SST2), N-terminal pro-B-type
Natriuretic Peptide (NT-proBNP), Creatinine, High Sensitivity C-Reactive Protein (HSCRP),
Prealbumin (PREA), Osteopontin (OPN), Mimican, and Insulin-like Growth Factor-Binding
Protein 7 (IGFBP7). The assays used to measure these markers are summarized in Table
2.2.
HF medications: The medication doses for the four most important HF drug classes: β-
blockers, Renin-Angiotensin System (RAS) blockers, Spironolactone and Loop diuretics
were available on a daily basis. Doses of β-blockers and RAS blockers are expressed
as the percentage of the target dose as reported in [87] (e.g. 5mg of Ramipril per day
is 50% of the target dose of 10mg/day). For combinations of Angiotensin-Converting-
Enzyme (ACE)-inhibition and Angiotensin-Receptor Blockers (ARB), the relative doses
were added and expressed as a combined dose. Spironolactone is given in mg as it was the
only Mineralocorticoid Receptor Antagonist (MRA) used in TIME-CHF. Loop diuretics
are expressed as the equivalent dose of furosemide (i.e. 40mg of furosemide = 10mg of
torasemide = 1mg of bumetanide).
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Patient characteristics Symptom-guided NT-proBNP-guided P-value
(n = 312) (n = 310)
Age (years) 77.3±7.7 76.6±7.4 0.247
Male sex (%) 177 (56.7) 192 (61.9) 0.951
Ischemic HF etiology (%) 171 (54.8) 159 (51.3) 0.379
Charlson Score 3.1 ± 1.7 3.2 ± 1.7 0.638
Kidney disease (%) 175 (56.1) 180 (58.1) 0.619
Diabetes (%) 121 (38.8) 101 (32.6) 0.107
Hypertension (%) 236 (75.6) 226 (72.9) 0.435
Stroke (%) 29 (9.3) 23 (7.4) 0.398
Cancer (%) 43 (13.8) 43 (13.9) 0.974
Anemia (%) 85 (27.2) 90 (29) 0.620
NYHA>II (%) 238 (76.3) 235 (75.8) 0.889
Rales (%) 146 (46.8) 134 (43.5) 0.411
Angina (%) 62 (20.1) 64 (20.8) 0.842
COPD (%) 57 (18.3) 67 (26.1) 0.297
LVEF (%) 35.1±13.2 34.8±12.7 0.785
Heart rate 76±14.4 75.1±13.9 0.359
Body mass index (kg/m2) 25.5±4.7 25.7±4.1 0.959
Systolic blood pressure (mmHg) 122.3±21 121.5± 19.4 0.781
Hemoglobin (g/l) 129.6±18 131.4±18.2 0.165
Potassium (mmol/l) 4.1±0.49 4.1±0.55 0.986
Table 2.1: Patient characteristics at the baseline visit in the TIME-CHF study. The vari-
ables are given for the Symptom-guided therapy and the NT-proBNP-guided therapy
groups. P-value indicates the difference for variables with respect to patients from the
Symptom-guided and the NT-proBNP-guided groups (the Mann-Whitney U-test for con-
tinuous variables and the χ2 test for binary variables).
NYHA: New York Heart Association functional classification; LVEF: Left Ventricular
Ejection Fraction; COPD: Chronic Obstructive Pulmonary Disease.
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2.2 Modelling Repeated Events
In many medical studies, an event of interest may occur twice or more often for the same
patient during the follow up period. However, most of the survival analysis methods
investigate only the first time-to-event and ignore repeated events [17, 113]. Examples
of repeated events data in heart disease clinical trials include: repeated hospitalisations
in HF patients, recurrent heart attacks of coronary patients, or relapses of cardiovascular
diseases.
Repeated events are likely to be correlated because they belong to the same patient.
For example a patient with an HF hospitalization is more prone to experience another
HF hospitalization or die. Hence, to correctly analyze repeated events, the correlated
nature of the data needs to be taken into account. Several models have been proposed for
analysing repeated events [10, 28, 54, 63, 106]. The most commonly used methods so
far analyze time to repeated events (either time from the start of a study to each event,
or time between repeated events) or simply the number of repeated events. Amongst the
latter such approaches, both Poisson and negative binomial regression are commonly used
for modelling the number of events [43, 55, 114]. However, the methods which take time
between repeated events into account, use different models.
The survival based model of Andersen-Gill (AG) [11] is an approach for analyzing re-
peated events. The AG model, as a generalization of the Cox proportional hazards model,
is formulated in terms of Gap-Times (times between successive events) for the same sub-
ject. The use of a robust variance estimator is recommended with the AG model to adjust
for the correlation among outcomes of the same subject [74]. However, a shortcoming of
the AG model is that it cannot take into account the order of events.
A more appropriate model to analyze repeated events is the Prentice, Williams and
Peterson model [10, 106] based on the Gap-Times (PWP-GT model). The PWP-GT
model is not only able to take into account the dependence of events within a subject,
but also the order of events. Below we explain how the PWP-GT model works.
Let N(t) be the number of events a subject has experienced by time t and X(t) the
vector of covariates of the subject at time t. For a subject with S events, let ts be the
sth recurrence time, s = 1, . . . , S, let t0 = 0 and let tS+1 be the time of censoring.
The censoring may occur because a subject has not experienced the event before the end
of the study or has withdrawn from the study. For a subject the sth gap-time and the
corresponding covariate vector at time ts are assigned to the stratum s. A subject moves
to stratum (s + 1) immediately after his sth recurrence time and remains there until the
(s + 1)st recurrence occurs or until censor time. We note that PWP-GT does not use the
information in stratum S +1, since there is no event in this stratum. The PWP-GT model
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is a stratified Cox-type model of the form:
λ(t|N(t), X(t)) = λ0s(t− ts−1) eβ
′
sX(t), ts−1 ≤ t < ts, s = 1, . . . , S, (2.1)
where λ0s ≥ 0 is an arbitrary baseline hazard function (depending on the Gap-Times
distribution), and βs is a vector of stratum-specific regression coefficients.
To illustrate the data layout for applying PWP-GT models, suppose subject i experi-
ences the sth event at time tsi. Then the gap-time usi = tsi − ts−1,i is the time duration
between the (s− 1)st and sth events for the subject in stratum s. Assume that there are n
subjects with at most S observed events, then the data layout is as illustrated in Table 2.3.
Note that in Table 2.3 the order of subject is regardless of the number of events.
Subject ID Start-Time Stop-Time Gap-Time Stratum Status∗
1 0 t11 u11 1 1
1 t11 t21 u21 2 1
1 t21 t31 u31 3 0
2 0 t12 u12 1 1
2 t12 t22 u22 2 0
...
...
...
...
...
...
k 0 t1k u1k 1 1
k t1k t2k u2k 2 1
...
...
...
...
...
k tS−1,k tSk uSk S 1
k tSk tS+1,k uS+1,k S + 1 0
...
...
...
...
...
n 0 t1n u1n 1 1
n t1n t2n u2n 2 0
Table 2.3: Layout of dataset for applying PWP-GT models. ∗Event status in the given
stratum (1=event and 0=censoring).
Now consider the estimation of stratum-specific regression coefficients βs in model
(2.1). To achieve this we should obtain the partial likelihood of the regression coefficients.
To indicate the order of gap-times in a stratum, we define the notation u(sj) as the jth
smallest gap-time in stratum s. For example, suppose that four gap-times are recorded
in stratum s, e.g., us1 = 5, us2 = 8 us3 = 6 us4 = 2. The ordered gap-times will be
denoted by u(s1) = 2, u(s2) = 5, u(s3) = 6 and u(s4) = 8.
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Let u(s1) < · · · < u(sks) denote the ordered gap-times for the ks events occurring
in stratum s, u(s0) = 0 and u(s,ks+1) = ∞, such that the subject with the jth ordered
gap-time u(sj) experiences the event at time tsj and the Xsj(tsj) be the corresponding
vector of covariates, j = 1, . . . , ks. Let R(u, s) be the set of subjects at risk in stratum
s at gap-time u ∈ [u(s,i−1), u(si)), i = 1, . . . , ks + 1. Under the above assumptions, the
partial likelihood L(β) can be written as:
L(β) =
∏
s≥1
ks∏
j=1
exp{βsXsj(tsj)}∑
l∈R(u(sj),s)
exp{βsXl(ts−1,l + u(sj))} , (2.2)
where, β = (β1, . . . ,βS)′, Xl(t) is the vector of covariates for the lth subject at time t.
We note that in PWP-GT modeling one may apply robust sandwich variance estimators
[74, 147] to estimate the variances of the estimated regression coefficients when we have
correlated observations from the same patient.
2.3 Bayesian Inference
Statistical inference is a collection of procedures with the aim of extracting information
from available data [20]. The Bayesian approach is an approach of statistical inference
which combines prior information about unknown parameters with the observations at
hand to reach updated (posterior) conclusions about the parameters [71].
Let Y = (Y1, . . . , Yn) be samples of n i.i.d. outcomes (discrete or continuous)
such that fY |Θ(yi|θ) presents a probability function or a density function of Yi given
a vector of continuous parameters θ ∈ Dθ, i = 1, . . . , n. Then the likelihood func-
tion of θ, L(θ|y), is defined as the joint distribution of Y1, . . . , Yn, given by L(θ|y) =
fY |Θ(y|θ) =
n∏
i=1
fY |Θ(yi|θ).
Assume that pi(θ) is the prior distribution function for θ, which presents the inform-
ation about parameter θ irrespective of any data that might become available. Then the
distribution fY,Θ(y,θ) can be split up into fY,Θ(y,θ) = fY |Θ(y|θ)pi(θ). Following
Bayes’ rule [71] the posterior distribution function for θ is given by:
pi(θ|y) = L(θ|y)pi(θ)
fY (y)
(2.3)
=
L(θ|y)pi(θ)∫
Dθ
L(θ|y)pi(θ)dθ .
Expression (2.3) shows that the posterior distribution of θ, given the data y, is propor-
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tional to the product of the likelihood function of θ with its prior distribution, i.e.
pi(θ|y) ∝ L(θ|y)pi(θ), (2.4)
since the denominator depends only on the observed data y which is assumed to be fixed
in the Bayesian context.
2.3.1 Bayes Estimator
Suppose Y = (Y1, . . . , Yn) are n i.i.d. samples from distribution fY |Θ(y|θ). Let pi(θ)
be the prior distribution and θˆ an estimator of θ and define D(θ, θˆ) as a loss function.
Then the Bayes estimator is defined as the estimator that minimizes the expected loss
E(D(θ, θˆ)|y) over the posterior distribution pi(θ|y), among all estimators [20].
Theorem 2.1: The Bayes estimator of θ under the squared error loss function, i.e.,
D(θ, θˆ) = (θ − θˆ)2, is the mean of the posterior distribution [20]:
θˆ = E(θ|y) =
∫
Dθ
θpi(θ|y)dθ. (2.5)
2.3.2 Posterior Equal Tail Credible Interval
Having the posterior distribution pi(θ|y), for a scalar parameter θ, let us denote the pos-
terior cumulative distribution function as F (θ). Then [a, b] is defined as a 100(1 − α)%
credible interval for θ when
Pr(a < θ ≤ b|y) = 1− α = F (b)− F (a). (2.6)
In this case, the 100(1−α)% equal tail credible interval can be obtained by calculating
a and b such that: Pr(θ ≤ a|y) ≡ F (a) = α/2 and Pr(θ ≥ b|y) ≡ 1− F (b) = α/2.
2.3.3 Markov Chain Monte Carlo Methods
When performing Bayesian inference to obtain the Bayes estimates or any properties
of posterior distributions we need to calculate integrals as in (2.5). Unfortunately, this
often requires calculating analytically intractable integrals (not expressible in elementary
functions). In such cases, instead of solving the analytical equations, we may use classical
numerical integration methods, but we may also resort to using sampling techniques based
upon Markov Chain Monte Carlo (MCMC) methods [40].
Monte Carlo integration can be used to approximate properties of posterior distribu-
tions required for a Bayesian analysis. For an arbitrary function of θ, h(θ), consider the
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integral: ∫
Dθ
h(θ)pi(θ|y)dθ. (2.7)
If we generate a large number θ(1), . . . ,θ(n) of random values from the posterior
distribution pi(θ|y), then:∫
Dθ
h(θ)pi(θ|y)dθ = E(h(θ)|y) ' 1
n
n∑
i=1
h(θ(i)). (2.8)
By choosing n sufficiently large, the right hand side value in (2.8) is known to con-
verge to that of the integral on the left hand side one aims to compute; the variance of the
estimate on the right hand side can also be tracked to obtain information on the accuracy
of this approximation. This is referred to as Monte Carlo integration [40].
Often the posterior distribution for θ has no known probability distribution form to
easily generate the samples. It may also happen that we even cannot obtain the posterior
distribution in a fully closed form and we may only know that it is proportional to the
product of the likelihood function and the prior distribution as in (2.4). Therefore, one
problem with Monte Carlo integration is in obtaining samples θ(1), . . . ,θ(n) from pi(θ|y)
to approximate the integral in (2.8). This problem can be solved using MCMC methods,
which are methods for sampling from probability distributions using Markov chains. A
Markov chain is a sequence of samples that transitions from one sample to another in
a probabilistic fashion such that the next sample only depends on the current sample.
By taking enough steps, the distribution underlying a Markov chain converges to the
stationary distribution and the samples can be used as samples of the desired distribution.
In this chapter, we introduce Metropolis-Hastings (M-H) [23] and the Gibbs sampling
method [38] as two widely used MCMC methods in the literature.
The Metropolis-Hastings Algorithm
Suppose our goal is to draw samples from some posterior distribution pi(θ|y) such that
pi(θ|y) ∝ L(θ|y)pi(θ). Define p(θ) = L(θ|y)pi(θ), then the Metropolis-Hastings (M-H)
algorithm generates n samples from pi(θ|y), through the following steps [23]:
1. Take any initial θ(0) value, satisfying p(θ(0)) > 0, and set t = 1.
2. Sample a candidate point θ∗ from an arbitrary distribution q(θ∗|θ(t−1)), which is
known as the proposal distribution, such that θ∗ has the same domain as θ.
3. Set α equal to min
(
p(θ∗)q(θ(t−1)|θ∗)
p(θ(t−1))q(θ∗|θ(t−1)) , 1
)
.
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4. Generate u from a uniform ditribution U(0, 1).
5. If α > u then (the candidate is accepted)
set θ(t) = θ∗.
else (the candidate is rejected)
set θ(t) = θ(t−1).
6. If t < n then
set t = t+ 1 and go to step 2.
else
stop.
The above M-H algorithm generates a Markov chain (θ(0), θ(1), . . . , θ(n)). Usually
it is necessary to throw away sufficient initial samples, say k, as a burn-in period that the
chain approaches to the stationary state. Then samples from the vector (θ(k), θ(k+1), . . . , θ(n))
are used as samples from pi(θ|y).
The advantage of the M-H algorithm is that by using a proposal distribution we can
indirectly sample from the desired distribution when it is too complex to directly sample
from. The disadvantage, of course, is that the M-H algorithm as an accept-reject algorithm
is computationally expensive when we need to sample multiple parameters.
Gibbs Sampling Method
For the benefit of the reader, and to give a basic understanding of Gibbs sampling, we shall
first consider it in a two dimensional set up. Gibbs sampling, in a two-dimensional set up,
provides a method to generate samples from the joint posterior distribution pi(θ1, θ2|y)
when direct sampling is difficult. The generated samples can be used to approxim-
ate the joint posterior distribution or the marginal posterior distributions pi(θ1|y) and
pi(θ2|y) [38]. This approach is based on the property that the joint posterior distribution
pi(θ1, θ2|y) can be uniquely determined from pi(θ1|θ2,y) and pi(θ2|θ1,y). The Gibbs
sampling starts by taking initial values for the parameters, say θ(0)1 and θ
(0)
2 in the range
of θ1 and θ2, respectively. Then it generates θ
(t)
1 and θ
(t)
2 (t = 1, 2, 3, . . .) in a sequential
manner such that for the given θ(t)1 and θ
(t)
2 at iteration t, the (t + 1)
st values for the
parameters are generated through the following iterative scheme:
• Sample θ(t+1)1 from pi(θ1|θ(t)2 ,y)
• Sample θ(t+1)2 from pi(θ2|θ(t+1)1 ,y)
We note that Gibbs sampling method is a special case of M-H sampling in which the
candidate value is always accepted (i.e. α = 1) [23].
22 Chapter 2. Background
Gibbs sampling with n iterations generates a sequence of values θ(1)1 , θ
(1)
2 , θ
(2)
1 , θ
(2)
2
, . . . , θ
(n)
1 , θ
(n)
2 . After a sufficient burn-in period the samples can be used to approximate
properties of the posterior distributions pi(θ1, θ2|y), pi(θ1|y) and pi(θ2|y).
Assuming a multivariate posterior distribution pi(θ|y), θ = (θ1, . . . , θp), Gibbs sampling
works according to the following iterative scheme. Given the initial value θ(0) = (θ(0)1 , . . . , θ
(0)
p ),
at iteration (t+ 1) the sampling procedure performs the following p steps:
• Sample θ(t+1)1 from pi(θ1|θ(t)2 , . . . , θ(t)p , y)
• Sample θ(t+1)2 from pi(θ2|θ(t+1)1 , θ(t)3 , . . . , θ(t)p , y)
...
• Sample θ(t+1)p from pi(θp|θ(t+1)1 , . . . , θ(t+1)p−1 ,y)
Gibbs sampling is easy to implement for multivariate distributions and does not de-
pend much on the initial values. Moreover there is no need to tune any proposal distri-
bution. However, the disadvantage of Gibbs sampling method is that we must be able to
derive the conditional distributions. Also, the conditional distributions should be relat-
ively easy to sample from.
2.4 Logistic-GEE Models
Clustered data are very common in biomedical, clinical, and social sciences research
[6, 68, 131]. Clustered data are defined as data with a clustered or grouped structure.
A cluster (group) can consist of variable measurements of related subjects or repeated
variable measurements for a single subject such that in either case the measurements may
correlate. For example, in the social sciences, members of the same household form a
cluster, since they are more likely to give rise to similar measurements than nonmembers.
In clinical trials, it is often the case that the observations for each subject are repeated
over time (longitudinal data). Since these observations are likely to be correlated, they
naturally form a cluster. In order to correctly analyze clustered data, the correlation within
clusters needs to be taken into account. However, this correlation may often be unknown
and there may be insufficient data to estimate such correlations accurately for each group.
In this thesis we study clustered data when the outcome variables are binary. A usual
model for analyzing data with binary outcomes is logistic regression. However, due to
the correlation between the observations (within clusters), such models cannot be directly
used to analyze clustered data. Therefore, Liang and Zeger in [73, 147] introduced Gen-
eralized Estimating Equations (GEEs), as an extension of the quasi-likelihood approach
[141] to estimate the parameters of a logistic regression model with a possible unknown
correlation between the outcomes or covariates. When we use GEEs to estimate the model
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parameters of a logistic regression model applied to clustered data, this is known as a
logistic-GEE model. Logistic-GEE models the relationship between the covariates and
the probability of a positive outcome (outcome = 1) on the population level, while there
are unknown correlations between outcomes within a cluster.
2.4.1 Bipartite Ranking and Logistic-GEE Models
The bipartite ranking task assumes that we have n subjects. The ith subject is represented
by a cluster ofmi observations such that the tth observation, t = 1, . . . ,mi is given with p
covariatesXit1, . . . , Xitp inR and a binary outcome variable Yit. Hence, the ith cluster is
identified by 〈Xi,Yi〉, whereXi = (Xi1, . . . ,Ximi)′ in whichXit = (Xit1, . . . , Xitp)′
is a p× 1 vector of covariates for observation t for subject i and Yi = (Yi1, . . . , Yimi)′ is
an mi × 1 vector of binary outcomes. For different clusters, i and j, we assume that the
correlation between Yi and Yj equals zero but correlation between Yis and Yik may be
nonzero, s 6= k, and the covariates may be either fixed or changing at every cluster level.
Given n clusters 〈Xi,Yi〉, i = 1, . . . , n, the task of bipartite ranking is to find an
ordering on the instances such that positive instances (outcome=1) are ranked higher than
negative ones (outcome=0). To solve the task we try to find a real-valued ranking function
that maps any covariate Xit, i = 1, . . . , n, t = 1, . . . ,mi, to a real number. The number
has to be high if covariate Xit has a positive outcome (Yit = 1); otherwise, it has to
be low. The ranking function can be used to induce an ordering over the covariates Xit,
i = 1, . . . , n, t = 1, . . . ,mi, to reflect their relationship with respect to positive outcome.
Logistic-GEE models solve the bipartite ranking task, since they essentially provide a
ranking function for clustered data. A logistic-GEE model explains the outcome variable
Yit, i = 1, . . . , n, t = 1, . . . ,mi, from the covariate Xit using a ranking function of the
form:
log
(
piit
1− piit
)
= β0 + βXit , i = 1, . . . , n, t = 1, . . . ,mi, (2.9)
where, piit = E(Yit|xit) = Pr(Yit = 1|xit) for t = 1, . . . ,mi, β0 is the population
averaged intercept term and β = (β1, . . . , βp) is the vector of population averaged coef-
ficients.
The logistic-GEE model can be obtained by estimating the unknown regression coeffi-
cient vector γ = (β0,β). Estimating the coefficients can be done by solving the following
generalized estimating equations [73]:
n∑
i=1
(
∂pii
∂γ
)′
Wi
−1(yi − pii) = 0, (2.10)
where pii = (pii1, . . . , piimi)
′ for i = 1, . . . , n, Wi = Ai1/2Ri(α)Ai1/2 is the working
covariance matrix for Yi and Ai is a diagonal matrix, diag[var(Yi1), . . . , var(Yimi)],
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such that var(Yimi), the variance of Yimi , equals to piimi(1−piimi). Ri(α) is themi×mi
working correlation matrix for Yi, where α may be an arbitrary h × 1 vector of some
unknown parameters involved in the working correlation structure.
We note that the working correlation matrix Ri(α) can be chosen in different ways
depending on the nature of the correlation between outcomes Yis and Yik, s 6= k, [21, 57].
For instance, assuming a cluster of size 4, the correlations between the outcomes of the
cluster may have the following structures:
• Exchangeable: if the observations from a subject have no time dependence. In this
case one may hypothesize that the outcomes within a cluster have a single common
correlation, that is, α is a scalar, such that:
Corr(Yis, Yik) =
{
1 if s = k
α if s 6= k,
which results in a correlation matrix of the form:
Ri(α) =

1 α α α
α 1 α α
α α 1 α
α α α 1

• Autoregressive (order one): if we assume a time dependence for the observations
from a subject. In this case the correlation structure may the assumed to beCorr(Yis, Yik) =
α|s−k|. This results in a correlation matrix of the form:
Ri(α) =

1 α α2 α3
α 1 α α2
α2 α 1 α
α3 α2 α 1

Note that one may also adopt an Autoregressive correlation structure with a higher
order. For more examples of correlation structures and their motivations, see [48]. We
note that an attractive property of a logistic-GEE model is that the resulting estimation of
regression coefficients of the model is consistent and asymptotically normal even when
the correlation structure within the clusters is imprecisely specified [73].
3
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ABSTRACT
Background: Although heart failure (HF) patients are known to experience repeated
hospitalizations, most studies only evaluated time-to-first event. N-terminal pro-B-type
Natriuretic Peptide (NT-proBNP)-guided therapy may improve HF-specific outcome, but
effects on recurrence of all-cause hospitalization are uncertain. Therefore, we investigated
the effect of NT-proBNP-guided therapy on repeated events in HF, using a time-between-
events approach in a hypothesis generating analysis.
Methods and Results: TIME-CHF randomized 499 HF patients, aged≥60 years, LVEF≤
45%, NYHA≥II to NT-proBNP-guided versus a symptom-guided therapy for 18 months,
with further follow-up for 5.5 years. The effect of NT-proBNP-guided therapy on re-
peated HF-related and all-cause hospitalizations and all-cause death was explored. One
hundred four patients (49 NT-proBNP-guided, 55 symptom-guided) experienced one and
275 patients (133 NT-proBNP-guided, 142 symptom-guided) two or more all-cause hos-
pitalization events. Regarding HF hospitalization events, 132 patients (57 NT-proBNP-
guided, 75 symptom-guided) experienced one and 122 patients (57 NT-proBNP-guided,
65 symptom-guided) two or more events. NT-proBNP-guided therapy was significant in
preventing second all-cause hospitalizations (Hazard Ratio (HR)=0.83, P=0.01) in con-
trast to non-significant results in preventing first all-cause hospitalization events (HR=0.91,
P=0.35). This was not the case regarding HF hospitalization events (HR= 0.85, P=0.14
vs. HR =0.73, P= 0.01). The beneficial effect of NT-proBNP-guided therapy was only
seen in patients aged <75 years, but not in those aged ≥75.
Conclusion: NT-proBNP-guided therapy reduces the risk of recurrent events in patients
aged <75 years. This included all-cause hospitalization by mainly reducing later events,
adding knowledge to the neutral effect on this endpoint when shown using time-to-first
event analysis only.
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3.1 Introduction
Although it is well known that heart failure (HF) patients suffer from repeated hospitaliz-
ations (both related to HF and other causes [29, 51]), most intervention trials for treatment
of HF have only evaluated the effect on time-to-first event. Since hospitalizations have
a great impact on disease burden, particularly quality of life, and on health care costs
[81, 127], it may be clinically more relevant to see whether any new HF therapy prevents
hospitalizations beyond the first event, i.e. repeated events [17, 113]. However, meth-
ods to investigate repeated events have not yet been widely established and such studies
are relatively scarce. The most commonly used methods so far, analyzed the number of
days alive outside the hospital or simply the number of repeated events. Among the latter
approach, the Poisson and negative binomial regressions are commonly used to compare
hospitalization (or other events) rates in different groups [43, 55, 114]. However these
methods do not take into account the time between repeated events. The Poisson distribu-
tion ignores intra-individual correlation of events within a patient, although the recurrence
of hospitalizations and consecutive death of a patient are correlated [41, 143]. Alternat-
ively, modeling the gap times between successive events (hospitalizations or death) as ran-
dom outcomes is an approach to investigate the treatment effect on recurrence of events
[10, 28, 54, 63, 106].
Heart failure therapy guided by N-terminal pro-B-type Natriuretic Peptide (NT-proBNP)
may be superior to standard therapy in patients with chronic HF as shown in various meta-
analyses [36, 104, 121]. However, results from individual trials have not been uniform
[69, 102, 133]. Various reasons may be responsible for this, including limited power of
these trials due to a relatively small sample size. The largest trial evaluating NT-proBNP-
guided management so far, i.e. the Trial of Intensified versus standard Medical therapy
in Elderly patients with Congestive Heart Failure (TIME-CHF)[19], was a neutral study,
because no significant effect on the primary endpoint hospital-free survival was found,
while the disease specific endpoint HF hospital-free survival was significantly improved
[102, 118]. As there was no safety problem present [119], positive effects might have
been concealed by non-cardiac events unrelated to the intervention, particularly because
in patients aged >75 years significant comorbidities reduced the benefit of HF therapy
on global hospitalization/death outcomes [102, 118]. Analysis of repeated events ana-
lysis might reveal effects on the primary endpoint not seen by time-to-first event ana-
lysis. Therefore in this chapter we employ the Prentice, Williams and Peterson Gap-Times
model (PWP-GT) [10, 106] to investigate the effect of NT-proBNP-guided therapy on the
recurrence of all-cause hospitalization events (all-cause hospitalization or death) and HF
hospitalization events (HF hospitalization or death) in TIME-CHF study. The PWP-GT
model is introduced in detail in Section 2.2.
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3.2 Methods
3.2.1 TIME-CHF Study and Design
The design and results of the TIME-CHF study have been described in detail in Sec-
tion 2.1. The study in this chapter includes 499 patients aged 60 years or older with
symptomatic HF, Left Ventricular Ejection Fraction (LVEF)<45% and New York Heart
Association (NYHA) ≥II from the TIME-CHF study. Patients were randomized to in-
tensified, NT-proBNP-guided versus a standard, symptom-guided therapy for 18 months,
with further follow-up for 5.5 years. Both treatment groups were stratified into two age
groups of 60 to 74 years and 75 years or older. For each patient, time to recurrence of
all-cause hospitalizations, HF hospitalizations and mortality were recorded, for 5.5 years.
3.2.2 Statistical Methods
Baseline characteristics are presented as mean ± standard deviation (SD) for continuous
normally distributed variables, median and quartiles for non-normally distributed continu-
ous variables, or as numbers and percentages for categorical variables, see Tables 3.1 and
3.2.
Differences in the baseline characteristics per number of HF hospitalization events and
all-cause hospitalization events (none vs. one, none vs. at least one, one vs. two or more),
recorded within 5.5 years follow-up, were assessed using a t-test for continuous normally
distributed variables, a Mann-Whitney U-test for non-normally distributed continuous
variables, and a χ2-test for categorical variables. All tests were two-sided at a 5 percent
level of significance and adjusted for multiple comparisons. The time between successive
hospitalizations was calculated (time-interval) for all-cause and HF-hospitalizations and
mortality within 5.5 years follow-up. The outcome variable was censored at the time of
last follow-up if a patient did not experience an event.
The effect of NT-proBNP-guided versus symptom-guided therapy was assessed using
the PWP-GT model [106]. The PWP-GT model formulation and usages are explained in
Section 2.2. It can be used to explore the effects based on the time between successive
events, using stratified Cox models. In PWP-GT, time intervals between repeated events
are outcomes of interest. Patients are not restricted to have the same number of events,
so depending on the number of repeated events, patients may have a different number
of outcomes. For each patient, the first measured outcome is the time from baseline
until the onset of first event (hospitalization or death). The second outcome (for patients
with at least one hospitalization during the study) is the time from the onset of the first
hospitalization until the onset of the second event, and so forth for patients with more
than two events. In the likelihood formulation, all the patients are at risk of an event for
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the first stratum, but only those who experienced hospitalization in the previous stratum
are at risk for a successive event. The approach considers the order in which events occur
and measures the effect of treatment on each consecutive event.
In this study, we considered the gap-time analysis only up to the second HF hospit-
alization events and third all-cause hospitalization events. All analyses were performed
with SAS (Version 9.2, SAS Institute Inc., Cary., NC).
Figure 3.1: The frequency of (1) all-cause hospitalizations (including death), (2) HF hos-
pitalizations (including death) for Symptom-guided and NT-proBNP-guided patients.
3.3 Results
3.3.1 Frequency of events and baseline characteristics
The frequency of hospitalization events, within 5.5 years follow-up, for NT-proBNP-
guided and symptom-guided patients is presented in Figure 3.1. 104 patients (49 NT-
proBNP-guided, 55 symptom-guided) experienced one and 275 patients (133 NT-proBNP-
guided, 142 symptom-guided) two or more all-cause hospitalization events. Regarding
HF hospitalization events, 132 patients (57 NT-proBNP-guided, 75 symptom-guided)
experienced one and 122 patients (57 NT-proBNP-guided, 65 symptom-guided) two or
more events. The median number of hospitalizations events was 2 for both groups, and
there was no significant difference between the two groups regarding the total number
of events. Among the patients without any event, the prevalence of patients randomized
to NT-proBNP-guided therapy was higher than the prevalence of patients randomized to
symptom-guided therapy, whereas this was the opposite for patients with one and two
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events. Baseline characteristics of patients with a different number of all-cause hospit-
alization events and HF hospitalization events are presented in Table 3.1 and Table 3.2,
respectively.
In comparison to patients without any event, those with one or more all-cause hospit-
alization event were older and more likely to suffer from coronary artery disease, kidney
disease, diabetes and, also a higher Charlson comorbidity score (Table 3.1). Moreover,
they had more severe symptoms, higher NT-proBNP and creatinine and lower hemoglobin
plasma concentrations at baseline. Interestingly, there were no significant differences
between patients with more than one versus those with just one event. A comparable
pattern is seen when considering HF hospitalization events as illustrated in Table 3.2.
All-cause hospitalization events
None One Two or more †P01 ‡P0 §P01
(n = 120) (n = 104) (n = 275)
Age (years) 73.9 ± 7.3 75.3 ± 7.5 77.3 ± 7.3 0.153 0.000 0.018
Male sex (%) 66 (55) 79 (76) 182 (66) 0.001 0.005 0.066
Ischemic HF etiology (%) 44 (37) 60 (57) 183(66) 0.002 0.000 0.108
Charlson Score, median [IQR] 2 [1-2] 3 [2-4] 3 [2-5] 0.000 0.000 0.103
Kidney disease (%) 48 (40) 62 (60) 167 (61) 0.003 0.000 0.843
Diabetes (%) 29 (24) 35 (34) 108 (39) 0.014 0.006 0.314
Hypertension (%) 81 (67) 76 (75) 198 (72) 0.363 0.312 0.834
Stroke (%) 4 (0.3) 11 (1.0) 26 (9) 0.030 0.025 0.742
Cancer (%) 16 (13) 18 (17) 34 (12) 0.408 0.914 0.211
Anemia (%) 13 (10) 23 (22) 96 (35) 0.021 0.000 0.016
NYHA>II (%) 87 (72) 77 (74) 207 (75) 0.795 0.594 0.804
Rales (%) 38 (31) 40 (38) 131 (48) 0.287 0.009 0.109
Angina (%) 18 (15) 20 (19) 69 (25) 0.400 0.048 0.229
NT-proBNP (ng/l), median [IQR] 3226 [1760-5590] 4592 [2067-8085] 4670 [2658-8069] 0.021 0.004 0.982
LVEF (%) 29.5 ± 7.5 29.42 ± 7.8 30 ± 7.8 0.921 0.695 0.522
Body mass index (kg/m2) 25.1 ± 4.7 25.5 ± 4.6 25.2 ± 3.9 0.502 0.634 0.545
Systolic blood pressure (mmHg) 119 ± 18 116 ± 19 118 ± 17 0.248 0.431 0.226
Hemoglobin (g/l) 136 ± 20 132 ± 20 130 ± 18 0.104 0.004 0.383
Creatinine (mmol/l) 100 ± 30 119 ± 37 123 ± 39 0.000 0.000 0.351
Potassium (mmol/l) 4.0 ± 0.4 4.0 ± 0.5 4.1 ± 0.5 0.615 0.195 0.019
Table 3.1: Baseline characteristics according to number of all-cause hospitalizations plus death.
†P01: p-value comparison between those patients not hospitalized and those hospitalized only once
(two sided t-test or Mann-Whitney U-test for continuous variables and χ2 test for categorical vari-
ables).
‡P0: p-value comparison between those patients not hospitalized and those hospitalized at least
once.
§P01: p-value comparison between those patients hospitalized once and those hospitalized two
times or more.
IQR: Interquartile range.
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HF hospitalization events
None One Two or more †P01 ‡P0 §P01
(n = 245) (n = 132) (n = 122)
Age (years) 74.1 ± 7.4 78.1 ± 7 77.9 ± 7.2 0.000 0.000 0.850
Male sex (%) 149 (60) 96 (72) 82 (67) 0.020 0.0295 0.337
Ischemic HF etiology (%) 109 (44) 88 (35) 90 (73) 0.000 0.000 0.216
Charlson Score, median [IQR] 2 [1-4] 3 [2-5] 3 [2-5] 0.000 0.0001 0.831
Kidney disease (%) 113 (46) 80 (60) 84 (68) 0.007 0.0001 0.169
Diabetes (%) 65 (26) 57 (43) 50 (40) 0.001 0.000 0.722
Hypertension (%) 170 (69) 99(75) 86(70) 0.250 0.395 0.419
Stroke (%) 13 (5) 14 (10) 14 (11) 0.056 0.020 0.825
Cancer (%) 30 (12) 22 (16) 16 (13) 0.234 0.376 0.427
Anemia (%) 51 (20) 40 (30) 41 (33) 0.040 0.005 0.572
NYHA>II (%) 176 (71) 103 (78) 92 (75) 0.190 0.206 0.621
Rales (%) 77 (31) 64 (48) 68 (55) 0.003 0.000 0.247
Angina (%) 44 (17) 30 (22) 33 (27) 0.231 0.062 0.425
NT-proBNP (ng/l), median [IQR] 3546 [1816-6148] 5046 [2465-8297] 5375 [2947-9238] 0.000 0.000 0.881
LVEF (%) 29.3 ± 7.5 30.7 ± 7.6 29.4 ± 8.2 0.086 0.260 0.192
Body mass index (kg/m2) 25.4 ± 4.5 25 ± 3.9 25.3 ± 4.1 0.292 0.363 0.554
Systolic blood pressure (mmHg) 119 ± 18 117 ± 18 116 ± 17 0.274 0.118 0.742
Hemoglobin (g/l) 135 ± 18 129 ± 20 129 ± 18 0.005 0.001 0.996
Creatinine (mmol/l) 104 ± 32 124 ± 38 133 ± 41 0.000 0.000 0.068
Potassium (mmol/l) 4.0 ± 0.4 4.1 ± 0.5 4.2 ± 0.5 0.593 0.049 0.066
Table 3.2: Baseline characteristics according to number of HF hospitalizations plus death.
†P01: p-value comparison between those patients not hospitalized and those hospitalized only once
(two sided t-test or Mann-Whitney U-test for continuous variables and χ2 test for categorical vari-
ables).
‡P0: p-value comparison between those patients not hospitalized and those hospitalized at least
once.
§P01: p-value comparison between those patients hospitalized once and those hospitalized two
times or more.
IQR: Interquartile range.
3.3.2 Hazards of HF and all-cause Hospitalization
The effect of NT-proBNP-guided therapy as compared to standard therapy on repeated
hospitalizations/death, within 5.5 years follow-up, is presented in Table 3.3. Overall, the
effect of NT-proBNP-guided therapy as compared to standard therapy on first all-cause
hospitalization event (adjusted for baseline characteristics) was not statistically signific-
ant. However, there was a statistically significant beneficial effect of NT-proBNP-guided
therapy on second and third all-cause hospitalization events. When considering pre-
stratified age groups, these effects were only seen in patients aged between 60 and 74
years, but not in patients ≥75 years (Table 3.3).
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Event p-value HR (95% CI) p-value HR (95% CI)
unadjusted unadjusted adjusted adjusted
All-cause
First
All patients 0.10 0.84 (0.69-1.03) 0.35 0.91 (0.75-1.11)
Age < 75 0.04 0.71 (0.51-0.98) 0.06 0.73 (0.53-1.0)
Age ≥ 75 0.87 0.97 (0.75-1.26) 0.83 1.02 (0.79-1.33)
Second
All patients 0.009 0.81 (0.69-0.95) 0.01 0.83 (0.709-0.97)
Age < 75 0.004 0.68 (0.53-0.88) 0.01 0.70 (0.54-0.92)
hospitalization Age ≥ 75 0.41 0.92 (0.75-1.12) 0.36 0.91 (0.74-1.11)
Third
All patients 0.03 0.85 (0.74-0.98) 0.04 0.87 (0.754-0.99)
Age < 75 0.009 0.73 (0.58-0.92) 0.02 0.75 (0.60-0.95)
Age ≥ 75 0.63 0.95 (0.80-1.14) 0.51 0.94 (0.78-1.12)
HF
First
All patients 0.006 0.70 (0.55-0.90) 0.01 0.73 (0.575-0.939)
Age < 75 0.004 0.51 (0.33-0.80) 0.006 0.53 (0.34-0.83)
Age ≥ 75 0.26 0.84 (0.62-1.13) 0.23 0.83 (0.62-1.12)
Second
All patients 0.08 0.83 (0.67-1.02) 0.14 0.85 (0.69-1.05)
hospitalization Age < 75 0.01 0.62 (0.43-0.90) 0.03 0.65 (0.44-0.95)
Age ≥ 75 0.82 0.97 (0.75-1.24) 0.74 0.95 (0.75-1.22)
Table 3.3: Estimations of Hazard ratios of NT-proBNP guided therapy compared to
symptom-guided therapy effect on recurrence of events (adjusted for age, gender, coron-
ary artery disease as main cause of HF, Charlson Score, Kidney disease, ejection fraction
centre, NYHA-class, and systolic blood pressure), using the PWP-GT model.
Overall, NT-proBNP-guided therapy showed a beneficial effect on first HF hospitaliz-
ation event, again predominantly in the younger age group. For second HF hospitalization
event, the beneficial effect of NT-proBNP-guided therapy was somewhat smaller in the
older group and failed to reach statistical significance in analysis of the overall group.
Again there was a difference between the younger and the older patient group.
p-value Rate ratio (95% CI) p-value Rate ratio (95% CI)
unadjusted unadjusted adjusted adjusted
All-cause
All patients 0.49 0.94 (0.79-1.11) 0.46 0.93 (0.79-1.11)
Age < 75 0.32 0.86 (0.63-1.16) 0.43 0.89 (0.67-1.19)
hospitalization Age ≥ 75 0.99 0.99 (0.82-1.22) 0.91 0.99 (0.81-1.21)
HF
All patients 0.15 0.84 (0.68-10.6) 0.12 0.84 (0.67-10.04)
Age < 75 0.04 0.63 (0.40-0.98) 0.07 0.66 (0.42-1.04)
hospitalization Age ≥ 75 0.92 0.98 (0.77-1.27) 0.80 0.97 (0.76-1.24)
Table 3.4: Estimations of Rate ratios of NT-proBNP guided therapy compared to
symptom-guided therapy effect on recurrence of events (adjusted for age, gender, coron-
ary artery disease as main cause of HF, Charlson Score, Kidney disease, ejection fraction
centre, NYHA-class, and systolic blood pressure), using the Negative Binomial regression
model.
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In this study our main focus was on treatment effect on recurrence time of events. For
this, we used the PWP-GT model as explained. There are also methods to evaluate the
association with numbers of all-cause and HF hospitalization events, such as the Negative
Binomial regression model. These kinds of models do NOT take into account the timing
of events, and therefore we feel this approach is less appropriate. However, we also
modeled using the Negative Binomial regression model, (Table 3.4). In general, results
are supporting our PWP-GT model results. Although the P-values are not significant,
the rate ratios do go into the same direction of hazard ratios and show that NT-proBNP-
guided therapy reduces the rate of events (mainly for patients aged<75), however it failed
to reach statistical significance.
3.4 Discussion
This chapter applied an approach for assessing treatment effects in HF patients on re-
peated events, which may be clinically more important for patients than first events only.
We used the TIME-CHF data to investigate potential differences between the traditional
approach and an adapted method that applies a Cox-regression not only for the first, but
also for repeated events, i.e. the PWP-GT model. Interestingly, using NT-proBNP to
guide intensification of HF medication to a greater extent than with standard care alone,
resulted in reduction of repeated all-cause hospitalization events, whereas the time to the
first event, i.e. all-cause hospitalization or death, was not significantly reduced. As re-
peated events may influence patient reported outcomes as well as costs more than first
events only, the PWP-GT model may be preferable and even more powerful to reveal the
effects of (new) interventions in diseases where repeated events are frequent and clinically
relevant, such as in HF.
3.4.1 Advantages of Considering Repeated Events
To investigate the effectiveness of treatment in terms of hospitalization-free survival,
standard approaches for survival analyses such as Cox regression models are usually ap-
plied, where repeated events are not taken into consideration. Obviously, this is the right
approach if patients can suffer only one event (i.e. death) and other events are not con-
sidered, repeated events are scarce, or if effects are similar on composite endpoints and do
not differ on consecutive endpoints [8]. However, taking only the first event into account
might underestimate the effect of treatment in complex chronic diseases such as HF. This
is in line with our findings that effects on the primary endpoint all-cause hospitalization
free survival was only revealed when considering repeated events, whereas first events
were primarily reduced for the disease-specific HF related endpoint. Consecutive HF-
related events were somewhat less affected. Therefore, in order to have a more accurate
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estimation, it makes more sense to take recurring events and their corresponding time in-
tervals into consideration [28, 106], particularly for all-cause events in complex diseases.
Additional similar analyses of trials in complex diseases may help to get more insight in
possible differences in the response of repeated events, depending on the selected end-
point and their potential clinical consequences.
When analyzing the times between the recurrences of events, these times, which form
the outcomes, may vary depending on different number of events per individual patient.
Thus, the outcomes are likely to be correlated because they belong to an individual patient
[41]. The PWP-GT model is not only able to evaluate the treatment effect on the time until
the first event, but also can be used to assess its effect on consecutive events [54, 106].
This approach considers the time from baseline to the first hospitalization event, time
from onset of the first until the second hospitalization event, and onset of the second until
the third hospitalization event, and so forth, as the outcome variables of interest. Each
patient contributes a set of data for each time interval (gap-time) corresponding to each
repeated event. Patients are not restricted to have the same number of outcomes, data sets,
and follow-up times and data sets of patients in their kth event construct the kth stratum.
The PWP-GT model, models the hazard of a subsequent event conditionally on the
entire sequence of previous events experienced by an individual patient, in each stratum
[28, 106]. In other words, this model specifies how the hazard of subsequent recurrences
depends on the past event history, in contrast to the classical Cox regression model which
models the hazard of an event regardless of the past event history. In the PWP-GT model,
we apply robust sandwich variance estimators [74, 147], to adjust the variances of the
estimated regression coefficients for the correlation of observations in the same patient.
Although there are a number of approaches available for analyzing repeated events
[28, 55], the PWP-GT model is recommended in the case that there is a strong relationship
between the first and subsequent events, and if one is more interested in the separate risk
for these events [45]. Unlike other approaches for analyzing repeated events, the PWP-GT
model takes into account the time between repeated events and intra-individual correlation
of events within a patient, making it particularly suitable for investigating repeated events
in chronic diseases.
3.4.2 Potential Impact of Considering Events - TIME-CHF as Example
TIME-CHF was a neutral study as reduction of the primary endpoint by the NT-proBNP-
guided versus symptom-guided therapy, i.e. all-cause hospitalization event, was not achieved.
Interestingly, considering repeated events of the primary endpoint instead of time-to-first
events, NT-proBNP-guided therapy resulted in a significant benefit as compared to symp-
tom guided therapy, which is in line with the positive findings on the disease-specific
endpoint [102], also found in this analysis, the positive effects on left-ventricular ejec-
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tion fraction [61], the excellent safety profile [119], and the maintained long-term effects,
at least in younger patients [118]. Despite these findings, TIME-CHF obviously cannot
be considered as a positive trial on the primary endpoint and this analysis is hypothesis
generating only regarding the clinical consequences. It might be seen as reassuring that
repeated all-cause hospitalization events are not negatively influenced by intensifying HF
medication even in the very elderly patients, supporting the positive safety profile of such
an intervention.
3.4.3 Limitations
This study has some limitations that need to be addressed. First, the PWP-GT model,
though very promising and addressing a relevant question in chronic diseases, is a relat-
ively new method that needs to be further tested before it can be widely recommended.
Second, this study differentially analyzed the primary and a secondary endpoint of a trial
that was not defined per protocol and must be considered as post-hoc analysis only, not
proving superiority of NT-proBNP-guided therapy on the primary endpoint in TIME-
CHF. Moreover, GUIDE-IT (Guiding evidence based therapy using biomarker Intensified
Treatment in heart failure) seems to be neutral, but as no further information is available,
published data must be awaited for further interpretation, which is expected in 2018 [1].
It is, however, important to note that the aim of this analysis is primarily to investigate po-
tential differences between methods to test the effects of interventions on outcome and not
on the role of NT-proBNP-guided therapy. Third, the method was not able to differentiate
fourth and consecutive events due to lack of a sufficient number of such events. Fourth,
the method is not able to distinguish death from hospitalization as event. Theoretically,
the effects of an intervention on mortality might influence results on repeated events (e.g.
longer survival may increase likelihood of repeated hospitalization). Still, we think that
this is unlikely in this study, as effects on mortality overall and in the two age groups are
very much in line with the results of this analysis (effects of NT-proBNP-guided therapy
as compared symptom-guided therapy on mortality: overall HR=0.85, p=0.25; age 60-74
years: HR=0.62, p=0.06; age ≥75 years: HR=1.07, p=0.71) [19]. Moreover, considering
only hospitalizations as events and censoring death did not influence results significantly
(data not shown). Fifth, there is no method available for calculating the PWP-GT model’s
power for the whole model as well as for consecutive events. In the present analysis, stat-
istical power may be particularly low for all-cause hospitalization or death as third event
and interpretation of it must be done with great caution. In addition, statistical methods
need to be developed to test power of the PWP-GT model, which is also true for other
analyses considering repeated events.
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3.5 Conclusions
Our analysis shows that NT-proBNP-guided therapy reduces the risk of recurrent events
in patients aged <75 years. This included all-cause hospitalization by mainly reducing
later events, adding knowledge to the neutral effect on this endpoint when shown using
time-to-first event analysis only. Our findings highlight the relevance of new methods to
address the clinically important question of the effects of interventions on repeated events.
The PWP-GT model may be promising, but needs to be further evaluated before widely
used for assessing the primary endpoint in future intervention studies in chronic diseases
such as HF, where repeated events are a clinically important problem.
4
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ABSTRACT
Dichotomizing continuous covariates is widespread in medical prognostic variable stud-
ies. Dichotomization of a covariate makes it easier for clinicians to interpret the cov-
ariate’s effect on the outcome variable and guides them in their choice of therapy. The
dichotomization point (cutpoint) for a covariate can be selected or estimated based on
the data distribution or in terms of the covariate’s effect on an outcome variable. In this
chapter we introduce a Bayesian approach to estimate cutpoints for continuous covariates
when dichotomized covariates are related to an outcome variable through linear regres-
sion. Using Markov Chain Monte Carlo (MCMC) methods, we obtain Bayesian estimates
for the cutpoints and their corresponding credible intervals. The proposed Bayesian ap-
proach does not limit the selected cutpoint to the observed values of the covariate and
the cutpoint can be any value in the range of the covariate. The proposed approach can
be used to dichotomize a subset or all the covariates when we are using a multivariate
regression model. To the best of our knowledge this is the first method which can deal
with multivariate dichotomization with respect to modeling a continuous outcome vari-
able. We validate the proposed Bayesian approach on data from a simulation study and
we demonstrate the use of this approach on the TIME-CHF study.
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4.1 Introduction
In medical studies, regression models are often used to investigate the relationship between
covariates and an outcome variable. Covariates can be dosages of medications, patient
characteristics, the levels of biomarkers, etc., and are usually measured on a continuous
scale. In practice, however, clinicians may prefer to use them in a dichotomized form
in their analysis. This arises from the fact that using covariates in a dichotomized form
makes it easier for clinicians to interpret the relationship between an outcome variable
and covariates and helps them to make treatment decisions.
From a statistical point of view, dichotomized covariates may also be preferred for
several other reasons: First, the interpretation of the effects of the covariates on the out-
come variable may be easier. For example, effect measures from statistical models such
as hazard ratio or odds ratio are easier to interpret for binary covariates, especially in
multivariate models. Moreover, using the covariates in dichotomized form will be helpful
for interpreting the interaction effect of more than two covariates in a model. Second,
it makes data summarization more efficient. Third, sometimes it is very difficult to have
exact measurements of a continuous variable, therefore by dichotomizing the variable one
may be less concerned about measurement errors. However, dichotomizing a continuous
variable may also lead to loss of statistical power [26, 92] and lead to a higher type-I error
[12, 108].
In the literature, there are two common types of methods for choosing the cutpoints for
dichotomizing continuous covariates: exploratory methods and outcome-oriented meth-
ods [82]. In exploratory methods, based on a data distribution, some value or percentile of
the data can be proposed as a cutpoint to dichotomize a continuous variable. In outcome-
oriented methods, the cutpoint is defined as a value of the continuous covariate that best
separates the data into two groups with respect to the outcome, using statistical criteria.
In many studies, when the objective is assessing the relationship between a covariate and
an outcome variable, one may explore the cutpoint through a regression model. Cutpoint
selection with the use of regression models has been proposed for different types of data
(with discrete or continuous outcomes, lifetime outcomes and longitudinal outcomes), by
a number of authors (see for example [33, 92, 149]).
Our main focus in this chapter is on outcome-oriented methods. Most of the methods
of this type, proposed so far in the literature, consider a selection of observed values of the
covariate and choose one of those as the cutpoint based on statistical criteria [92, 134]. For
instance, they choose the value which best separates the classes according to the minimum
Chi-squared p-value. Unfortunately, as a drawback this method is well known to possibly
inflate the type-I error, due to multiple testing [9].
Breiman et al. [18] introduced Classification and Regression Trees (CART) as a non-
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parametric method to build a decision tree. The CART method essentially selects that
value as a cutpoint that splits the data into two most homogeneous groups based on the
Gini index.
O’Brien [92] proposed a method based on the assumption that the outcome variable Y
and covariate X are related through a conditional distribution f(Y |X) which preferably
belongs to an exponential family of distributions. Then based on each covariate value
(cutpoint candidate) subjects will be split up into two groups. The best cutpoint is defined
as the candidate that minimizes a measure of distance between the true expected value of
the outcome for each subject and the estimated average outcome among subjects in the
same group.
Tunes-da-Silva and Klein [134] proposed a test statistic to select a cutpoint for a con-
tinuous covariate when performing a regression analysis based on generalized estimating
equations.
Liu [75] defined a concordance probability as a criterion evaluating the classification
accuracy of a dichotomized covariate, which is defined as a function of sensitivity and
specificity at the cutpoint. He applied a nonparametric approach to search for the cutpoint,
maximizing the concordance probability.
To the best of our knowledge all outcome-oriented methods (with respect to a con-
tinuous outcome) in the literature derive the cutpoint using univariate analysis for a single
covariate only, and there is no method dealing directly with multivariate dichotomization.
Moreover, in most of them the choice of cutpoint is limited to the observed values of the
covariate.
In this chapter, we propose employing a Bayesian approach for dichotomizing con-
tinuous covariates when assuming the dichotomized covariate is related to the outcome
variable through a regression model. The method can be used both in univariate and in
mutivariate settings. We assume there exists prior knowledge of the regression paramet-
ers and that the cutpoint may be characterized by prior distributions. Using new data, we
can update the prior knowledge and obtain the corresponding posterior distributions of
the unknown parameters. Then, by deriving the posterior distribution of the cutpoint we
can obtain the Bayes estimate of the cutpoint for the continuous covariate with respect to
any feasible loss function. However, we often see that the posterior distributions of the
parameters do not exist in a closed form and therefore we use Markov Chain Monte Carlo
(MCMC) methods such as the Gibbs sampling algorithm [38] or the Metropolis-Hastings
(M-H) algorithm [23], to estimate the parameters (see Section 2.3). In this case, in addi-
tion to finding the Bayesian point estimates of the parameters (the cutpoint and regression
parameters) we can also compute credible intervals.
The proposed Bayesian approach does not limit the selected cutpoint to the observed
values of the covariate anymore and it can be applied in a multivariate setting. In addition,
by employing the Bayesian approach, the inflation of the type-I error is no longer an issue
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due to avoiding multiple testing. In most of the classical approaches, due to lack of a
pivotal quantity [52], we are not able to find a confidence interval for the determined
cutpoint. However, with the use of the Bayesian approach, it is straightforward to derive
a credible interval for the estimated cutpoint.
The rest of the chapter is organized as follows: In Section 4.2, by setting up a mul-
tivariate regression model we apply a Bayesian approach to estimate the cutpoints for
dichotomizing continuous covariates. In Section 4.3, we conduct a simulation study to
assess the properties of the proposed Bayesian approach employing non-informative pri-
ors. In Section 4.4, we employ the proposed Bayesian approach, to dichotomize some
covariates in the TIME-CHF study. Finally in Section 4.5 we conclude this chapter by
discussing the obtained results, disadvantages of the proposed approach and future work.
4.2 Dichotomization Using Linear Regression Models
In this section, we consider multivariate dichotomization of continuous covariates. We
assume that covariates in dichotomized form are related to the outcome variable through
a multivariate linear regression model. In this set up we employ a Bayesian approach to
estimate the cutpoints for the covariates. Since we are not able to find the Bayes estimates
of the regression parameters and cutpoints in a closed form we propose using MCMC
methods to approximate these values.
Suppose that Yi ∈ R, i = 1, . . . , n, are independent continuous outcome variables
for n subjects. Assume for each subject there exist p continuous covariates X1, . . . , Xp.
Let Xl = (X1l, . . . , Xnl)
′
denote the vector of values for the lth covariate, l = 1, . . . , p,
for all subjects andX = (X1,X2, . . . ,Xp) be the matrix of covariate values. Let T1l =
min(Xl) and T2l = max(Xl), then for the ith subject define Zil as the dichotomized
covariate obtained fromXl at cutpoint δl, i = 1, . . . , n, l = 1, . . . , p, i.e.,
Zil =
{
0 if Xil ≤ δl
1 if Xil > δl,
(4.1)
where, δl ∈ (T1l, T2l). To estimate the cutpoint δl, we assume that the outcome variable
and the dichotomized covariates are related through the following multivariate regression
model:
Yi = Z
′
iβ + i, i = 1, . . . , n, (4.2)
where, i ∼ N (0, σ2), Z ′i = (1, Zi1, . . . , Zip) and β
′
= (β0, β1, . . . , βp). Then the joint
likelihood function of β, δ = (δ1, . . . , δp) and σ2 given realizations y = (y1, . . . , yn)
′
and x = (x1, . . . , xn)
′
is
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L(β, σ2, δ|y, x) ∝ (σ2)−n/2 exp
(
− 12σ2 (y − zβ)
′
(y − zβ)
)
. (4.3)
where, z = (z1, . . . ,zn)
′
is an n× (p+ 1) matrix which depends on x and δ.
4.2.1 Bayesian Parameter Estimation
Specifying an appropriate prior distribution for the parameter is a key aspect in a Bayesian
analysis. The prior distribution for a parameter is called a conjugate prior [109] if it is
chosen such that the posterior distribution follows the same family as the prior distribu-
tion. By choosing a conjugate prior we will have a known class for the posterior distribu-
tion which is a computational convenience.
Let us assume the joint conjugate prior (see, [42, 140]) for (β, σ2) to be independent
of the joint prior distribution for the cutpoints, and to have the following structure:
pi(β, σ2) = pi(β|σ2)pi(σ2), (4.4)
where the conditional prior for β given σ2 is the multivariate normal distribution,
N (µ0, σ2 V−10 ) with a known mean µ0 and covariance matrix σ2V−10 , where V0 is a
known matrix. Assume that the prior for σ2 is the Inverse Gamma distribution, IG(a0, b0),
with hyperparameters a0 and b0. Let us assume that δl, l = 1, . . . , p, have independent
prior distributions pil(δl), where δl ∈ (T1l, T2l). Then the joint posterior density function
of β, σ2 and δ is:
pi(β, σ2, δ|y,x) ∝ (σ2)−n/2 exp
(
− 12σ2 (y − zβ)
′
(y − zβ)
)
×(σ2)−p/2 exp
(
− 12σ2 (β − µ0)
′
V0(β − µ0)
)
×(σ2)−(a0+1) exp (− b0σ2 ) p∏
l=1
pil(δl).
(4.5)
Let µ = (z
′
z + V0)
−1(z
′
y + V0µ0). Then the quadratic terms in (4.5) can be rewritten
as:
(y − zβ)′(y − zβ) + (β − µ0)′V0(β − µ0) =
(β − µ)′(z′z + V0)(β − µ) + y′y − µ′(z′z + V0)µ+ µ′0V0µ0
(4.6)
From (4.5) and (4.6), the conditional posterior density function of β given σ2 and δ is
pi(β|σ2, δ,y,x) ∝ exp
(
− 1
2σ2
(β − µ)′V (β − µ)
)
, (4.7)
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and thus,
β|σ2, δ,y,x ∼ N (µ, σ2V −1) ,
where, V = z
′
z + V0. The conditional posterior density function of σ2 given δ is:
pi(σ2|δ,y,x) ∝ (σ2)−(n+2a0)/2−1 exp
(
−2b0 + y
′
y − µ′V µ+ µ′0V0µ0
2σ2
)
, (4.8)
and thus,
σ2|δ,y,x ∼ IG (a, b) ,
where a = a0 + n/2 and b = b0 + 12 (y
′
y − µ′V µ+ µ′0V0µ0).
Finally, the conditional posterior density function of δ given β and σ2, is:
pi(δ|β, σ2,y,x) ∝ exp
(
− 1
2σ2
(y − zβ)′(y − zβ)
) p∏
l=1
pil(δl). (4.9)
From the conditional posterior distributions (4.7) – (4.9), we can generate samples
for β, δ and σ2 using the Gibbs sampling algorithm [38] to compute their correspond-
ing Bayes estimates (see Section 2.3). Note that since the conditional posterior density
function for δ has no closed form, we use the M-H algorithm to generate samples from
pi(δ|β, σ2,y,x) (see Section 2.3). Once we have the MCMC samples, it is possible to
compute the Bayes estimates of any function of the unknown parameters with respect to
any loss function.
Alternatively we can assume non-informative prior distributions for the parameters.
This will make the estimated cutpoints less dependent on the prior information and more
comparable to cutpoints obtained by classical methods. A non-informative prior distribu-
tion that is commonly used for β and σ2 in a multivariate linear regression [42] is:
pi(β, σ2) ∝ 1
σ2
, (4.10)
which can be obtained from the conjugate prior (4.4) with a0 = −p/2, b0 = 0 and
V0 → 0 [94].
Assume also that δl, l = 1, . . . , p, have independent uniform prior distributions that are
U(Tl1, Tl2). Then the joint posterior density function of β, σ2 and δ is:
pi(β, σ2, δ|y,x) ∝ (σ2)−(n+2)/2 exp
(
− 12σ2 (y − zβ)
′
(y − zβ)
)
. (4.11)
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Furthermore, the conditional posterior density function of β given σ2 and δ is
pi(β|σ2, δ,y,x) ∝ exp
(
− 1
2σ2
(β − µ1)′V1(β − µ1)
)
, (4.12)
that is,
β|σ2, δ,y,x ∼ N (µ1, σ2V −11 ) ,
where V1 = z
′
z and µ1 = V −11 z
′
y. The conditional posterior density function of σ2
given δ is
pi(σ2|δ,y,x) ∝ (σ2)−(n−p)/2−1 exp
(
−y
′
y − µ′1V1µ1
2σ2
)
(4.13)
and thus,
σ2|δ,y,x ∼ IG (a1, b1) ,
where a1 = (n− p)/2 and b1 = 12 (y
′
y − µ′1V1µ1).
The conditional posterior density function of δ given β and σ2, is
pi(δ|β, σ2,y,x) ∝ exp
(
− 1
2σ2
(y − zβ)′(y − zβ)
)
. (4.14)
Note that in the proposed multivariate setting we can either dichotomize all the co-
variates in the model (in case all of them are continuous) or only dichotomize a sub-
set of covariates. For example, suppose we are interested in dichotomizing covariates
X1, . . . , Xp−1, in the presence of Xp. Define Z
′
i = (1, Zi1, . . . , Zi(p−1), Xip), i =
1, . . . , n in the multivariate regression model (4.2) and δ = (δ1, . . . , δp−1). Assume the
joint prior distribution
p−1∏
l=1
pil(δl) for δ and joint priors (4.4) or (4.10) for β and σ2. Then
we can follow the same procedure as above to estimate the cutpoints and the regression
parameters.
4.3 Simulation study
In this section, we perform an analysis using simulated data to assess the performance of
the proposed Bayesian approach in estimating cutpoints of covariates in univariate and
bivariate settings. In the univariate setting we assume there is a continuous covariate X1
such that its corresponding dichotomized covariate Z1, at true cutpoint δ1, is related to
the outcome variable Y through the univariate regression model Y = β0 + β1 Z1 + ,
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where  ∼ N (0, σ2). Likewise in the bivariate setting we assume there are covariates X1
and X2 with dichotomized covariates Z1 and Z2, at true cutpoints δ1 and δ2, respectively,
which are related to the outcome variable through the bivariate regression Y = β0 +
β1Z1 + β2Z2 + .
In the simulation study we evaluate the performance of the Bayesian approach in es-
timating the true cutpoints points and the regression parameters. To this end we consider
data sets with different numbers of subjects to observe the effect of the size of the data on
our estimations. Letting the data be scaled such that the covariates range between 0 and
50, we then consider situations for which the true cutpoints range from the median to the
90th percentile of the covariates. In addition we assess the effect of the variance of the
error term, when it ranges from 0.01 to 9, on the performance of the Bayesian approach.
We perform the simulation study in a univariate and in a bivariate setting in the following
scenarios:
In the univariate setting:
1. X1 ∈ [0, 50], β0 = 1, β1 = −2, δ1 = 25, σ2 = 1 and n = 50, 100, 200, 500.
2. X1 ∈ [0, 50], β0 = 1, β1 = −2, δ1 = 25, 30, 35, 40, 45, σ2 = 1 and n = 500.
3. X1 ∈ [0, 50], β0 = 1, β1 = −2, δ1 = 25, σ2 = 0.01, 0.25, 1, 4, 9 and n = 500.
In the bivariate setting:
1. X1 ∈ [0, 50], X2 ∈ [0, 50], β0 = 1, β1 = −2, β2 = 2, δ1 = 25, δ2 = 25, σ2 = 1
and n = 50, 100, 200, 500, 1000.
2. X1 ∈ [0, 50], X2 ∈ [0, 50], β0 = 1, β1 = −2, β2 = 2, (δ1, δ2) = (25, 25),
(30, 30), (35, 35), (40, 40), (45, 45), σ2 = 1 and n = 500.
3. X1 ∈ [0, 50], X2 ∈ [0, 50], β0 = 1, β1 = −2, β2 = 2, δ1 = 25, δ2 = 25,
σ2 = 0.01, 0.25, 1, 4, 9 and n = 500.
In each scenario, for the given parameters, we generate k = 1000 data sets. We as-
sume the non-informative prior in (4.10) for the regression parameters and uniform (0, 50)
prior distributions for the cutpoints δ1 and δ2. Then for a given data set we apply the
Gibbs sampling algorithm to generate 10000 samples from the conditional posterior dens-
ity functions (4.12)–(4.14), with burn-in period = 1000. We note that within the Gibbs
sampling algorithm, in order to sample δ1 and δ2 from their posterior density functions
(4.14), we use the M-H algorithm. Then for the ith data set, we obtain the Bayes estimates
for the cutpoints δˆ1i, δˆ2i and for the regression coefficients (βˆ0i, βˆ1i, βˆ2i), i = 1, . . . , k,
under the Squared Error Loss (SEL) function.
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δ = 25, σ2 = 1 Parameter quality (MSE and bias)
n δ (O’Brien) δ (Bayes) β0 β1 σ2
50
4.36784 2.55616 0.04225 0.07991 0.05813
(-0.84824) (-0.00085) (-0.0068) (0.01385) (0.07337)
100
1.05984 0.60995 0.02035 0.03951 0.02371
(-0.42401) (-0.0339) (0.00067) (0.00807) (0.02354)
200
0.28496 0.147 0.01012 0.01919 0.01038
(-0.18848) (0.014) (0.00016) (0.00437) (0.00763)
500
0.04349 0.02236 0.00382 0.00773 0.0039
(-0.08043) (0.00178) (-0.00014) (0.00174) (0.00499)
Table 4.1: Quality of cutpoints and regression parameters using a univariate linear regres-
sion model, when X1 ∈ [0, 50], β0 = 1, β1 = −2, δ1 = 25, σ2 = 1 and n = 50, 100,
200, 500
In each box the first row presents the M̂SE of the estimates and in the second row the
corresponding bias is reported within parentheses.
n = 500, σ2 = 1 Parameter quality (MSE and bias)
δ δ (O’Brien) δ (Bayes) β0 β1 σ2
25
0.04349 0.02236 0.00382 0.00773 0.0039
(-0.08043) (0.00178) (-0.00014) (0.00174) (0.00499)
30
0.04982 0.02535 0.00353 0.00875 0.00413
(-0.07994) (-0.00222) (-0.00251) (0.00722) (0.00739)
35
0.05347 0.02615 0.00307 0.00978 0.00409
(-0.09206) (-0.00259) (-0.00137) (0.00251) (0.00323)
40
0.04037 0.02424 0.00275 0.01303 0.00401
(-0.07695) (0.00633) (-0.00119) (-0.00295) (0.00748)
45
0.04164 0.02398 0.00223 0.02168 0.00433
(-0.08028) (-0.00612) (-0.00389) (0.01634) (0.00639)
Table 4.2: Quality of cutpoints and regression parameters using a univariate linear regres-
sion model, when X1 ∈ [0, 50], β0 = 1, β1 = −2, δ1 = 25, 30, 35, 40, 45, σ2 = 1 and
n = 500.
In each box the first row presents the M̂SE of the estimates and in the second row the
corresponding bias is reported within parentheses.
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n = 500, δ = 25 Parameter quality (MSE and bias)
σ2 δ (O’Brien) δ (Bayes) β0 β1 σ2
0.01
0.01955 0.00543 0.00004 0.00008 0.000004
(-0.10166) (0.00038) (-0.00033) (0.00004) (0.00005)
0.25
0.02108 0.00577 0.00097 0.00186 0.00026
(-0.09609) (0.00138) (-0.00072) (0.00085) (0.00087)
1
0.04349 0.02236 0.00382 0.00773 0.0039
(-0.08043) (0.00178) (-0.00014) (0.00174) (0.00499)
4
0.34816 0.23815 0.01683 0.03329 0.06341
(-0.06625) (-0.00952) (-0.00583) (0.0158) (0.03492)
9
1.90617 1.41844 0.03879 0.07481 0.31347
( -0.06601) (-0.00667) (-0.01006) (0.01655) (0.04772)
Table 4.3: Quality of cutpoints and regression parameters using a univariate linear regres-
sion model, when X1 ∈ [0, 50], β0 = 1, β1 = −2, δ1 = 25, σ2 = 0.01, 0.25, 1, 4, 9 and
n = 500.
In each box the first row presents the M̂SE of the estimates and in the second row the
corresponding bias is reported within parentheses.
δ1 = 25, δ2 = 25, σ2 = 1 Parameter quality (MSE and bias)
n δ1 δ2 β0 β1 β2 σ2
50
2.84054 3.58429 0.07004 0.09654 0.09607 0.05326
(0.00984) (0.05485) (-0.00589) (0.02788) (-0.01524) (0.06038)
100
0.6336 0.71235 0.03038 0.04043 0.03997 0.02544
(0.01561) (0.01159) (0.00419) (0.00276) (-0.01406) (0.02154)
200
0.13543 0.16293 0.01604 0.02059 0.0209 0.01117
(0.00329) (0.00329) (0.00081) (0.00271) (-0.00767) (0.0169)
500
0.02425 0.02526 0.00603 0.00773 0.00825 0.00393
(0.01097) (0.00454) (0.00037) (0.00081) (-0.00555) (0.00433)
1000
0.0065 0.00576 0.0028 0.00411 0.0039 0.00197
(-0.00145) (-0.00073) (0.00063) (0.00041) (0.00082) (0.00346)
Table 4.4: Quality of cutpoints and regression parameters using a bivariate linear regres-
sion model, when X1 ∈ [0, 50], X2 ∈ [0, 50], β0 = 1, β1 = −2, β2 = 2, δ1 = 25,
δ2 = 25, σ2 = 1 and n = 50, 100, 200, 500, 1000.
In each box the first row presents the M̂SE of the estimates and in the second row the
corresponding bias is reported within parentheses.
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n = 500, σ2 = 1 Parameter quality (MSE and bias)
(δ1, δ2) δ1 δ2 β0 β1 β2 σ2
(25, 25)
0.02425 0.02526 0.00603 0.00773 0.00825 0.00393
(0.01097) (0.00454) (0.00037) (0.00081) (-0.00555) (0.00433)
(30, 30)
0.02149 0.02562 0.00478 0.00906 0.00819 0.00403
(-0.00408) (-0.00263) (-0.00187) (0.00023) (-0.00352) (0.00617)
(35, 35)
0.02551 0.02626 0.00337 0.00934 0.00888 0.00411
(-0.00334) (0.00217) (0.00057) (-0.00274) (-0.00015) (0.00593)
(40, 40)
0.02329 0.02618 0.00295 0.01348 0.01267 0.00404
(0.00251) (-0.00415) (-0.00101) (-0.00568) (0.00225) (0.00445)
(45, 45)
0.02168 0.02316 0.00231 0.02263 0.02278 0.00409
(-0.00668) (-0.00559) (-0.00166) (0.01309) (-0.00244) (0.00445)
Table 4.5: Quality of cutpoints and regression parameters using a bivariate linear re-
gression model, when X1 ∈ [0, 50], X2 ∈ [0, 50], β0 = 1, β1 = −2, β2 = 2,
(δ1, δ2) = (25, 25), (30, 30), (35, 35), (40, 40), (45, 45), σ2 = 1 and n = 500.
In each box the first row presents the M̂SE of the estimate and in the second row the
corresponding bias is reported within parentheses.
n = 500, δ1 = 25, δ2 = 25 Parameter quality (MSE and bias)
σ2 δ1 δ2 β0 β1 β2 σ
2
0.01
0.00466 0.00519 0.000006 0.000008 0.000008 0.000001
(0.00207) (0.00078) (-0.00019) (0.00012) (0.00029) (0.00003)
0.25
0.0065 0.00697 0.00155 0.00202 0.00209 0.00025
(-0.00267) (-0.00099) (0.0016) (0.00019) (-0.00185) (0.00025)
1
0.02425 0.02526 0.00603 0.00773 0.00825 0.00393
(0.01097) (0.00454) (0.00037) (0.00081) (-0.00555) (0.00433)
4
0.25289 0.26982 0.02707 0.03213 0.03642 0.07056
(0.00685) (0.01054) (0.0077) (0.00162) (-0.01604) (0.03399)
9
1.50236 1.4011 0.05492 0.06989 0.07469 0.33771
(-0.00628) (-0.04681) (0.00081) (0.01139) (-0.01388) (0.06543)
Table 4.6: Quality of cutpoints and regression parameters using a bivariate linear regres-
sion model, when X1 ∈ [0, 50], X2 ∈ [0, 50], β0 = 1, β1 = −2, β2 = 2, δ1 = 25,
σ2 = 0.01, 0.25, 1, 4, 9 and n = 500.
In each box the first row presents the M̂SE of the estimate and in the second row the
corresponding bias is reported within parentheses.
For each parameter we obtain the estimated Mean Squared Error (M̂SE) of its estim-
ates (from K=1000 simulated data sets) as:
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M̂SE =
1
k
k∑
i=1
(θ − θˆi)2,
where, θ is either δ1, δ2, β0, β1, β2, σ2. The simulation study is performed with the R soft-
ware, version 3.2.1 [128]. The results for models with one covariate and two covariates
are tabulated in Tables 4.1 - 4.3 and Tables 4.4 - 4.6, respectively.
In the univariate setting we compare the Bayesian approach with O’Brien’s [92] ap-
proach as a classical method. However, to the best of our knowledge there is no method
available dealing with the multivariate dichotomization with respect to a continuous out-
come, to compare with the Bayesian approach.
From the results of Tables 4.1 - 4.6, we observe that the performance of the Bayesian
approach in estimating the cutpoints and the regression parameters is quite satisfactory
with very small average biases and M̂SEs relative to the parameter values. Tables 4.1 and
4.4 clearly show that the M̂SE decreases as the sample size increases, for both the cut-
points and regression parameters. In the univariate setting, the Bayesian approach clearly
outperforms O’Brien’s method with M̂SEs of almost half of those using O’Brien’s method
and smaller average biases. For the given sample sizes, Tables 4.2 and 4.5 show that the
cutpoints have almost the same M̂SEs when the true cutpoints range from the median
to the 90th percentile of the covariates. Note that the proposed Bayesian approach still
performs twice as good as O’Brien’s method in terms of the M̂SE, for the range of true
cutpoint. From Tables 4.3 and 4.6, we observe that the M̂SEs obtained using the proposed
Bayesian approach are close to zero when σ2 is very small. As we expected M̂SE in-
creases as σ2 increases. From Table 4.3 we also see that the proposed Bayesian approach
performs better than O’Brien’s method in terms of M̂SE and average bias for different
values of σ2. Note that we could also use more informative priors for the parameters of
the model which would then give better Bayes estimates in terms of M̂SE.
4.4 Application to the TIME-CHF Study
The use of biomarkers, as diagnostic and prognostic factors in clinical decision making,
is increasingly important in many areas of medicine. For instance, N-terminal pro-B-type
Natriuretic Peptide (NT-proBNP) is a very well-known prognostic biomarker of heart fail-
ure and is used to exclude Heart Failure (HF) in patients presenting themselves with signs
and symptoms of heart failure, both in the outpatient setting and in the emergency room
[103]. The NT-proBNP level is normally very low in healthy individuals, it is increased
in HF, and it correlates well with ventricular wall stress and the severity of HF [58, 80].
In this section we apply the proposed Bayesian approach to estimate the cutpoints for
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covariates in the TIME-CHF study with respect to NT-proBNP as the outcome variable.
The design of the TIME-CHF study has been described in detail in Section 2.1. The ana-
lysis in this section includes 622 heart failure patients from the TIME-CHF study.
The covariates of which we are interested to find the cutpoints are: the BMI (Body
Mass Index) and two biomarkers: SST2 (soluble ST2) and Mimecan at the baseline visit.
In Table 4.7, we have the descriptive summaries of these covariates.
Variable Mean Standard deviation Median (Min, Max)
BMI (kg/m2) 25.4985 4.1987 25.014 (15.058, 37.716)
SST2 (ng/ml) 45.2249 32.0763 35.8423 (12.223, 302.45)
Mimecan (ng/ml) 132.2549 59.4857 119.04 (20.34, 349.03)
Table 4.7: Descriptive summaries of the three covariates, BMI, SST2 and Mimecan.
In order to estimate the cutpoints for these covariates using the proposed Bayesian
method of this chapter, we assume that the covariates in dichotomized form have a rela-
tionship with NT-proBNP (as an outcome variable) through a multivariate linear regres-
sion model. For notational convenience, we denote:
Y = NT-proBNP (in logarithmic form)
X1 = BMI
X2 = SST2
X3 = Mimecan
Following Equation (4.1) and the notations in Section 4.2, we assume that the dicho-
tomized covariates are related to NT-proBNP through the following multivariate regres-
sion model:
Yi = β0 + β1Zi1 + β2Zi2 + β3Zi3 + i,
where Zil is the dichotomized covariate obtained from Xil, l = 1, . . . , 3, i = 1, . . . , 622,
at cutpoints δ1, δ2 and δ3, respectively.
Assuming the non-informative prior in (4.10), where β = (β0, β1, β2, β3), and δ1 ∼
U(15.058, 37.716), δ2 ∼ U (12.223, 302.45) and δ3 ∼ U(20.34, 349.03), we generate
1,000,000 Gibbs samples to estimate the unknown parameters with a burn-in period of
size 500,000. Geweke’s convergence diagnostic test [39] confirms the convergence of
generated Gibbs samples at a 5 percent level of significance for β0, β1, β2, β3, δ1, δ2 and
δ3 with p-values of 0.44398, 0.69872, 0.52921, 0.37318, 0.49566, 0.47216 and 0.53591,
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respectively.
The Bayes estimates of the unknown parameters (under the SEL function) with their
corresponding Standard Deviation (SD) and 95% credible intervals are presented in Table
4.8.
Parameter Bayes Estimates SD 95% Credible interval
β0 -0.06988 0.04698 (-0.16763, 0.01839)
β1 -0.18026 0.04058 (-0.25831, -0.10268)
β2 0.24356 0.03435 (0.17582, 0.31081)
β3 0.23072 0.03344 (0.16502, 0.29618)
δ1 23.18228 1.28176 (22.19415, 26.86243)
δ2 41.53612 3.52424 (33.30335, 49.53026)
δ3 135.2686 6.73549 (118.3009, 146.763)
Table 4.8: Bayes estimates of regression parameters and cutpoints.
From Table 4.8 the estimated cutpoint for BMI, SST2 and Mimecan are 23.18228
kg/m2, 41.53612 ng/ml and 135.2686 ng/ml, respectively. We observe that the effects of
dichotomized SST2, Mimecan and BMI on NT-proBNP are significant since the credible
intervals for β1, β2 and β3 do not include zero. In addition, by applying the multivariate
regression model with dichotomized covariates we observe that the Shapiro-Wilk normal-
ity test [126] is not significant (p-value= 0.5575) which shows there is no reason to reject
the assumption of normality.
Numerous studies have addressed the relationship between BMI and NT-proBNP or
risk of HF and investigated the best cutpoint to explain these relationships [24, 64]. Recent
studies have demonstrated that patients with underweight (BMI < 25 kg/m2) have higher
NT-proBNP and higher risk of HF [25]. This observation is known as the ‘obesity para-
dox’ [89]. The estimated coefficient for dichotomized BMI (β1 = −0.18026) in Table 4.8
also confirms the negative association previously observed between BMI and NT-proBNP.
We note that, the obtained credible interval of the estimated cutpoint for BMI (22.19415,
26.86243) also includes the recommended cutpoint of 25. Several studies have shown
the positive association between SST2 and NT-proBNP [62] and have recommended the
cutpoint of 35 ng/ml for SST2 [59]. It has been demonstrated that patients are at a higher
risk of adverse events when SST2 levels are above 35 ng/ml [59, 66]. The estimated coef-
ficient (β2 = 0.24356) in Table 4.8 confirms the positive association between SST2 and
NT-proBNP. Moreover, the obtained credible interval of the estimated cutpoint for SST2
(33.30335, 49.53026) includes the previously recommended cutpoint of 35 ng/ml. The
level of SST2 (and consequently the cutpoint) depends on different factors including age
and severity of heart failure. Given the high age of the population studied (older than 65
years), this may explain why the estimated cutpoint in our study is slightly higher than
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previously suggested. Mimecan is a very new biomarker for which to the best of our
knowledge this is the first study to recommend a cutpoint.
4.5 Discussion
In this chapter we proposed a Bayesian approach to estimate cutpoints for continuous
covariates assuming that the covariates in dichotomized form are related to an outcome
variable through a univariate or a multivariate linear regression model. The proposed
Bayesian approach has the great advantage that it can be applied in a multivariate setting.
In the multivariate setting with the use of this Bayesian method we may dichotomize all
or only a selected subset of the covariates. To the best of our knowledge this is the first
method dealing with multivariate dichotomization with respect to a continuous outcome
variable directly. Unlike most of the available methods, in using the Bayesian approach
the estimated cutpoint is not limited to the observed values of the covariate and can take
any value in the range of the covariate.
We applied our simulation study in univariate and bivariate setting considering the
effect of sample sizes, true value of the cutpoint and the variance of the error terms. It
showed that the proposed Bayesian approach provides good estimates of the true cutpoint
even when the variance of the error term is relatively high (equal to 9). In addition, the
simulation study showed that in a univariate setting, the Bayesian approach has better
performance compared to O’Brien’s method. However, the simulation study is only ap-
plied for a limited range of choices of the parameters. Therefore, it might be interesting
to further investigate the performance of the proposed Bayesian approach for different
choices of the parameters and models with more than two covariates. The noninformative
prior performs very well in the simulation study. However, one might be interested to also
see the performance of the other noninformative priors such as Bernardo’s prior [14] and
Jeffreys [56] prior.
To demonstrate the proposed approach with real data, we applied it to estimate the
cutpoints for three markers in the TIME-CHF study, BMI, SST2 and Mimecan, with re-
spect to NT-proBNP. We observed that the estimated cutpoints and associations of the
dichotomized BMI and SST2 with NT-proBNP were well in line with the recommended
cutpoints and previously observed associations in other studies. The recommended cut-
points in these other studies are mostly based on experience or on assessing the individual
effect of the dichotomized biomarker on an outcome of interest. Moreover, these recom-
mended cutpoints vary slightly from study to study, suggesting that more sophisticated
methods for cutpoint selection are important. The cutpoint for a given covariate may also
depend on other covariates. In contrast with other studies, with the use of the proposed
Bayesian approach we estimated the cutpoints in a multivariate setting. We note that one
might be interested to estimate the cutpoints as well in the presence of the other covari-
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ates or for more biomarkers. However, this should be done with caution due to the limited
number of observations in the study and possible multicollinearity between the biomark-
ers which may lead to low accuracy of results. We also note that the estimated cutpoint
for Mimecan should be validated in future studies since, to the best of our knowledge, this
is the first study which investigated a cutpoint for Mimecan.
Finally we note that the inferences in this chapter are under the assumption of mul-
tivariate normality that may not be applicable to other distributions. Therefore, as a
generalization of the approach in this chapter one may consider dichotomization using
generalized linear regression models.
5
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ABSTRACT
Logistic Generalized Estimating Equations (logistic-GEE) models have been extensively
used for analyzing clustered binary data. However, assessing the goodness-of-fit and the
predictive performance of logistic-GEE models is problematic due to the fact that the out-
comes are correlated within a cluster and no likelihood is available. In this chapter we
address this issue and we propose a new performance measure for logistic-GEE models,
which we call the Generalized Ranking Accuracy (GRA). We define GRA as the prob-
ability that a randomly selected instance with positive outcome is ranked higher than a
randomly selected instance with negative outcome from another cluster. GRA can be
used for assessing the goodness-of-fit and the predictive performance of logistic-GEE
models, depending on the type of evaluation method (e.g. cross-validation, or hold-out).
A simulation study is conducted to evaluate and compare GRA with other goodness-of-fit
criteria when logistic-GEE models are trained on clustered data. In addition, we employ
GRA as a model selection criterion in the TIME-CHF study.
56 Chapter 5. Generalized Ranking Accuracy for Logistic-GEE Models
5.1 Introduction
The Logistic Generalized Estimating Equations (logistic-GEE) model 1 is a widely used
model for analysing clustered binary data [47]. However, evaluating goodness-of-fit and
predictive performance of the constructed logistic-GEE model still is a challenging area of
research [31, 32]. This is due to the fact that no likelihood is available and, moreover, the
model’s predicted probabilities are correlated within a cluster. In addition, the logistic-
GEE model disregards the unknown correlation between the outcomes within a cluster
and treats it as a nuisance parameter and simply models the mean of outcomes on the
population level [73].
In this chapter we address the problem of evaluating the logistic-GEE model and
propose a new criterion as a goodness-of-fit criterion for this model. This problem has
been considered by several authors (see e.g, [13, 31, 32, 49, 97, 98, 107, 142]). Several
criteria and tests have been proposed for assessing the goodness-of-fit of logistic-GEE
models. However, most of them have their own shortcomings making it impossible to
have a commonly applicable and accepted criterion or test. In addition, to the best of our
knowledge, so far, no predictive performance criterion has been proposed for the logistic-
GEE model in the literature. The new proposed criterion in this study, to some extent, can
also be used for assessing the predictive performance of the logistic-GEE model. To put
this research into perspective, we first describe relevant work, after which we propose our
approach.
Barnhart and Williamson in [13] proposed a model-based and robust goodness-of-fit
tests for logistic-GEE models. The method is based on partitioning the space of covari-
ates into distinct regions and forming score statistics that are asymptotically distributed
as chi-square random variables. The main disadvantage of this method is that the test
statistics and the corresponding degrees of freedom depend on the subjective choice of
cutpoints for covariate partitioning. Moreover, the authors mentioned that in order to en-
sure the asymptotic properties of the tests, each partitioned region should contain at least
10 clusters and only 25% of the regions should have less than 25 clusters. Therefore, ap-
plying this method might be problematic in studies such as TIME-CHF when we would
like to have many continuous covariates in the model, or when sample sizes are small.
Pan in [98] introduced two goodness-of-fit statistics for logistic-GEE models: the
Pearson chi-square statistic and an unweighted sum of squares statistic. These two statist-
ics are based on comparing observed and predicted residual values. The major drawback
of both statistics lies in the necessity of involving at least one continuous covariate in the
model. In addition, the author mentioned that in practice the power of these statistics may
be limited since these statistics are proposed to detect only general model departures.
1The formulation and usage of the logistic-GEE model are explained in detail in Section 2.4.
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Another criterion for assessing the goodness-of-fit of logistic-GEE models is a Kappa-
like classification statistic proposed by Williamson et al. in [142]. This Kappa-like stat-
istic depicts how well the binary outcomes are predicted from the logistic-GEE model
[142]. It takes the value of one if prediction is perfect and zero if the fitted model predicts
no better than an intercept-only model. The disadvantage of the statistic is that for two-
class imbalanced data it usually tends to be close to zero, i.e., it states that the model is
poorly fitted. Moreover, since no distribution of the statistic is given, interpretation of the
statistic is not obvious. The authors made suggestions for interpreting the statistic, based
on Landis and Koch’s labeling of Kappa-like statistic values [70]. They recommended
that a value from 0 to 0.20 indicates a poor fit, a value from 0.21 to 0.40 indicates a fair
fit, a value from 0.41 to 0.60 indicates a good fit, and a value from 0.61 to 1.00 indicates
an excellent fit. However, this interpretation might not be suitable for some sensitive stud-
ies. For instance, the value of 0.61 means that 39% of the sample evaluations is predicted
wrong which in a clinical study would be a serious problem.
One of the well-established goodness-of-fit statistics for GEE models is a Quasilike-
lihood under the independence model Information Criterion (QIC) [97] which is an ex-
tension of Akiake’s information criterion (AIC)[7]. QIC is recommended to be useed as
a criterion for choosing between working correlation structures rather than as a model-
selection criterion [49]. As an alternative, QICu (as an extension of QIC) is proposed
to be used as a model-selection criterion [49], such that the model with smaller QICu is
preferred. Since QICu is a function of both quasilikelihood (which depends on the size
of the working dataset) and the number of estimated parameters in the model, it indicates
the quality of a model relative to other models, fitted with the same data set. When using
different data sets, the QICu values may be very different. To the best of our knowledge
there is no way to normalize the QICu value which makes it impossible to use QICu as an
absolute quality measure. Therefore, QICu is not an applicable criterion for comparing
the goodness-of-fit of GEE models for different data sets, even with the same covariates.
Moreover, QICu is only a goodness-of-fit criterion and it does not provide information on
the predictive performance of the model, since it is based on the training data.
Each of the aforementioned goodness-of-fit test statistics and criteria for logistic-GEE
models has at least one of the following shortcomings:
(a) restriction on the number and types of covariates in the model being evaluated,
(b) bias in case of two-class imbalanced data,
(c) difficulty of interpretation,
(d) a relative range of the criterion values (i.e., the range depends on the number of
subjects and number of covariates in the model),
(e) inability to indicate the predictive performance of the model being evaluated.
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To propose a criterion that does not suffer from problems (a)-(e), we observe that:
(1) logistic-GEE models are trained on clustered data,
(2) logistic-GEE models provide probabilities for the outcomes to be positive,
The latter implies that logistic-GEE models provides scores (continuous range, between
0 and 1) over the instances. Thus, logistic-GEE models actually solve the bipartite
ranking task for clustered data [3], see Section 2.4.1. The task is as follows: given
labeled clustered data, find an ordering on the instances such that instances with pos-
itive outcomes (outcome=1) are ranked higher than instances with negative ones (out-
come=0).2The standard measure for the quality of that ordering is the Ranking Accuracy
(RA), see [3]. However, its applicability for logistic-GEE models is questionable, since it
does not take into account the within-cluster correlation that might be present, and thus it
can be invalid.
In this chapter we extend the concept of ranking accuracy to clustered data. We pro-
pose a new measure that we call the Generalized Ranking Accuracy (GRA) for models
based on clustered binary data. It is defined as the probability that a randomly selec-
ted instance with positive outcome (positive instance) is ranked higher than a randomly
selected instance with negative outcome (negative instance) from another cluster. The
definition of GRA is such that it avoids using multiple correlated observations from the
same cluster at the same time. We note that, (logistic-)GEE models also aim to disreg-
ard within-cluster correlation, to build a population-average model. Therefore, the GRA
definition is chosen to be in line with the same concept.
We also propose a computationally efficient algorithm for GRA (Section 5.2.2). The
algorithm employs only the model’s predicted probabilities and the outcome values; i.e., it
does not use any internal information from the model being used. This implies that GRA
is applicable for logistic-GEE models as well as for any other valid model for bipartite
ranking based on clustered data.
We show that GRA can be used both as a goodness-of-fit criterion and as a predictive
performance criterion (Section 5.2.3). For the latter we propose a modification to the
standard cross-validation method to make it applicable for clustered data.
When comparing GRA with the presented standard goodness-of-fit test statistics and
criteria for logistic-GEE models we observe that GRA overcomes problems (a) to (e)
given above. The main reasons are that: (1) GRA does not impose any restriction on the
number and types of covariates in the models being evaluated; (2) GRA is not biased for
binary imbalanced data (since it indicates class separation); (3) GRA is a probability that
is fairly easy to interpret; (4) GRA has an absolute range; and (5) GRA can be used both
as a goodness-of-fit criterion and as a predictive performance criterion.
2We note that a good solution for the bipartite ranking task implies a good solution for the binary classifica-
tion task. However, the opposite is not always true [3].
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The rest of the chapter is organized as follows. In Section 5.2 we introduce GRA
in full detail. We use experiments in Section 5.3 on simulated data to compare GRA as
a goodness-of-fit criterion with a Kappa-like statistic, QICu, and RA, when evaluating
logistic-GEE models. In addition, we compare GRA (using cross-validation) as a model
selection criterion with QICu. In Section 5.4 we employ GRA as a model selection cri-
terion in the TIME-CHF study and in Section 5.5 we conclude this chapter by discussing
our results and highlighting the importance and advantages of the GRA.
5.2 Generalized Ranking Accuracy
In this section we define Generalized Ranking Accuracy (GRA) for models trained on
clustered binary data and we explain how it relates to logistic-GEE models. We present an
algorithm for computing the GRA together with a complexity analysis. Then we evaluate
the obtained GRA both as a goodness-of-fit criterion and as a predictive performance
criterion for logistic-GEE models.
5.2.1 Definition and Computation of the GRA
According to Eqn. (2.9) any logistic-GEE model is essentially a scoring classifier model
[22]. Following the definitions and notations in Section 2.4, given a data set of n clusters
〈Xi,Yi〉, i = 1, . . . , n, each consisting of instances (xit, yit), t = 1, . . . ,mi, a logistic-
GEE model provides a probability piit for the outcome Yit to be positive, given the vector
xit, i = 1, . . . , n, t = 1, . . . ,mi. This probability piit is a value in [0, 1], which can
be interpreted as a score: a higher score implies a higher probability to be dealing with
a positive outcome, and a good model is expected to provide higher scores for instances
with a positive outcome than for instances with a negative outcome. The standard measure
for such a comparison is RA [3]. It is defined as the probability that a randomly selected
instance with positive outcome (positive instance) is ranked higher by the scoring model
than a randomly selected instance with negative outcome (negative instance).
To apply the concept of the RA to a logistic-GEE model, or any scoring model trained
on clustered binary data, we introduce GRA. The GRA aims to measure RA, by avoiding
to compare rankings within a cluster – as they are known to be correlated (but in an
unknown way) which may distort the validity of the comparison.
Definition 1. The GRA of a scoring model trained for clustered data is defined as the
probability that a randomly selected positive instance (from an arbitrary cluster) ranks
higher than the randomly selected negative instance from another cluster.
The GRA is easy to interpret, since it is a probability (i.e., it ranges between 0 and 1).
The value 1.0 indicates perfect ranking on the given data (i.e., all positive instances are
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ranked higher than all negative instances from another cluster); and the value 0.0 indicates
the opposite scenario. The value 0.5 corresponds to a noninformative model.
Below we introduce the exact formula for GRA. Following the GRA definition, provided
above, first for any positive instance (xit, yit) i.e., with yit = 1, we determine the number
Dit of negative instances from other clusters:
Dit =
n∑
j=1,j 6=i
mj∑
s=1
I{yjs = 0}, i = 1, . . . , n, t = 1, . . . ,mi, (5.1)
where I is the indicator function having the value 1 when yjs = 0, otherwise 0.
The numberDit can be interpreted as the number of pairs consisting of instances with
a particular positive outcome, yit, from cluster i and one negative instance from other
clusters. We note that this number stays the same for each positive instance in cluster i.
This implies that the numberDi of pairs consisting of instances, one positive from cluster
i, one negative from another cluster, is equal to:
Di =
mi∑
t=1
DitI{yit = 1}. (5.2)
Then the total number of pairs consisting a positive and a negative instances not from the
same cluster, is equal to:
D =
n∑
i=1
Di. (5.3)
Now following the GRA definition, we are interested to know how many of these D
pairs correctly are ranked by the logistic-GEE model. We assume that for each instance
(xit, yit) the logistic-GEE model provides a (score) probability of being positive, piit,
i = 1, . . . , n, t = 1, . . . ,mi. We rank instance (xit, yit) according to piit. For any
positive instance (xit, yit), we compute Cit as the number of correct pairs, produced
by the ranking through combining with all negative instances (xjs, yjs) from all other
clusters j, such that j 6= i. In case of equal scores, the probability of properly ranking the
instances is taken to be 1/2. The number Cit then is given by:
Cit =
n∑
j=1,j 6=i
mj∑
s=1
(I{piit > pijs}+ 1
2
I{piit = pijs})I{yjs = 0}. (5.4)
The number Cit does not stay the same for each positive instance in cluster i. Hence,
the number of correctly ranked pairs of a positive instance from cluster i with negative
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instance from another cluster j (j 6= i) is equal to:
Ci =
mi∑
t=1
CitI{yit = 1}. (5.5)
Thus, C as the number of correctly ranked pairs of positive and negative instances from
distinct clusters is equal to:
C =
n∑
i=1
Ci. (5.6)
Finally the GRA is given by,
GRA =
C
D
. (5.7)
5.2.2 Algorithm for GRA
Below, in Algorithm 1, we provide an algorithm for efficient computation of the GRA.
The input of the algorithm consists of n clusters 〈xi,yi〉 and their corresponding vectors
pii of probabilities piit, i = 1, . . . , n, t = 1, . . . ,mi, computed by a logistic-GEE model.
The output of the algorithm is the GRA induced by the probabilities piit with respect to
the instances (xit, yit).
The algorithm consists of two parts: an initialization part (steps 1-23) and a compu-
tation part (steps 24-43). During the initialization a list L of outcome-probability tuples
is set to empty. The algorithm scans sequentially the clusters and the probability vectors
to add all the outcome-probability tuples 〈yit, piit〉 to the list L. When the list L is being
handled, the statistics imposed by the outcomes yit are being computed: the numbers m+i
and m−i of the positive and negative instances for each cluster i and the total number m
−
of negative instances. These numbers are used to calculate the numberDi for each cluster
i (see formula (5.2)) and total number D (see formula (5.3)).
The algorithm completes the initialization by setting statistics related to the ordering
imposed by probabilities piit. For each cluster i it sets two statistics: (1) the number Ci
(see formula (5.5)), and (2) a counter Hi that represents the number of negative instances
in cluster i that can be potentially paired with positive instances from any other cluster if
the probabilities associated with those outcomes do not exceed a certain probability. The
number Ci receives initially a value of 0 and the counter Hi receives the value of m−i .
Once the counters Hi are determined, i = 1, . . . , n, the algorithm computes their sum H
(initially set equal to m−).
The computation part starts with sorting the list L. The list is sorted on three levels.
First, the list is sorted in a decreasing order of probability values piit. If they are ties,
the outcome-probability tuples with the same probability piit are sorted in an increasing
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order of the cluster number. Again, if they are ties, the outcome-probability tuples with
the same cluster number i are sorted in a decreasing order of the outcomes yit.
Once the listL is sorted, the algorithm sequentially scansL to compute the numberCj
(see formula (5.5)) for each cluster j. For any distinctive probability piit, in the decreasing
order provided in L, the number Cj receives an update equal to:
Pj(H −Hj)− Pj(Q−Qj)
2
, (5.8)
where,
• Q is the number of negative instances whose probabilities piks equal to piit;
• Pj is the number of positive outcomes from cluster j whose probabilities pijs equal
to piit;
• Qj is the number of negative outcomes from cluster j whose probabilities pijs equal
to piit.
The term Pj(H −Hj) in the expression (5.8) is the total number of positive-negative
pairs that can be formed by positive outcomes from cluster j whose probabilities pijs
equal to piit and negative outcomes from other clusters with probabilities less than or
equal to piit. The term Pj(Q−Qj) in the expression (5.8) is the total number of positive-
negative pairs that can be formed by positive outcomes from cluster j whose probabilities
pijs equal to piit and negative outcomes from other clusters with probabilities equal to piit.
We take only half of the term Pj(Q−Qj), since in this case, the probability of properly
ranking the outcomes is 12 . Thus, the expression (5.8) represents an update for forming
the number Cj when we aim at estimating an averaged GRA.
Once all the numbers Ci are computed, the algorithm computes number C (see for-
mula (5.6)) and then outputs the GRA (see formula (5.7)).
The algorithm for GRA is computationally efficient. Its space complexity is O(nm),
where n is the number of clusters and m is the size of the clusters. The time complex-
ity is O(nm log2(nm)). To derive the time complexity of the algorithm for GRA we
analyze the steps of the algorithm that involve sorting or search; i.e., the most compu-
tationally expensive steps. Step 24 executes sorting on three levels. On the first level
the time complexity is O(nm log2(nm))
3. On the second level the time complexity is
O(pnmp log2(
nm
p )) = O(nm log2(
nm
p )), where p is the number of distinctive probabilit-
ies piit. On the third level the time complexity isO(npnmnp log2(
nm
np )) = O(nm log2(
m
p )).
Thus, the time complexity of step 24 is O(nm log2(nm)) .
3We assume usage of efficient sorting algorithms like merge sort.
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Algorithm 1 Computing generalized ranking accuracy for models based on clustered data
Input: n clusters 〈xi,yi〉, i = 1, . . . , n.
vector pii of probabilities piit for each cluster 〈xi,yi〉, i = 1, . . . , n, t = 1, . . . ,mi.
Output: GRA induced by the probabilities piit with respect to instances (xit, yit).
1: Set list L equal to ∅
2: m− := 0
3: for i := 1 to n do
4: m−i := 0
5: for t := 1 tomi do
6: Access outcome yit and probability piit and add tuple 〈yit, piit〉 to the list L
7: if yit = 0 then
8: m−i := m
−
i + 1
9: end if
10: end for
11: m+i := mi −m−i
12: m− := m− +m−i
13: end for
14: D := 0
15: for i := 1 to n do
16: Di := m+i (m
− −m−i )
17: D := D +Di
18: end for
19: for i := 1 to n do
20: Ci := 0
21: Hi := m−i
22: end for
23: H = m−
24: Sort the list L according to the following priority order of tie-break rules: (i) decreasing probability piit, (ii) increasing
cluster number i, and (iii) decreasing outcome yit;
25: while L 6= ∅ do
26: Visit the first tuple 〈yit, piit〉 of the list L
27: Create a sublist Lpiit of the tuples 〈yks, piks〉 of the list L whose probabilities piks equal piit
28: SetQ equal to the number of the tuples 〈yks, piks〉 of the sublist Lpiit whose outcomes yks equal 0
29: for j := 1 to n do
30: Create a sublist Lpiit,j of the tuples 〈yjs, pijs〉 of the sublist Lpiit whose cluster numbers equal j
31: Set Pj equal to the number of the tuples 〈yjs, pijs〉 of the sublist Lpiit,j whose outcomes yjs equal 1
32: SetQj equal to the number of the tuples 〈yjs, pijs〉 of the sublist Lpiit,j whose outcomes yjs equal 0
33: Cj := Pj(H −Hj)− Pj(Q−Qj)2 + Cj
34: Hj := Hj −Qj
35: end for
36: Remove the tuples of sublist Lpiit from the list L
37: H := H −Q
38: end while
39: C := 0
40: for i := 1 to n do
41: C := C + Ci
42: end for
43: return CD
The steps 27, 28, 30, 31, and 32 perfom binary search due to the fact that the list
L is sorted on three levels. The time complexity of step 27 is O(p log2(nm)), the time
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complexity of step 284 isO(p(log2(nmp +n log2(
nm
pn ))) = O(p(log2(
nm
p +n log2(
m
p ))),
the time complexity of step 30 is O(pn log2(
nm
p )), and the time complexity of steps 31
and 32 is O(pn log2(
m
p )). Thus, the time complexity of the search steps is determined by
the sum of the time complexities of steps 27 to 30.
From the derivations provided above we observe that the time complexity of the sort-
ing step 24 prevails that of the search steps 27, 28, 30, 31, and 32 . Thus, we may conclude
that the time complexity of the algorithm for GRA is indeed O(nm log2(nm)).
5.2.3 Goodness-of-fit and Predictive Performance
The proposed GRA can be used both as a criterion of the model’s goodness-of-fit and
as a criterion of the model’s predictive performance. If a logistic-GEE model has been
trained and tested on the same data, then GRA acts as a goodness-of-fit criterion. In this
case GRA estimates how the logistic-GEE model fits the data when only combinations of
uncorrelated observations are taken into account.
If the GRA is computed on the test data (on which the model was not trained), then
the GRA acts as a predictive performance criterion for the model [100].
We note that the GRA, to the best of our knowledge, is the first criterion proposed for
usage to assess a logistic-GEE model’s predictive performance. There are several methods
for computing the GRA as a predictive performance criterion, such as by combining it
with the hold-out method, k-fold cross-validation, etc. In this thesis we employ the k-fold
cross-validation method due to its relatively lower variance of the resulting estimates [15].
The k-fold cross-validation method for clustered data should be designed such that all the
instances belonging to one and the same cluster, are either all in the test set or all in the
training set. This avoids training and testing with correlated data. This method operates
as follows. First, the data is split randomly into k disjoint sets (folders) of clusters. Then,
for each of the k − 1 folders we train a logistic-GEE model (or any of the model trained
on clustered data), and test this model on the remaining folder. For each test instance we
estimate the probability piit from the model according to Eqn. (2.9) and in this way we
form the vector pii. When this vector has been formed for all the clusters we can run the
algorithm for GRA. The GRA computed using the cross-validation method we denote as
GRA-CV.
We note that the extreme version of the k-fold cross-validation method is cluster-out
cross-validation when each fold contains a single cluster and k equals the number of
clusters.
4Note that step 28 involves double binary search.
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5.3 Simulation study
To evaluate various aspects of the usefulness of GRA, in this section we carry out a simu-
lation study to assess GRA as a goodness-of-fit criterion and as a model-selection criterion
for logistic-GEE models. We do this through the following comparisons and evaluations.
We first compare GRA with a Kappa-like classification statistic [142] as goodness-of-fit
criterion in the presence of two-class imbalanced and balanced data. Then we compare
GRA and QICu [49]. As model selection criteria, we study both criteria as a function of
logistic-GEE model complexity and we compare them in the context of model selection.
Finally, we assess and compare GRA and the conventional RA.
5.3.1 Data generation
The first step of our simulation study is to generate a data set. Below we explain how
to generate a data set that contains n clusters of sizes mi, i = 1, . . . , n, with correlated
binary outcomes. Assume the ith subject is represented by a cluster of mi observations
such that the tth observation, t = 1, . . . ,mi is given with p covariates Xit1, . . . , Xitp in
R and a binary outcome variable Yit. We generate the pth covariate for the ith subject
X
(p)
i = (Xi1p, . . . , Ximip) from a known distribution. Then we assume that the marginal
model generating the data is given by:
log
(
piit
1− piit
)
= β0 + βXit , i = 1, . . . , n, t = 1, . . . ,mi, (5.9)
where Xit = (Xit1, . . . , Xitp)′, piit = E(Yit|xit) = Pr(Yit = 1|xit), i = 1, . . . , n,
t = 1, . . . ,mi, β0 is the population averaged intercept term and β = (β1, . . . , βp) is the
vector of population averaged coefficients.
Here, we would like to generate outcomes Yit in {0 , 1} with probability piit, i =
1, . . . , n, t = 1, . . . ,mi, for the outcome 1. However, within each cluster i we also want
to achieve a specified correlation (with zero correlation between different clusters).
Now, assume that corr(Yit, Yih) = ηth, 1 ≤ t, h ≤ mi, t 6= h, where ηth is
given. Then we can generate binary outcomes Yi1, . . . , Yimi with this specified cor-
relation structure using the approach proposed in [30] considering the constraint that
max(−√(piitpiih/qitqih),−√(qitqih/piitpiih))< ηth <min(√(piitqih/qitpiih),√(qitpiih/piitqih)),
where qks = 1−piks. We used the R package “SimCorMultRes” [132] to implement this.
5.3.2 GRA versus Kappa-like Classification Statistic
In this subsection we present a comparison of the GRA with a Kappa-like classification
statistic (proposed by Williamson et al. [142]) as goodness-of-fit criteria for a logistic-
GEE model trained on simulated data.
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We generated data sets with n = 25, 50, 75, 100, 500, 1000 clusters and cluster sizes
m = 2, 5, 10, 20 with exchangeable correlation structure (correlation equal to 0.3). For
a given n and m we used the model in Eqn. (5.9) with two covariates where each is
distributed as uniform(0,1) (using R package “SimCorMultRes”).
In order to having two-class imbalanced data, we chose the regression coefficients
β0 = 0, β1 = 1 and β2 = −10, which led to data sets with a proportion of positive
instances between 8% and 12%.
After fitting the logistic-GEE model we obtained GRA and Kappa-like values to eval-
uate the goodness-of-fit of model. This process was replicated 1000 times and Table 5.1
presents the averages of GRA and Kappa-like values.
We repeated this process in the presence of two-class balanced data sets with a pro-
portion of positive instances between 46% to 54% by choosing β1 = 10 and β2 = −10.
The results are given in Table 5.2.
The results in Table 5.1 indicate that, in the case of two-class imbalanced data, after
fitting the correct logistic-GEE models, GRA indicates an excellent fit of the models.
Instead, the Kappa-like statistic indicates either a poor or a fair fit of the models (based
on Landis and Koch’s labeling of the Kappa-like statistic interpretation [70]). The results
in Table 5.2 indicate that in the case of two-class balanced data, the Kappa-like statistic,
just the same as GRA, then shows an excellent fit of the models.
m n=25 n=50 n=75 n=100 n=500 n=1000
2
GRA 0.96084 0.95992 0.95811 0.95939 0.95988 0.95936
Kappa-like 0.29808 0.25663 0.24101 0.23035 0.20785 0.20945
5
GRA 0.96038 0.95981 0.95950 0.95945 0.95971 0.95936
Kappa-like 0.24936 0.22345 0.22041 0.21179 0.21041 0.21228
10
GRA 0.95919 0.95963 0.95941 0.96020 0.95935 0.95947
Kappa-like 0.21885 0.21299 0.20544 0.20376 0.21016 0.21141
20
GRA 0.95985 0.95982 0.95948 0.95983 0.95947 0.95949
Kappa-like 0.21380 0.20625 0.20439 0.20729 0.210455 0.21232
Table 5.1: GRA and Kappa-like averaged values of 1000 replications when the proportion
of positive instances is between 8% and 12%.
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m n=25 n=50 n=75 n=100 n=500 n=1000
2
GRA 0.98267 0.98312 0.98250 0.98280 0.98297 0.98300
Kappa-like 0.70594 0.71279 0.71071 0.71185 0.71468 0.71475
5
GRA 0.98268 0.98262 0.98303 0.98305 0.98301 0.98299
Kappa-like 0.71041 0.71185 0.71293 0.71440 0.71474 0.71472
10
GRA 0.98322 0.98305 0.98304 0.98317 0.98299 0.98302
Kappa-like 0.71224 0.71364 0.71451 0.71438 0.714706 0.71496
20
GRA 0.98317 0.98301 0.98307 0.98299 0.98301 0.98307
Kappa-like 0.71284 0.71375 0.71424 0.71427 0.71481 0.71516
Table 5.2: GRA and Kappa-like averaged values of 1000 replications when the proportion
of positive instances is between 46% and 54%.
5.3.3 GRA versus QICu in terms of the logistic-GEE model complexity
In this subsection, using simulated data, we compare GRA with QICu in terms of the
logistic-GEE model complexity when we are adding covariates one by one into the model.
We generated a data set of binary outcomes containing 5000 clusters with cluster
sizes m equal to 10 with exchangeable correlation structure (correlation equal to 0.3). To
generate the data set we used the model in Eqn. (5.9) with ten covariates. We chose each
covariate to be distributed as uniform(0,1) and β0 = 0, β1 = 10, β2 = 9.5, β3 = 9,
β4 = 8.5 , β5 = 8, β6 = 7.5, β7 = 7, β8 = 6.5, β9 = 6 and β10 = 5.5. Then, we
fitted a logistic-GEE model as follows: we started with the intercept-only model and then
at each step we added one more covariate into the model (in decreasing order of their
magnitudes of regression coefficients) and computed the GRA and QICu (using the R
package “MuMIn”) of the model. We obtained the relative improvement of each criterion
at each step as: the difference (increase for GRA and decrease for QICu) between the
value of the criterion in the previous step and the current step, divided by its value in the
previous step.
Figures 5.1a and 5.1b present the GRAs and QICus of the model with different num-
bers of covariates when adding covariates one by one into the model. The QICu and GRA
improve (decrease and increase) by increasing the number of covariates in the model as
we expected. However, they are very different in terms of their percentages of improve-
ment at each step. We expected that at the early steps (especially at the first step) when
we add covariates with larger effects (bigger coefficients) into the model we get higher
percentages of goodness-of-fit improvement compared to those covariates we are adding
in the last steps. Figures 5.1c and 5.1d illustrate the percentages of improvement in QICu
and GRA by adding covariates one by one into the model, respectively. From Figure 5.1d
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we observe that entering the first covariate improves the model’s GRA the most, by 49%,
whereas the model’s QICu improved only by 13% which is smaller than the percentage
of improvement in each of the next eight steps.
The model’s GRA reaches 0.97 when there are six covariates in the model and then
adding four more covariates improves the GRA with less than 2%, at each step. Contrary
to what is expected, percentages of improvement in QICu are increasing up to the seventh
covariate and only the last two covariates improve the model’s QICu less than 13% (less
that the first covariate).
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Figure 5.1: The QICu and GRA as functions of logistic-GEE model complexity.
These results show that unlike GRA, QICu does not exhibit monotonous relative im-
provements when adding covariates one by one in the logistic-GEE model. For smaller
contributions to explaining variation in the outcomes (i.e., for smaller values of the re-
gression coefficients) the relative change in QICu may be larger, but not for GRA.
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5.3.4 Comparing GRA-CV with QICu as a Model-Selection Criterion
The selection of the best subset of covariates maximizing the performance of the model
is known as the model selection problem. In this subsection we compare GRA-CV (using
cluster-out cross-validation) with QICu as the model-selection criterion, when we apply
a forward (greedy) model selection process. The forward-selection technique begins with
no covariate in the model. As the first step for every covariate we set a univariate model
and obtain the GRA-CV and QICu of each model. The first model includes the covariate
with the highest model’s GRA-CV (the lowest QICu, in the case of using QICu as a
selecting criterion). At each following step, each covariate that is not already in the model
is tested for inclusion in the model by obtaining its GRA-CV (and QICu) and we then
include the covariate that best improves the criterion value.
In the simulation study we consider a number of different logistic-GEE models to
compare GRA-CV and QICu as greedy model selection criteria. Table 5.3 presents a
list of the models with different parameters that we evaluate. We study the following
situations:
(1) the covariates in the models are considerably different in their magnitude of effects
(magnitudes of coefficients), models 1-4;
(2) the data is two-class imbalanced data, models 5-8;
(3) the covariates in the models are slightly different in their magnitude of effects,
models 9-12;
Model Coefficients Correlation Positive instance proportion
1 β1 = 1, β2 = 2, β3 = −3 0.1 44% to 56%
2 β1 = 1, β2 = 2, β3 = −3 0.3 44% to 56%
3 β1 = 1, β2 = 2, β3 = −3 0.6 44% to 56%
4 β1 = 1, β2 = 2, β3 = −3 0.9 44% to 56%
5 β1 = 1, β2 = −2, β3 = −3 0.1 12% to 20%
6 β1 = 1, β2 = −2, β3 = −3 0.3 12% to 20%
7 β1 = 1, β2 = −2, β3 = −3 0.6 12% to 20%
8 β1 = 1, β2 = −2, β3 = −3 0.9 12% to 20%
9 β1 = 1, β2 = 1.3, β3 = −1.6 0.1 52% to 64%
10 β1 = 1, β2 = 1.3, β3 = −1.6 0.3 52% to 64%
11 β1 = 1, β2 = 1.3, β3 = −1.6 0.6 52% to 64%
12 β1 = 1, β2 = 1.3, β3 = −1.6 0.9 52% to 64%
Table 5.3: Simulation study factors for comparing GRA-CV and QICu as model selection
criteria.
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Model Criterion 321∗ 312 231 213 132 123
Model 1 QICu 1000 0 0 0 0 0GRA-CV 1000 0 0 0 0 0
Model 2 QICu 1000 0 0 0 0 0GRA-CV 1000 0 0 0 0 0
Model 3 QICu 1000 0 0 0 0 0GRA-CV 1000 0 0 0 0 0
Model 4 QICu 992 5 3 0 0 0GRA-CV 996 3 1 0 0 0
Model 5 QICu 1000 0 0 0 0 0GRA-CV 1000 0 0 0 0 0
Model 6 QICu 1000 0 0 0 0 0GRA-CV 1000 0 0 0 0 0
Model 7 QICu 994 3 3 0 0 0GRA-CV 994 3 3 0 0 0
Model 8 QICu 935 31 34 0 0 0GRA-CV 941 31 28 0 0 0
Model 9 QICu 962 18 20 0 0 0GRA-CV 959 21 20 0 0 0
Model 10 QICu 907 39 54 0 0 0GRA-CV 904 41 55 0 0 0
Model 11 QICu 752 120 120 4 3 1GRA-CV 758 117 117 4 3 1
Model 12 QICu 575 184 193 20 17 11GRA-CV 583 183 189 16 20 9
Table 5.4: Frequencies of different permutations of covariates X1, X2, X3 selected by
GRA-CV versus QICu using forward selection method for 1000 replications. The true
order is {X3, X2, X1}.
∗ijk: the set of covariates in the order {Xi, Xj , Xk}.
For each model, we generated a data set with n = 500 clusters with cluster size
m = 10 with exchangeable correlation structure using the model in Eqn. (5.9) where
each covariate within a cluster is distributed as uniform(0,1). Then we started two forward
selection processes: one using GRA-CV (based on cluster-out cross-validation) and one
using QICu as a model selection criterion. We replicated this process 1000 times by
generating 1000 independent data sets. Frequencies of the sets of covariates (in different
orders) selected by GRA-CV versus QICu for each model are presented in Table 5.4.
Results in Table 5.4 show that both QICu and GRA-CV perform well in selection of
the covariates in the right order, when the covariates in the models are considerably dif-
ferent in their magnitude of effects. However, in case of two-class imbalanced data QICu
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and GRA-CV in 93.5% and 94.1% of replications, respectively, select the covariates in the
right order when the within-cluster correlation equals to 0.9. That is, even for two-class
imbalanced data, both QICu and GRA-CV perform the same when the covariates in the
models are considerably different in their magnitude of effects. But when there is a high
within-cluster correlation, GRA-CV performs slightly better than QICu. For balanced
data, when the covariates in the models are only slightly different in their magnitude of
effects and the correlation is 0.1, both criteria select the covariates in the right order in
almost 96% of replications which decreases to 57.5% and 58.3%, respectively for QICu
and GRA-CV, when correlation increases to 0.9. In general in Table 5.4 we observe that
GRA-CV may perform better in some cases when there is a high correlation (equal to
0.6 or 0.9) within clusters. We note that GRA-CV uses less data than QICu due to its
cross-validation nature, but still has comparable or even better results.
5.3.5 Comparing GRA with RA
As mentioned in Section 5.1, RA is not suggested for use as a goodness-of-fit criterion for
logistic-GEE models, because the instances from which the model is built are assumed
to be correlated (with unknown correlations) within clusters. However, if there are no
within-cluster correlations, RA coincides with the Area Under the ROC Curve (AUC) [3]
and we may take advantage of having a ROC curve.
In this section we consider different scenarios to assess the magnitude of difference
between RA and GRA using simulated data. We assess this difference in terms of different
factors, such as: the magnitude of correlation, the number of clusters and cluster sizes,
and presence of two-class imbalanced data.
We generated data similar to the procedure described in the previous subsections us-
ing the model in Eqn. (5.9) with two covariates and exchangeable correlation structure.
For each experiment we generated 1000 data sets and obtained the average and standard
deviation (SD) of the RAs and GRAs.
Tables 5.5-5.8 present the averages of RAs and GRAs and their SDs assuming differ-
ent magnitudes of correlation, numbers of clusters, and cluster sizes. Results in Tables
5.5-5.8 indicate that on average there are negligible differences between GRAs and RAs.
We investigated the situations in which there are data sets with a small number of clusters
of large sizes, see the results in Table 5.9. The results show that RA may be slightly
overoptimistic compared to GRA. We in addition assessed the magnitude of the differ-
ences between RA and GRA in the case of two-class imbalanced data; see the results in
Table 5.10. The results show that on average GRAs and RAs are almost the same.
In general, the results in Tables 5.5-5.10 indicate that, considering the data sets with
different specifications, on average the differences between GRAs and RAs are very
small. Therefore, in practice (depending on sensitivity of the analysis) one may opt to
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m n=50 n=100 n=200 n=500 n=1000
2
GRA 0.943201 0.942800 0.943364 0.943092 0.943041(0.020808) (0.014367) (0.009875) (0.006572) (0.004476)
RA 0.943201 0.942805 0.943368 0.943093 0.943042(0.020783) (0.014363) (0.009875) (0.006572) (0.004476)
5
GRA 0.942842 0.944597 0.943178 0.943035 0.943204(0.013212) (0.010329) (0.006479) (0.004070) (0.002909)
RA 0.942860 0.944619 0.943185 0.943037 0.943205(0.013200) (0.010328) (0.006478) (0.004069) (0.002909)
10
GRA 0.943698 0.943135 0.943330 0.943210 0.943038(0.009092) (0.006513) (0.004650) (0.002819) (0.002060)
RA 0.943724 0.943149 0.943330 0.943213 0.943039(0.009085) (0.006509) (0.004651) (0.002819) (0.002060)
20
GRA 0.942931 0.943312 0.943097 0.943220 0.943125(0.006475) (0.004775) (0.003274) (0.002088) (0.001479)
RA 0.942958 0.943326 0.943104 0.943213 0.943126(0.006463) (0.004771) (0.003273) (0.002088) (0.001478)
Table 5.5: Average and SD (within parentheses) of GRAs and RAs of 1000 replications
when β0 = 0, β1 = 5, β2 = −5, correlation equal to 0.1 and the proportion of positive
instances is between 46% to 54%.
m n=50 n=100 n=200 n=500 n=1000
2
GRA 0.943327 0.942997 0.9433297 0.942989 0.942881(0.021569) (0.014893) (0.010358) (0.006585) (0.004600)
RA 0.943349 0.943020 0.943334 0.942992 0.942883(0.021532) (0.014881) (0.010355) (0.006584) (0.004599)
5
GRA 0.943421 0.943257 0.943051 0.943233 0.943027(0.013518) (0.009688) (0.006843) (0.004343) (0.003107)
RA 0.943467 0.943287 0.943064 0.943238 0.943029(0.013468) (0.009672) (0.006839) (0.004342) (0.003106)
10
GRA 0.943039 0.943384 0.943284 0.943165 0.943166(0.010293) (0.007164) (0.005059) (0.003198) (0.002210)
RA 0.943102 0.943413 0.943299 0.943171 0.943169(0.010254) (0.007149) (0.005054) (0.003197) (0.002209)
20
GRA 0.942728 0.943074 0.943108 0.943197 0.943083(0.007995) (0.005674) (0.003765) (0.002540) (0.001748)
RA 0.942798 0.943105 0.943123 0.943203 0.943086(0.007942) (0.005657) (0.003759) (0.002538) (0.001747)
Table 5.6: Average and SD (within parentheses) of GRAs and RAs of 1000 replications
when β0 = 0, β1 = 5, β2 = −5, correlation equal to 0.3 and the proportion of positive
instances is between 46% to 54%.
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m n=50 n=100 n=200 n=500 n=1000
2
GRA 0.942864 0.943243 0.943305 0.943190 0.943053(0.022794) (0.015729) (0.010975) (0.006960) (0.004806)
RA 0.942896 0.943263 0.943316 0.943193 0.943055(0.022737) (0.015712) (0.010966) (0.006959) (0.004805)
5
GRA 0.944019 0.943109 0.94311 0.942940 0.943001(0.015669) (0.010871) (0.008049) (0.004926) (0.003496)
RA 0.944095 0.943142 0.943125 0.942947 0.943004(0.015585) (0.010839) (0.008038) (0.004923) (0.003495)
10
GRA 0.943510 0.943314 0.942942 0.943101 0.943222(0.013632) (0.009353) (0.006776) (0.004212) (0.002898)
RA 0.943582 0.943351 0.942960 0.943107 0.943226(0.0135347) (0.0093223) (0.006764) (0.0042096) (0.0028972)
20
GRA 0.943122 0.943419 0.943173 0.943025 0.943243(0.011472) (0.008268) (0.005856) (0.003810) (0.002539)
RA 0.943210 0.943456 0.943191 0.943033 0.943246(0.011371) (0.008234) (0.005843) (0.003807) (0.002538)
Table 5.7: Average and SD (within parentheses) of GRAs and RAs of 1000 replications
when β0 = 0, β1 = 5, β2 = −5, correlation equal to 0.6 and the proportion of positive
instances is between 46% to 54%.
m n=50 n=100 n=200 n=500 n=1000
2
GRA 0.943366 0.943117 0.943263 0.943358 0.943301(0.024965) (0.018496) (0.012602) (0.007858) (0.005429)
RA 0.943396 0.943132 0.943269 0.943360 0.943302(0.024903) (0.018476) (0.012596) (0.007856) (0.005428)
5
GRA 0.942375 0.943501 0.943490 0.943117 0.943506(0.022207) (0.014922) (0.010560) (0.006467) (0.004491)
RA 0.942432 0.943519 0.943499 0.943121 0.943508(0.022108) (0.014891) (0.010549) (0.006464) (0.004491)
10
GRA 0.942856 0.942854 0.943654 0.943189 0.942946(0.021065) (0.013952) (0.009940) (0.006384) (0.004429)
RA 0.942906 0.942878 0.943665 0.943193 0.942948(0.020963) (0.013916) (0.009929) (0.006382) (0.004428)
20
GRA 0.942088 0.942866 0.943188 0.9433976 0.943319(0.020537) (0.014036) (0.009712) (0.006272) (0.004374)
RA 0.942147 0.942893 0.943199 0.943401 0.943321(0.020423) (0.013995) (0.009700) (0.006268) (0.004373)
Table 5.8: Average and SD (within parentheses) of GRAs and RAs of 1000 replications
when β0 = 0, β1 = 5, β2 = −5, correlation equal to 0.9 and the proportion of positive
instances is between 46% to 54%.
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m n=2 n=5 n=10 n=20
20
GRA 0.939558 0.943114 0.943596 0.942949(0.049858) (0.021458) (0.017361) (0.012947)
RA 0.944343 0.9440347 0.943955 0.943145(0.037969) (0.019281) (0.016848) (0.012724)
50
GRA 0.941605 0.942511 0.942575 0.943071(0.039075) (0.027787) (0.014080) (0.009868)
RA 0.944812 0.9436875 0.942979 0.943241(0.028668) (0.025688) (0.013421) (0.009651)
100
GRA 0.941950 0.942400 0.942654 0.943342(0.032201) (0.018271) (0.012602) (0.008886)
RA 0.945108 0.943253 0.943059 0.943511(0.022387) (0.016141) (0.011890) (0.008633)
200
GRA 0.942829 0.943135 0.942741 0.943059(0.031309) (0.017648) (0.011756) (0.007943)
RA 0.946077 0.943960 0.943128 0.943232(0.020400) (0.015379) (0.011024) (0.007692)
Table 5.9: Average and SD (within parentheses) of GRAs and RAs of 1000 replications
when β0 = 0, β1 = 5, β2 = −5, correlation equal to 0.3 and the proportion of positive
instances is between 46% to 54%. In these experiments we have relatively few clusters,
which however are relatively large.
m n=50 n=100 n=200 n=500 n=1000
2
GRA 0.909811 0.908838 0.908888 0.908514 0.908642(0.037325) (0.025555) (0.017677) (0.011278) (0.007962)
RA 0.909665 0.908776 0.908848 0.908501 0.908634(0.037336) (0.025551) (0.017672) (0.011277) (0.007962)
5
GRA 0.909582 0.908738 0.908176 0.908436 0.908545(0.023585) (0.016895) (0.011802) (0.007756) (0.005533)
RA 0.909374 0.908636 0.908119 0.908415 0.908534(0.023526) (0.016872) (0.011796) (0.007754) (0.005532)
10
GRA 0.908877 0.908615 0.908818 0.908525 0.908371(0.018811) (0.012508) (0.008933) (0.005672) (0.004061)
RA 0.908658 0.908484 0.908756 0.908501 0.908358(0.018736) (0.012484) (0.008926) (0.005670) (0.004060)
20
GRA 0.908788 0.908388 0.908255 0.908516 0.908444(0.011738) (0.009589) (0.006995) (0.004506) (0.003080)
RA 0.908687 0.908263 0.908191 0.908491 0.908431(0.011729) (0.009565) (0.006986) (0.004503) (0.003079)
Table 5.10: Average and SD (within parentheses) of GRAs and RAs of 1000 replications
when β0 = 0, β1 = 0.5, β2 = −5, correlation equal to 0.3 and the proportion of positive
instances is between 8% to 12%. In these experiments we have unbalanced data.
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neglect this difference and use RA instead of GRA and take advantage of having a ROC
curve.
5.4 Application to the TIME-CHF Study
In this section, we present an example in order to evaluate GRA-CV as a model-selection
criterion using the TIME-CHF data when the method of validation is cluster-out cross-
validation. The design of the TIME-CHF study is described in detail in Section 2.1. The
analysis in this section includes 499 patients aged 60 years or older with Hearth Fail-
ure (HF), Left Ventricular Ejection Fraction (LVEF)≤45%, New York Heart Association
functional classification (NYHA)≥II.
Six biomarkers are included in this experiment: Prealbumin (PREA), Soluble ST2
(SST2), Interleukin-6 (IL6), High Sensitivity C-Reactive Protein (HSCRP), Growth Dif-
ferentiation Factor 15 (GDF15), Soluble FMS-Like Tyrosine kinase-1 (SFLT). The bio-
markers, systolic Blood Pressure (BPsyst) and Rales were measured at every visit and
dosages of the Heart Failure medication Loop (Loop diuretics) were available on a daily
basis. In addition to Loop, biomarkers, BPsyst and Rales (1=abnormal lung sounds,
0=normal lung sounds) as time dependent covariates we used eight fixed covariates that
were measured only at the baseline: Age, Gender (1=male, 0=female), Coronary Artery
Disease (CAD), LVEF, Kidney-disease, Diabetes, Anemia, and Charlsonscore (Charlson
comorbidity score), where CAD, Kidney-disease, Diabetes, and Anemia are binary vari-
ables that indicate whether a patient is suffering from these diseases or not (1=yes, 0=no).
We defined a binary outcome variable with a value of one if a given patient was hos-
pitalized for HF or died during a given time interval of one month; otherwise the value
was zero. The follow-up period was nineteen months. Note that the outcome values for a
given patient can change from one time interval to another and are likely to be correlated.
Therefore, the logistic-GEE model is a suitable model for this study.
For this analysis, we gave more weight to the outcome death (two times of HF hospit-
alization) when applying the weighted logistic-GEE model [105]. For patients who either
died or withdrew from the study before nineteen months, the number of outcome values
equals the number of follow-up months. In order to apply the weighted logistic-GEE
model, we also included the covariate values at the same time resolution as the outcomes.
Therefore, we converted the covariate values into monthly base variables as follows, see
Table 5.11.
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Patient ID HF Hospitalization Time point Medication Biomarkers and Fixed
or death in the next month time dependent covariates covariates
1 0 M0 M0 M0 M0
1 1 M1 Avg(M0, M1) M1 M0
1 0 M2 Avg(M1, M2) M1 M0
1 0 M3 Avg(M2, M3) M3 M0
1 1 M4 Avg(M3, M4) M3 M0
1 0 M5 Avg(M4, M5) M3 M0
1 1 M6 Avg(M5, M6) M6 M0
2 1 M0 M0 M0 M0
2 0 M1 Avg(M0, M1) M1 M0
2 0 M2 Avg(M1, M2) M1 M0
2 1 M3 Avg(M2, M3) M3 M0
2 1 M4 Avg(M3, M4) M3 M0
2 1 M5 Avg(M4, M5) M3 M0
...
...
...
...
...
...
499 1 M0 M0 M0 M0
499 1 M1 Avg(M0, M1) M1 M0
499 0 M2 Avg(M1, M2) M1 M0
499 1 M3 Avg(M2, M3) M3 M0
499 0 M4 Avg(M3, M4) M3 M0
499 0 M5 Avg(M4, M5) M3 M0
499 0 M6 Avg(M5, M6) M6 M0
499 0 M7 Avg(M6, M7) M6 M0
499 0 M8 Avg(M7, M8) M6 M0
499 0 M9 Avg(M8, M9) M6 M0
499 0 M10 Avg(M9, M10) M6 M0
499 0 M11 Avg(M10, M11) M6 M0
499 0 M12 Avg(M11, M12) M12 M0
499 0 M13 Avg(M12, M13) M12 M0
499 0 M14 Avg(M13, M14) M12 M0
499 0 M15 Avg(M14, M15) M12 M0
499 0 M16 Avg(M15, M16) M12 M0
499 0 M17 Avg(M16, M17) M12 M0
499 0 M18 Avg(M17, M18) M18 M0
Table 5.11: Layout of dataset for applying logistic-GEE models. Mi: month i;M0: baseline; Avg:
average.
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Step GRA-CV-Covariates† GRA-CV QICu QICu-Covariates‡
0 No covariate 0.5 1917.965 No covariate
1 GDF15 0.738816 1753.5338 GDF15
2 SST2 0.767409 1691.7556 SST2
3 CAD 0.775987 1660.4315 Loop
4 Loop 0.784891 1649.2790 CAD
5 HSCRP 0.790796 1645.5022 BPsyst
6 Age 0.794360 1639.8644 Age
7 BPsyst 0.795732 1635.7392 HSCRP
8 Rales 0.796831 1635.2799 Rales
9 Gender 0.796649 1636.1769 SFLT
10 SFLT 0.796255 1636.2276 Anemia
11 Diabetes 0.795786 1638.1868 Gender
12 LVEF 0.794863 1640.6347 IL6
13 PREA 0.793678 1643.1331 PREA
14 Charlsonscore 0.792385 1645.8925 Diabetes
15 IL6 0.791043 1648.6419 LVEF
16 Kidney-disease 0.789549 1651.4346 Kidney-disease
17 Anemia 0.787360 1654.2852 Charlsonscore
Table 5.12: Selected covariates at each step of forward model-selection method.
† Selected covariates at each step using GRA-CV (with one-cluster-out cross-validation)
as a model-selection criterion.
‡ Selected covariates at each step using QICu as a model-selection criterion.
The bolded covariates are those that are selected.
The medication covariate Loop was down-sampled to monthly values by taking the
average drug dosage during the previous month. As the first observation of drug dosage,
in the absence of a previous month, the dosage at baseline was used. The biomarkers,
BPsyst and Rales were measured at the scheduled follow-up visits (baseline,1st, 3rd, 6th,
12th and 18th months). To get the monthly values between these six visits, we used the
last observation carried forward method (LOCF) [144] and put the value of the previous
visit. For other fixed covariates we used the baseline value at every time interval. The
data layout is further illustrated in Table 5.11.
In this setup we applied the forward model-selection method, using either only GRA-
CV or only QICu as a model-selection criterion to find the best subset of covariates
through a weighted logistic-GEE model. As explained in Section 5.3.4 the forward model-
selection method begins with no covariate in the model. At each step, each covariate is
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tested for inclusion in the model by obtaining the GRA-CVs (and QICus) and we included
the covariate that best increased (decreased) GRA-CV (QICu).
Table 5.12 shows the selected covariates for weighted logistic-GEE at each step, sep-
arately when, we apply GRA-CV and QICu as the model-selection criteria. We observe
from Table 5.12 that GRA-CV increases in the first eight steps, QICu decreases, and after
that no covariate inclusion further improves GRA-CV (and QICu). Using both criteria
leads to the same selected subset of covariates, (GDF15, SST2, CAD, Loop, HSCRP,
Age, BPsyst and Rales), however, the selected subsets were obtained in slightly different
orders for each criterion.
5.5 Conclusion
In this chapter we proposed GRA as a new measure for assessing the goodness-of-fit as
well as the predictive performance of logistic-GEE models. GRA was defined as the prob-
ability that a randomly selected instance with positive outcome is ranked higher than a
randomly selected instance with negative outcome from another cluster. There are several
advantages with GRA compared with other standard goodness-of-fit criteria for logistic-
GEE models: (a) there is no restriction in the computation of GRA regarding the number
and types of covariates in the model, unlike the goodness-of-fit test and statistic proposed
by Barnhart and Williamson [13] and Pan [98]; (b) in Section 5.3.2 a simulation study
showed that GRA is not biased in the presence of two-class imbalanced data, whereas
by contrast the Kappa-like statistic tends to indicate a poor fit of the model; (c) GRA
is a probability that is fairly easy to interpret, unlike the Kappa-like statistic and QICu;
(d) in contrast with QICu as a widely used goodness-of-fit and model-selection criterion
for GEE models, GRA has an absolute range and can therefore be used for comparing the
goodness-of-fit of different logistic-GEE models for different data sets; (e) by using cross-
validation, GRA-CV can be used as a predictive performance criterion for logistic-GEE
models.
In a simulation study, we also compared the behavior of GRA with QICu as a function
of logistic-GEE model complexity. The results showed that unlike GRA, QICu does not
perfectly reflect model improvements when adding covariates one by one into the logistic-
GEE model. As a model-selection criterion, both QICu and GRA-CV (with cluster-out
cross-validation) performed well in selecting of the covariates in the right order, when the
covariates are considerably different in their magnitude of effects, even in case of two-
class imbalanced data. In models for which the covariates are only slightly different in
their magnitude of effects, GRA-CV performed better than QICu when the within-cluster
correlation was high (equal to 0.6 and 0.9). In general GRA-CV had comparable results
or even better results than QICu, although GRA-CV uses cross-validation, which reduces
possibilities for overfitting.
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The simulation study also showed that considering effects of the magnitude of cor-
relation, the number of clusters, size of clusters, and the proportion of positive instances,
on average the obtained GRAs and RAs are almost the same. Therefore, in practice re-
searchers may opt to use RA instead of GRA and take advantage of having a ROC curve
and using available software packages for calculating the RA.
Note that, in this chapter, in our simulation study we only studied limited values for
the parameters and other factors to assess the performances of GRA and GRA-CV. This
implies that our findings are to be regarded as preliminary, but promising. It therefore
could be interesting to extend the simulation study considering other values for the size
of the data, cluster sizes, magnitude and type of within-cluster correlation, regression
coefficients and using different type of cross-validation to evaluate GRA and GRA-CV
more precisely.
Finally, we note that although GRA has been initially designed for logistic-GEE mod-
els, it is applicable to any model for bipartite ranking trained on clustered data. This is due
to the fact that GRA employs the model’s probabilities and data labels; i.e., it only uses
a score but it does not use any internal information from the model being tested. Thus,
we conclude that GRA is applicable as a general measure for models for bipartite ranking
trained on clustered data.
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ABSTRACT
Background: It is uncertain whether repeated measurements of biomarkers may help to
optimize medical HF therapy in order to improve outcome in chronic heart failure (HF).
Methods and Results: This analysis included 499 patients from the Trial of Intensi-
fied versus Standard Medical Therapy in Elderly Patients with Congestive Heart Fail-
ure (TIME-CHF), aged ≥60 years, LVEF≤45%, NYHA≥II who had repeated clinical
visits within 19 months follow-up. The interaction between repeated measurements of
biomarkers and treatment effects of loop diuretics, spironolactone, β-blockers and Renin-
Angiotensin-System (RAS) blockers on risk of HF hospitalization or death was invest-
igated, in a hypothesis generating analysis. Generalized Estimating Equations (GEE)
methods were used to account for the correlation between recurrences of events in a pa-
tient.
Results: One hundred patients (20%) had just one event (HF hospitalization or death)
and 87 (17.4%) had at least two events. Loop diuretics up-titration had a beneficial ef-
fect for patients with high Interleukin-6 (IL6) or high High-Sensitivity C-Reactive Protein
(HSCRP) (interaction, P=0.013 and P=0.001), whereas the opposite was the case with low
HSCRP (interaction, P=0.013). Higher dosage of loop diuretics was associated with poor
outcome in patients with high Blood Urea Nitrogen (BUN) or prealbumin (interaction,
P=0.006 and P=0.001), but not in those with low levels of these biomarkers. Spironolac-
tone up-titration was associated with lower risk of HF hospitalization or death in patients
with high Cystatin C (CysC)(interaction, P=0.021). β-blockers up-titration might have a
beneficial effect in patients with low Soluble Fms-Like Tyrosine kinase-1 SFLT (interac-
tion, P=0.021). No treatment biomarker interactions were found for RAS blockers.
Conclusion: The data of this post hoc analysis suggest that repeated measurements of
biomarkers might be used to tailor HF treatment individually. Clearly, prospective testing
is needed before this novel concept can be adopted.
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6.1 Introduction
Medical therapy for chronic heart failure (HF) with reduced Ejection Fraction (HFrEF)
has evolved greatly over the past decades [88]. Several medication classes - i.e. Renin-
Angiotensin System (RAS) blockers encompassing Angiotensin-Converting-Enzyme (ACE)-
inhibitors and Angiotensin-Receptor Blockers (ARBs), β-blockers and Mineralocorticoid
Receptor Antagonists (MRAs) - have been shown to improve prognosis in HFrEF and are
therefore recommended in high doses by current guidelines [103, 145]. In addition, (loop)
diuretics are recommended for decongestion to relieve symptoms [103, 145]. However, in
clinical practice, it is often difficult to implement all medication classes and especially to
reach guideline recommended dosages, especially in elderly and comorbid patients [78].
N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) is widely used and accepted
as diagnostic and prognostic biomarker in HF [133]. The level of NT-proBNP is changing
as response to therapy [60, 125]. Therefore, it was suggested as a tool to tailor and
intensify medical HF therapy.
Several trials and meta-analyses suggest that performing repeated measurements of
(NT-pro)BNP may help to establish guideline recommended medical therapy in HFrEF
patients to improve outcome [65, 96]. However, the large GUIDE-IT trial [35] that aimed
to prove this concept in a sufficiently large patient population was stopped early due to
futility [1]. Moreover, guiding HF therapy by a single marker is limited because one
biomarker cannot cover the extensive pathophysiological pathways involved in HF. In
fact, the approach to guide therapy using (NT-pro)BNP is based on the idea that patients
at highest risk of poor outcome are in need of intensified therapy, but there is no specific
tailoring of individual drugs.
Since different medication classes in HF interfere with different pathways, a combin-
ation of biomarkers that reflect these pathways may be better suited to indicate which
medication class is most important to up or possibly down-titrate in a specific patient.
That may lead towards precision medicine in HF. Such an attempt has, however, never
been made.
As a first step towards the development of a biomarker-guided treatment algorithm for
individually tailoring medical HFrEF therapy, we, therefore, investigated the interaction
between multiple repeatedly measured biomarkers and the response to the four most im-
portant classes of HF medication regarding the risk of HF hospitalization or death. Thus,
the main objective of the study, as a purely hypothesis generating study, was to explore
which biomarkers in repeated testing would be most predictive of the response to HF
drugs during follow-up.
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6.2 Methods
6.2.1 Study and Design
Since an important prerequisite to address the objective was the availability of detailed
data on patient characteristics at different time points, medication over time, and re-
peatedly measured multiple biomarkers, we used the database of the Trial of Intensified
vs. standard Medical therapy in Elderly patients congestive heart failure (TIME-CHF)
for this analysis. The study design and methods of the TIME-CHF have been described
in detail in Chapter 1. In brief, the study included 499 patients aged 60 years or older
with symptomatic HF, Left Ventricular Ejection Fraction (LVEF)≤45%, New York Heart
Association functional classification (NYHA)≥II, from 15 centers in Switzerland and
Germany.
After baseline assessment, patients were followed for 5 pre-specified compulsory vis-
its after 1, 3, 6, 12, and 18 months. For each patient, time to recurrence of clinical events
was recorded, up to 5.5 years. The primary endpoint for the present analysis was the
combined endpoint of HF hospitalization or death during the 18 months trial period plus
one month of additional follow-up, i.e. 19 months in total.
History was taken, patients were clinically investigated and blood samples were drawn
at every visit. Samples were stored at -80◦C until analysis. At the end of the trial, twenty
biomarkers were measured from these stored samples at all available visits. Selection
of biomarkers was based on the representation of different pathways that are known to
reflect important pathophysiological pathways as previously reported [120]. Daily med-
ication doses for all drugs including the four drug classes investigated in this analysis,
i.e. β-blockers, RAS blockers, spironolactone, and loop diuretics were available daily as
described [112].
The study was approved by the ethics committees of each center and each patient gave
written informed consent before entering the study.
6.2.2 Data Description
The study contains three types of covariates presented in Table 6.1:
Patient characteristics: Age, gender, coronary artery disease (CAD), Charlson co-morbidity
score, LVEF and history of kidney disease were recorded only at the baseline visit.
Systolic blood pressure (BPsyst) and rales on auscultation were recorded at every visit.
These 8 characteristics were used as covariates in the multivariable model in this chapter.
Biomarkers: The biomarkers in the TIME-CHF study were measured at every visit as
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we explained in Section 2.1. Table 2.2 illustrates all the biomarkers that were used in this
study.
HF medications: The four most important classes of HF medications were considered
for this analysis, i.e. β-blockers, RAS blockers, spironolactone, and loop diuretics were
recorded on a daily basis for each patient, as explained in Section 2.1.
Outcome measurements: For the present analysis any HF hospitalization or death oc-
curring at each month during the nineteen months follow-up were considered as outcome
events (primary endpoint).
6.2.3 Statistical methods
Patient characteristics, biomarkers at baseline and average medication dosages are presen-
ted as mean and standard deviation (SD) for continuous normally distributed variables,
median and interquartile range for non-normally distributed continuous variables, or as
numbers and percentages for categorical variables (Table 6.1). Variables were compared
between those patients without an event and those who experienced an event (i.e. HF hos-
pitalization or death) within nineteen months follow-up. Differences in these variables
per number of events (none vs. at least one) were assessed using a t-test for continuous
normally distributed variables, a Mann-Whitney U-test for non-normally distributed con-
tinuous variables, and a χ2-test for categorical variables. All tests were two-sided at a
5 percent level of significance. Calculations were performed with the use of the SPSS
statistical package version 22.0.
The main objective of the study was to explore which biomarkers are most predictive
for the response to HF drugs during the follow-up period. In order to achieve this, we
tested whether there was a significant interaction between biomarkers and further treat-
ment effects of the four medication classes in our cohort of HF patients, applying the
weighted logistic Generalized Estimating Equations (logistic-GEE) model [47, 147, 148].
Logistic-GEE model were applied using R (version 3.3.2, package ‘geepack’).
To this end, we defined a binary outcome variable with a value of one if a given patient
was hospitalized for HF or died during a certain time interval of follow up; otherwise the
value was zero. Note that the outcome values for a given patient can change from one
time interval to another and that these outcome values are likely to be correlated. For
this analysis, we discretized using time intervals of 1 month and gave more weight to
the outcome death (two times that of HF hospitalization) when applying the weighted
logistic-GEE model [105]. Giving a weight of three to the outcome death resulted in the
same findings as for a weight of two. For patients who either died or withdrew from the
study before nineteen months, the number of outcome values equals the number of follow
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up months. In order to apply the weighted logistic-GEE model, we also included the
covariate values at the same time resolution as the outcomes. Therefore, we converted the
covariate values into monthly base variables as explained in Section 5.4, see Table 5.11.
Figure 6.1: Method layout for assessing the interactions between biomarkers and medic-
ations. Mt: month t; M0: baseline.
LOCF: last observation carried forward method.
In order to test the interaction between a given biomarker (in logarithmic form) and
medication in the presence of other patient characteristics, we use the following weighted
logistic-GEE model:
logit(Pit) = b0 + b1Ageit + b2Genderit + b3CADit + b4CharlsonScoreit + b5LVEFit
+b6KidneyDiseaseit + b7Ralesit + b8BPsystit + b9Biomarkerit + b10Medicationit
+β Biomarkerit ×Medicationit, i = 1, ..., 499, t = 0, ..., 18,
(6.1)
where, Pit is the probability of hospitalization or death in the month following month t for
patient i and Covariateit is the value of the covariate at month t for patient i. Biomarker
×Medication indicates the interaction term and β is the interaction coefficient.
In order to investigate whether medications have a different effect on risk of HF hos-
pitalization or death for certain levels of the biomarkers, the interaction coefficient β was
tested for all possible paired combinations of medication classes and biomarkers. We
used GRA-CV using one-cluster-out cross-validation, see Chapter 5, to estimate the pre-
dictive performance of the models. In this study, only those logistic-GEE models with
a good predictive performance - set at a GRA-CV of > 0.7 - were predefined as being
statistically solid and meaningful (see Figure 6.1).
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6.3 Results
The frequency of HF hospitalizations (including death) during the nineteen months follow-
up is presented in Figure 6.2. Of the 499 patients, 312 (62.5%) did not experience any HF
hospitalization and were alive after nineteen months, 100 (20%) had one and 87 (17.4%)
had at least two HF related events (HF hospitalization or death) within the nineteen month
follow-up period.
Concentrations of biomarkers, baseline characteristics and average drug dosages dur-
ing the first month are shown in Table 6.1. In comparison to patients without event, those
with event(s) were older and more likely to have coronary artery disease, kidney disease,
rales, more comorbidities and higher NYHA-class. Moreover, they had higher SFLT,
GDF15, CYSC, IL6, STFR, HSTNT, Uric acid, BUN, SST2, NT-proBNP, Creatinine and
HSCRP at the baseline and higher average dosages of loop diuretic and spironolactone
during the first month, whereas RAS blockers dose was lower.
The p-values of testing interaction (Biomarker×Medication) in 84 weighted logistic-
GEE models (covering all possible paired combinations of 4 medications and 20 biomark-
ers and PLGF/sFlt) and their corresponding GRA-CVs, are presented in Table 6.2.
Figure 6.2: The frequency of HF hospitalizations (including death) during 19 months follow up.
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All Patients No events One or more events †p-value
Baseline characteristics (n = 499) (n = 312) (n = 187)
Age (years), mean(sd) 76.1 (7.5) 75.1 (7.5) 77.9 (7.2) 0.000
Male gender (%) 327 (65.5) 200 (64.1) 127 (67.9) 0.386
CAD (%) 287 (57.5) 153 (49) 134 (71.7) 0.000
Charlson Score, median [IQR] 3 [2-4] 3 [2-4] 3 [2-5] 0.000
LVEF (%) (sd) 29.8 (7.8) 29.7 (7.7) 29.9 (8.0) 0.844
Kidney disease (%) 277 (55.5) 150 (48.1) 127 (67.9) 0.000
BPsyst, mean (sd) 118.5 (18) 119.6 (18) 116.7 (18.1) 0.098
Rales (%) 209 (42.1) 100 (35.5) 99 (52.9) 0.000
NYHA>II (%) 371 (74.3) 219 (70.2) 152 (81.3) 0.006
Biomarkers, median [IQR]
SFLT 98.8 [81-128] 93.9 [77.3-124.2] 105.6 [88.4-132.8] 0.000
GDF15 3940 [2697-5891] 3530 [2416-5125] 4786 [3433-7183] 0.000
CYSC 1.7 [1.4-2.1] 1.6 [1.3-1.9] 1.9 [1.6-2.4] 0.000
Ferritin 152 [80-258] 159 [85-261] 151 [66-248] 0.314
IL6 7.3 [3.9-14.1] 6.6 [3.5-11.9] 9.3 [4.6-16.8] 0.001
PLGF 22.6 [18.3-26.5] 22.3 [18.0-26.1] 22.8 [18.8-27.1] 0.222
SHBG 30.1 [22.3-40.6] 30.1 [22.7-42.3] 30.1 [21.4-38.9] 0.232
STFR 4.1 [3.2-5.4] 3.9 [3.0-5.2] 4.3 [3.3-5.9] 0.016
HSTNT 33.6 [19.1-62.7] 28.6 [17.9-53.3] 45.8 [24.4-85.4] 0.000
TP1NP 36.7 [23.7-55.5] 34.9 [23.7-51.5] 38.2 [23.7-62] 0.170
Uric 7.7 [6.1-9.2] 7.3 [5.9-8.8] 8 [6.7-9.5] 0.003
BUN 10.4 [7.6-13.5] 9.4 [7.3-12] 12.5 [8.6-16.1] 0.000
SST2 35.9 [26-54] 32.5 [24-45.5] 43.5 [31-64.2] 0.000
NT-proBNP 4194 [2270-7414] 3675 [1831- 6301] 5465 [3049-9743] 0.000
Creatinine 109 [88-141] 102 [84-127] 132 [99-157] 0.000
HSCRP 6.7 [2.5-15.8] 5.5 [1.9-14.8] 8.9 [3.6-20.4] 0.008
PREA 0.19 [0.15-0.23] 2.00 [0.15-0.24] 0.17 [0.14-0.22] 0.015
OPN 26.0 [17.0-40.9] 22.6 [16.1-33.6 ] 33.5 [21.2-55.2] 0.000
Mimican 116 [85.9-164] 107 [84.1-145] 143[93.4-198] 0.000
IGFBP7 242 [201-291] 226 [197-274] 265 [221-315] 0.000
Medications, median [IQR]
RAS blockers 59.7 [44.3-100] 59.6 [44.3-100] 50 [40.3-100] 0.048
β-blockers 25 [11.7-50] 25 [12.1-50] 25 [10.5-46.1] 0.119
Loop diuretic 60.6 [40-92.4] 43.2 [33.1-80] 80 [40-129] 0.000
Spironolactone 1.6 [0-25] 0 [0-25] 12.5 [0-25] 0.003
Table 6.1: Baseline characteristics and biomarkers and the average drug dosages at the first month
in patients without versus with event (HF hospitalizations or death) within nineteen months.
† p-value of testing whether the variables are the same in the mean (for continuous normally dis-
tributed variables) or median (for continuous non-normally distributed variables) or percentage (for
categorical variables) between those patients not hospitalized and those hospitalized or died (two
sided t-test or Mann-Whitney U-test for continuous variables and χ2 test for categorical variables).
IQR: interquartile range.
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Biomarkers β-blockers LOOP diuretics Spironolactone RAS blockers
SFLT
p-value 0.02 0.33 0.28 0.50
GRA-CV 0.74 0.76 0.73 0.74
GDF15
p-value 0.57 0.45 0.35 0.13
GRA-CV 0.75 0.76 0.75 0.75
CYSC
p-value 0.83 0.57 0.02 0.40
GRA-CV 0.70 0.72 0.70 0.71
Ferritin
p-value 0.50 0.91 0.31 0.47
GRA-CV 0.66 0.70 0.66 0.67
IL6
p-value 0.27 0.01 0.43 0.43
GRA-CV 0.73 0.75 0.73 0.73
PLGF
p-value 0.20 0.52 0.04 0.33
GRA-CV 0.67 0.71 0.66 0.67
SHBG
p-value 0.58 0.86 0.47 0.12
GRA-CV 0.65 0.69 0.65 0.67
STFR
p-value 0.09 0.19 0.90 0.88
GRA-CV 0.71 0.73 0.70 0.71
HSTNT
p-value 0.42 0.52 0.44 0.95
GRA-CV 0.70 0.73 0.70 0.71
TP1NP
p-value 0.04 0.52 0.54 0.28
GRA-CV 0.67 0.71 0.66 0.67
Uric
p-value 0.18 0.48 0.46 0.27
GRA-CV 0.67 0.70 0.66 0.68
BUN
p-value 0.86 0.00 0.26 0.55
GRA-CV 0.67 0.70 0.67 0.69
SST2
p-value 0.53 0.27 0.63 0.41
GRA-CV 0.76 0.77 0.76 0.77
NT-proBNP
p-value 0.81 0.77 0.89 0.06
GRA-CV 0.75 0.76 0.74 0.76
Creatinine
p-value 0.82 0.07 0.12 0.58
GRA-CV 0.69 0.71 0.68 0.70
HSCRP
p-value 0.26 0.00 0.21 0.40
GRA-CV 0.72 0.75 0.71 0.72
PREA
p-value 0.29 0.00 0.90 0.88
GRA-CV 0.69 0.74 0.69 0.70
OPN
p-value 0.30 0.96 0.09 0.79
GRA-CV 0.70 0.72 0.70 0.71
Mimican
p-value 0.96 0.24 0.07 0.63
GRA-CV 0.67 0.70 0.67 0.68
IGFBP7
p-value 0.50 0.90 0.11 0.74
GRA-CV 0.70 0.73 0.70 0.71
PLGF/SFLT
p-value 0.67 0.58 0.20 0.87
GRA-CV 0.71 0.73 0.71 0.72
Table 6.2: Results of the interaction (biomarker × medication) coefficient β tests using weighted logistic-
GEE models (adjusted for age, gender, coronary artery disease as main cause of HF , Charlson Score, left
ventricle ejection fraction, kidney disease, rales, systolic blood pressure, medication, and biomarker in logar-
ithmic form) and their corresponding GRA-CVs.
p-value: p-value of the interaction coefficient β tests in weighted logistic-GEE models.
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We note that in our analysis for each medication we have 21 interaction tests. There-
fore, due to the multiple testing, at a 5 percent level of significance, the Bonferroni correc-
tion suggests to reject the null hypothesis (H0: β = 0) for each test with the p-value less
than 0.05/21= 0.0024. However, since in this study the results are regarded as hypothesis
generating, we consider the interaction tests with p-value less than 0.05 as being signific-
ant. Moreover, we note that, p-value adjustments may raise several practical objections
[34]. For example you may increase the chance of making a type II error [101, 117].
Figure 6.3: Effect of different levels of HF medications and biomarkers on risk of HF hospitaliza-
tion or death.
∗P: Probability of HF hospitalization or death in a month. Range of biomarkers (in logarithmic
form) and medications are standardized between -1 and 1, for the range of the biomarker and med-
ications concentration in our population.
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The results indicate that interaction of i) SFLT and TP1NP with treatment effect of
β-blockers, ii) IL6, BUN, HSCRP and PREA with loop diuretics and iii) CYSC and
PLGF with spironolactone were significant. That means that these biomarkers might
indicate which medication class is most important to up-titrate or possibly down-titrate
for improvement of outcome. No significant interactions between biomarkers and RAS
blockers were found.
Figure 6.3 depicts the models with significant biomarker – medication interaction, for
which GRA-CV > 0.7. It suggests a beneficial effect of higher doses of loop diuretics
in patients with high IL6 and/or high HSCRP. Higher loop diuretic doses seem to have
adverse effects in patients with low HSCRP and/or high BUN and PREA. In contrast,
high doses of loop diuretics do not seem to harm in patients with low BUN and PREA
values. Spironolactone was associated with better outcome (low risk of HF or death) for
patients with high CYSC. It also demonstrates that up-titration of β-blockers for patients
with high SFLT might not decrease the risk of HF or death, but that such patients might
be better off with low β-blockers doses.
6.4 Discussion
This study investigated the hypothesis whether biomarkers may be able to predict the re-
sponse to therapy in HF. Several significant biomarker treatment-effect interactions were
found. We consider these results as promising signals which may predict a specific re-
sponse to therapy in individual patients. It must be noted that this study is purely hy-
pothesis generating regarding a novel approach to personalize medicine in HF with the
use of biomarkers. Clearly, the results of this study need to be tested in prospective in-
tervention studies before individualized therapy may be applied to HF patients. But our
data provide the first attempt to not just predict outcome, but rather to select specific HF
therapy based on individual biomarker patterns with the aim to improve outcome.
The need for such an individualized therapy approach in HF has been raised on many
occasions, supported by several facts. But in real-life practice, there is still a very high
mortality and morbidity despite drug development in the past decades [138]. Moreover, it
is often difficult or sometimes even impossible to establish guideline recommended drug
therapy in HF [78, 103]. In such cases, it would be crucial to know which drug may be
most important to be given in high doses to improve prognosis and which may be less
important. At present, it is impossible to make this decision for an individual patient
and HF drugs have been investigated on top of previous established therapies only, i.e.
β-blockers on top of ACE-inhibitors, MRAs on top of both previous drugs. Despite a
beneficial effect of these drugs as shown in large trials, not every drug will always have
the same benefit in a specific patient or patient subgroup. Given the large heterogeneity
of HF patients in terms of aetiology and comorbidities, a ‘one-size-fits-all’ approach is
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likely not optimal [138]. The dose of loop diuretics is even more so a clinical challenge
and is largely intuitive. Guidelines recommend diuretics for symptom relief of congestion
and recommend to lower diuretics whenever possible [103], but in many instances, they
are inappropriately withheld or maintained because of fear of renal dysfunction or fear of
decompensation, respectively.
6.4.1 Considerations regarding statistics
This investigation is highly strengthened by the fact that both the covariates (i.e. bio-
markers at the beginning of a given time interval, medication and clinical covariates) as
well as the outcome (i.e. HF hospitalization or death at the end of a given time inter-
val), have been measured at multiple points in time. These multiple time-points help to
make the interactions we were investigating clinically relevant, by only looking into the
treatment effect that occurred after the measurement of the biomarker in more than just
one single time point. However, the difficulty with investigating repeated measurements
lies within the fact that the outcomes for a single patient are correlated, because a pa-
tient with a hospitalization is prone to suffer from a re-hospitalization or die. Moreover,
repeated measurements of biomarkers, medication and other covariates are correlated as
well. Therefore, the correlation between outcomes and variation of covariates in time
needs to be taken into account for proper analysis.
One approach available for analyzing such data is using survival analysis methods,
like time-dependent Cox regression models or recurrent analysis methods such as the
Prentice, Williams and Peterson model [106]. However, these methods take into account
the values of time-dependent covariates only at the time of events (e.g., time of death or
HF hospitalization) and the covariate values between events are disregarded, which was
not acceptable to address the objective of this analysis. More proper alternative methods
are longitudinal analysis methods [76] that not only take into account correlation in hos-
pitalizations but also can involve more information about the variation of biomarkers and
medications and their interactions over time.
Among longitudinal methods, the GEE models [47, 147, 148] have become very
popular regression methods in medical studies [2, 68, 93, 123, 131]. The most attract-
ive property of GEE models is that the resulting estimation of regression coefficients of
those models is easy to interpret, especially for binary outcomes. Moreover, applying
GEE models, scholars may hypothesize different structures of correlation between out-
comes, but the resulting estimation of regression coefficients of GEE models is consistent
and asymptotically normal, even when the correlation structure is imprecisely specified
[147, 148]. Another advantage of GEE models for binary outcomes (logistic-GEE mod-
els) is that with the use of GRA not only we can assess the adequacy of the model but also
we can assess how the obtained results will generalize to a future data set.
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Therefore in this study, we applied the weighted logistic-GEE model with its underly-
ing a logistic regression model not only for the first, but also for repeated hospitalizations
(or death) to test the interaction of biomarkers with the treatment effects of medications
over time.
6.4.2 Underlying pathways of biomarker drug interactions
First, we found a significant interaction between SFLT and β-blockers, suggesting that
patients with a high SFLT concentration may have a worse outcome with higher doses of
β-blockers as compared to those on lower doses. Patients with low SFLT levels have a
more favorable outcome overall, largely irrespective of β-blocker dose in our population.
This raises the hypothesis that uptitration of β-blockers should be avoided in patients with
high SFLT levels. SFLT is the soluble form of the endothelial -and macrophage-bound
VEGF-receptor FLT-1. SFLT is formed after alternative splicing of FLT-1 RNA [124] and
acts as a decoy receptor, thereby inhibiting VEGF and PLGF. This is assumed to result in
anti-angiogenetic and anti-inflammatory effects [124]. SFLT concentrations are increased
in HF [44, 46], myocardial infarction [95], pre-eclampsia and coronary disease [124] and
higher concentrations of SFLT are associated with adverse outcome in these disease entit-
ies [44, 46, 67, 95, 139]. Higher SFLT is also associated with more severe HF according to
NYHA-class and NT-proBNP [44, 67]. Nevertheless, the exact role of SFLT in the patho-
physiology of HF and cardiovascular disease is not yet fully unraveled. SFLT-knockout
mice developed more overt HF after aortic ligation, but on the other hand administration
of adenovirus expressing SFLT-1 caused diastolic dysfunction and decreased vascular
density in wildtype mice [124]. Thus, both extremes of SFLT may have negative effects
in the pathogenesis of HF, requiring a precise balance in the SFLT/PLGF pathway for ad-
equate homeostasis. Another explanation could be that analogous to natriuretic peptides
SFLT production is on itself a protective response to cardiac or vascular injury, but SFLT
is associated with worse outcome because it also reflects the presence and magnitude of
the injury itself. With regard to the interaction of SFLT with β-blockers on outcome in
our study, it is interesting to note that baseline β-blockers use was independently asso-
ciated with a lower baseline SFLT concentration previously [67]. Although this was a
cross-sectional finding, it might suggest that β-blockers lower SFLT, but if this cannot be
achieved, high doses of β-blockers might be less favorable. Another explanation could be
that an elevated SFLT reflects an advanced stage of HF where β-blockers are difficult to
uptitrate and might result in (temporary) deterioration. This would mean that other drugs
might be given first to improve HF and reduce SFLT and β-blockers uptitration might be
postponed. In addition, β-blockers have been found to have anti-angiogenetic effects in
cancer [99]. Although to the best of our knowledge, such anti-angiogenetic effects of β-
blockers have not been properly investigated in HF, it might be speculated that high levels
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of SFLT acting anti-angiogenetically may cause the potential anti-angiogenetic effects of
β-blockers becoming evident. Obviously, this explanation is speculative and it needs to
be investigated in animal studies if there is indeed such an interaction in HF.
Second, there was a significant interaction between CYSC and spironolactone. Thus,
patients with a low CYSC had a less favorable prognosis on higher doses of spironolac-
tone compared to those on lower doses, whereas patients with a high CYSC had a better
outcome with high versus low doses of spironolactone. We note that the results showed
also the same pattern for BUN and creatinine, although the interactions were not signific-
ant (Data is not shown). CYSC is associated with inflammation and is the most sensitive
marker of renal function in terms of glomerular filtration rate [53]. CYSC is strongly as-
sociated with risk of cardiovascular disease (CVD) and adverse outcome in HF, but also
in the general population. Despite some biological plausible links between CYSC and
CVD and HF, a recent mendelian randomization study found no causative role for CYSC
in the development of CVD nor in the development of HF [136]. Nevertheless, it remains
a very reliable biomarker of high risk of events and disease progression in HF. We are not
aware of any previous publication about the interaction between CYSC and MRAs such as
spironolactone. However, we and others previously found a similar treatment interaction
with serum creatinine levels [79, 112] . A possible explanation could be that an impaired
renal function reflected by elevated CYSC or creatinine in the light of chronic HF is usu-
ally a form of cardio-renal syndrome which can be improved when HF is improved. Our
results suggest that in this case, the preferred HF-drug could be spironolactone. MRAs
are considered to have anti-fibrotic and anti-inflammatory effects, which can also support
the link between CYSC and spironolactone that we found.
Finally, we found 4 biomarkers that interacted significantly with loop diuretic dose
and outcome. First, in patients with high levels of BUN, higher doses of loop diuret-
ics (HDLD) were associated with worse outcome, whilst this negative association with
HDLD was not observed in patients with low BUN. Similar results were previously found
by Testatni et al.[130] evaluating 2,456 patients in the BEST-trial. In that study, HDLD
was associated with worse outcome when BUN was ≥21 mg/dl, but this was not the case
when BUN was low. In fact, after controlling for possible confounders, HDLD actually
was associated with improved survival in those with low BUN, but with reduced sur-
vival in those with high BUN [129]. This interaction between BUN and loop diuretics
was confirmed by Nunez et al [91], who further elaborated on this by adding CA125 to
the model, leading to a further specification of subgroups with differential risk associ-
ated with HDLD. Also supportive of our findings, higher levels of BUN were previously
associated with poor diuretic response in HF patients with acute decompensation [129].
PREA revealed an interaction with loop diuretics in a similar direction – HDLD was as-
sociated with worse outcome when PREA was high, whereas HDLD was associated with
good outcome when PREA was low. A recent study linked signs of intestinal congestion
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with elevated right atrial pressures and with cachexia [135]. Additionally, prealbumine
was lower in patients with hypoalbuminemia [16] and both low prealbumine itself [77]
as well as the presence of hypoalbuminemia [16] were associated with adverse outcome.
This supports the idea that patients with low concentrations of PREA could have a bene-
fit of HDLD because low PREA indirectly reflects a state of chronic venous congestion.
Additionally, both low PREA [77] and cachexia in HF [135] are linked with increased
inflammation, linking this interaction also to the inflammation markers. In this regard,
two markers of inflammation - HSCRP and IL6 - showed similar patterns of interaction
with loop diuretics on outcome in the present analysis. Thus, when inflammation markers
were low, HDLD was associated with an increased event risk, whereas when inflammation
markers were high, HDLD was associated with a lower risk. Pro-inflammatory activation
is linked to congestion [27, 135], but is also considered a major underlying mechanism
of HF progression and a poor prognostic factor, supporting the interaction we found for
inflammatory markers and loop diuretics.
6.4.3 Limitations
This is a post-hoc exploratory analysis of data from a randomized trial. Therefore, our res-
ults must be seen as means to identify potential relationships and to generate hypotheses.
Further research - preferably prospective - is needed to confirm these interactions and
their mechanisms. In addition, animal studies are required to test the hypotheses raised
by our findings. Possible limitations of this analysis are selection bias, reverse causality,
and residual confounding factors. Nevertheless, because patients in the TIME-CHF trial
were all attempted to be uptitrated on HF drugs either based on clinical symptoms and/or
based on NT-proBNP levels, this may limit the selection bias for starting or uptitrating
drugs compared to other cohorts. RAS blockers were given in rather high doses in almost
all patients and this may also explain why we did not find any interactions between RAS
blockers and biomarkers.
6.4.4 Conclusion
Our analysis suggests that repeated measurements of biomarkers may be helpful to in-
dividually tailor HF treatment, which may optimize the balance between beneficial and
adverse effects of HF drugs. Our data provide ground for prospective testing which will
be needed before this novel and innovative concept can be adopted.
7
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This chapter concludes the thesis. First we summarize the contributions made in the
various chapters, to answer the proposed research questions in Chapter 1. Then we discuss
possible directions for future work.
7.1 Answer to the Research Questions
This thesis started with the aim of investigating the hypotheses that biomarkers can be
useful tools for: (1) predicting the treatment effects of medication in HF patients; (2)
guiding the therapy in patients with chronic HF. Therefore the research questions of this
thesis were based on these two clinical hypotheses and new statistical methods that can
be developed to answer these and other relevant clinical questions.
In this section we return to the research questions that were proposed in Chapter 1
and we discuss each question based on the investigations and obtained results in Chapters
3 to 6.
Research Question 1: Does the NT-proBNP guided therapy reduce repeated HF hospit-
alizations?
In Chapter 3 we assessed the effect of NT-proBNP-guided therapy compared to
symptom-guided therapy on repeated hospitalization events (hospitalizations plus death),
within 5.5 years follow-up in the TIME-CHF study. For this, we used PWP-GT model-
ing as explained in Section 2.2. Regarding to the all-cause hospitalization events, results
showed that there was a statistically significant beneficial effect of NT-proBNP-guided
therapy on second and third all-cause hospitalization events, predominantly in the younger
age group (aged < 75 years). However, the effect of NT-proBNP-guided therapy as com-
pared to standard therapy on first all-cause hospitalization events was not statistically sig-
nificant. Regarding to the HF hospitalization event, NT-proBNP-guided therapy showed a
beneficial effect on first HF hospitalization event, again predominantly in the younger age
group. Only the younger age group has a beneficial effect of NT-proBNP-guided therapy
on second HF hospitalization events.
Research Question 2: What is the best cutpoint for dichotomization of continuous vari-
ables?
From a statistical and clinical point of view, using dichotomized covariates are often of
interest for various reasons. However finding the best cutpoint for dichotomization of
continuous variables is still a challenging area of research. In Chapter 4 we proposed a
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Bayesian approach to estimate cutpoints for continuous covariates assuming that the di-
chotomized covariates are related to an outcome variable through a linear regression. The
proposed Bayesian approach has the advantage that it can be applied in a multivariate set-
ting. In the multivariate setting with the use of the Bayesian method we may dichotomize
all or just a subset of the covariates. To the best of our knowledge this is the first method
dealing with multivariate dichotomization with respect to a continuous outcome variable.
Unlike most of the available methods, for the proposed Bayesian approach the estimated
cutpoint is not limited to the observed values of the covariate and can take any value in
the range of the covariate.
We observed in the simulation study that in the both univariate and bivariate settings
the performance of the Bayesian approach is satisfactory in terms of estimated mean
squared errors and average biases of the estimations. In addition, in the univariate setting
the Bayesian approach has a better performance when compared to O’Brien’s method.
We applied the proposed Bayesian approach to estimate the cutpoints for BMI, SST2
and Mimecan in the TIME-CHF study with respect to modeling NT-proBNP. We ob-
served that the estimated cutpoints and associations of the dichotomized BMI and SST2
with NT-proBNP were in the same line with the recommended cutpoints and previously
observed associations in other studies. We are not aware of any previous study suggesting
a cutpoint for dichotomizing Mimecan.
Research Question 3: How to measure the goodness-of-fit and predictive performance
of a logistic-GEE model?
Logistic-GEE is one of the most popular models for analyzing clustered binary data.
We in fact also applied this model ourselves to address Research Question 4 in this thesis.
However, assessing the goodness-of-fit and the predictive performance of logistic-GEE
models is problematic due to the fact that the outcomes are correlated within a cluster and
no likelihood is available. In addition, the logistic-GEE model disregards the unknown
correlation between the outcomes within a cluster and simply models the mean of out-
comes.
Several criteria and tests have been proposed for assessing the goodness-of-fit of
logistic-GEE models in the literature. However, each of them has at least one of the
following shortcomings:
(a) restriction on the number and types of covariates in the model being evaluated,
(b) bias in case of two-class imbalanced data,
(c) difficulty of interpretation,
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(d) a relative range of the criterion values (i.e., the range depends on the number of
subjects and number of covariates in the model),
(e) inability to indicate the predictive performance of the model being evaluated.
In Chapter 5 we proposed the Generalized Ranking Accuracy (GRA) as a new meas-
ure for assessing the goodness-of-fit as well as the predictive performance of logistic-
GEE models. We defined GRA as the probability that a randomly selected instance with
positive outcome (outcome=1) is ranked higher than a randomly selected instance with
negative outcome (outcome=0) from another cluster. The GRA ranges from 0.0 to 1.0,
such that the value 1.0 indicates perfect ranking on the given data (i.e., all instances with
positive outcome are ranked higher than all instances with negative outcome from another
cluster); and the value 0.0 indicates the opposite scenario. The value 0.5 corresponds to a
noninformative model.
The proposed GRA does not suffer from problems (a) to (d). In addition, by using
cross-validation, GRA-CV is proposed to use as a predictive performance criterion for
logistic-GEE models.
In addition, we compared the behavior of GRA with QICu (as an extension of QIC
[97]) as a function of logistic-GEE model complexity. The results showed that unlike
GRA, QICu does not perfectly compute model improvements when adding covariates
one by one into the logistic-GEE model. As a model-selection criterion, both QICu and
GRA-CV (with cluster-out cross-validation) performed well in selection of the covariates
in the right order, when the covariates are considerably different in their magnitude of
effects, even in the case of two-class imbalanced data. In models for which the covariates
are only slightly different in their magnitude of effects, GRA-CV performed better than
QICu when the within-cluster correlation was high (equal to 0.6 or 0.9). In general GRA-
CV had comparable results, or even better results than QICu, although GRA-CV uses
cross-validation, which reduces possibilities for overfitting.
We note that GRA is also applicable to any model for bipartite ranking traind on
clustered data.
Research Question 4: Can biomarkers predict treatment effects of medication in patients
with systolic HF?
In Chapter 6, we took the first step towards the development of a biomarker-guided
treatment algorithm for individually tailoring medical HFrEF therapy. We investigated
the interaction between multiple repeatedly measured biomarkers and response to the
four most important classes of HF medication regarding the risk of HF hospitalization or
death. This has been done with the use of weighted logistic-GEE models.
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The results presented in Chapter 6 confirm the hypothesis that biomarkers may be
able to predict response to therapy in HF. Several significant biomarker treatment-effect
interactions were found that are promising for potentially predicting response to therapy in
individual patients. First, we found a significant interaction between SFLT and β-blockers
suggesting that patients with a high SFLT concentration may have a worse outcome with
higher doses of β-blockers as compared to those on lower doses. Patients with low SFLT
levels have a more favorable outcome overall, largely irrespective of β-blocker dose in
our population. This raises the hypothesis that uptitration of β-blockers should possibly
be avoided in patients with high SFLT levels. Second, there was a significant interaction
between CYSC and spironolactone. Thus, patients with a low CYSC have a less favorable
prognosis on higher doses of spironolactone compared to those on lower doses, whereas
patients with a high CYSC have a better outcome with high versus low doses of spirono-
lactone. Finally, we found 4 biomarkers that interacted significantly with the loop diuretic
dose with respect to outcome. The results suggested a beneficial effect of higher doses of
loop diuretics in patients with high IL6 and/or high HSCRP. Higher loop diuretic doses
might have adverse effects in patients with low HSCRP and/or high BUN and PREA. In
contrast, high doses of loop diuretics do not seem to harm in patients with low BUN and
PREA values.
7.2 Directions for Future Research
In this thesis we investigated four research questions in Chapter 3 to 6 in order achieve
the objective of the study. Now we discuss some challenging research directions related
to each of these chapters.
Chapter 3- In this study, unfortunately, we were not able to assess the effect of NT-
proBNP-guided therapy on the fourth and consecutive hospitalization events due to lack
of a sufficient number of such events. Therefore, repeating this analysis on a larger trial
with more number of patients and hospitalization events may help to validate the obtained
results. In this thesis we applied PWP-GT model to deal with repeated events; however,
there are two shortcomings with this model that needs to be addressed in the future. The
PWP-GT model is not able to distinguish death from hospitalization as event. Moreover,
there is no method available for calculating the PWP-GT model’s power for the whole
model as well as for consecutive events. Therefore, as future work, statistical methods
need to be developed to assess power of the PWP-GT model and to distinguish death
from hospitalization as event. We believe that the PWP-GT model is superior to other
methods in dealing with repeated events. This is due to the fact that it takes into account
the time between repeated events; it distinguishes the order of events; it takes into con-
sideration the dependence of events within a subject. However, more simulation studies
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or clinical validations are required comparing the PWP-GT model with different methods
addressing repeated events.
Chapter 4- We applied a simulation study to evaluate the proposed Bayesian ap-
proach for dichotomization in univariate and bivariate settings. However, the simulation
study was only applied for limited choices of the parameters. Therefore, it might be in-
teresting to investigate the performance of the proposed Bayesian approach for different
choices of the parameters and for models with more than two covariates. The proposed
Bayesian approach in this thesis is based on the assumption that the dichotomized cov-
ariates are related to a continuous outcome variable through a linear regression model. In
future work one may consider dichotomization with respect to a binary outcome through a
generalized linear or through non-linear regression models. We point out that it also might
be interesting to see the performance of other noninformative priors such as Bernardo’s
prior [14] and Jeffreys [56] prior. We believe, more work is needed along these directions.
Moreover, the proposed Bayesian approach needs to be tested more in the clinical setting
to show superiority as compared to previous approaches, and to demonstrate clinical ap-
plicability.
Chapter 5- The proposed criterion, GRA, is applicable to any model for bipart-
ite ranking trained on clustered data. However, in this thesis we only evaluated the
GRA when using logistic-GEE models. Therefore assessing the GRA as a criterion
for goodness-of-fit and predictive performance of other existing bipartite ranking mod-
els trained on clustered data might be interesting. In this thesis we proposed GRA-CV as
a model selection criterion when we applied a forward model selection technique. This
may be assessed for other model selection techniques, e.g., backward or stepwise tech-
niques. In this thesis, in our simulation study we only specified limited values for the
parameters and other factors to assess the performances of GRA and GRA-CV. It there-
fore might be interesting to extend the simulation study considering other values for the
size of the data, cluster sizes, magnitude and type of within-cluster correlation, regression
coefficients and using different types of cross-validation to evaluate GRA and GRA-CV
more precisely. It might also be interesting to extend GRA to models dealing with ordinal
or categorical clustered outcomes.
Chapter 6- Although in this thesis several significant biomarker treatment-effect in-
teractions were found, the results of this study still need to be explicitly tested in prospect-
ive intervention studies before individualized therapy may be applied to HF patients. In
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addition, animal studies can be required to test the hypotheses raised by our findings.
From the machine learning point of view we may look at the problem in Chapter 6
as a classification problem dealing with correlated outcomes. Therefore, it might be inter-
esting as future work to develop a method in the machine learning domain that can deal
with correlated outcomes to get the advantages of available algorithms and techniques in
machine learning. We believe, more work is needed along these directions.
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Summary
Heart failure (HF) occurs when the heart muscle does not pump sufficient blood to ful-
fill the requirements of the body as it should. HF is one of the most important causes
of hospitalization for patients aged 65 and over, which increasingly imposes high health
care costs related to relatively long hospital stays. HF is a very complex disease and it is
difficult to diagnose and monitor the progression of the disease based on clinical signs and
symptoms only. This is even more difficult for elderly patients with multiple comorbid-
ities. Therefore, biomarkers (circulating markers that can be measured in the blood) that
reflect one or several pathways might be useful as diagnostic or prognostic factors in HF.
Biomarkers may also have therapeutic implications for individualized therapy. Guiding
HF therapy by a single biomarker, measured only at one time point, is limited because
one biomarker at one time point cannot cover the extensive pathophysiological pathways
involved in HF. Performing repeated measurements of several biomarkers, however, may
lead towards precision in medical therapy in HF patients.
This thesis had two main objectives; namely a medical objective and a methodolo-
gical one. The medical objective of this thesis was to investigate the predictive value of
biomarkers to predict the response to therapy in the Trial of Intensified versus standard
Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF) study.
The methodological objective of the thesis was to develop new methods with the aim to
be used for addressing the medical objective and to facilitate investigation of biomarkers.
In Chapter 2, we provided general background information about the TIME-CHF
study and the statistical methods applied in this thesis.
In Chapter 3, we employed the Prentice, Williams and Peterson Gap-Times model
[10, 106] to investigate the effect of N-terminal pro-B-type Natriuretic Peptide (NT-
proBNP)-guided therapy on the recurrence of all-cause hospitalization events (all-cause
hospitalization or death) and HF hospitalization events (HF hospitalization or death) in
the TIME-CHF study. We observed that the NT-proBNP-guided therapy as compared to
standard therapy did not reduce the risk of first all-cause hospitalization event. However,
we showed that NT-proBNP-guided therapy has a beneficial effect on the second and
third all-cause hospitalization events, indicating that considering repeated events may be
meaningful in interventional clinical trials. When considering pre-stratified age groups,
these effects were only seen in patients aged <75 years, but not in patients aged ≥75
years. In addition, NT-proBNP-guided therapy reduced the risk of first and second HF
hospitalization again predominantly in patients aged <75 years.
In this thesis we aimed to move towards developing a biomarker-guided treatment
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algorithm for personalized medical HFrEF (HF with reduced Ejection Fraction) therapy
(Chapter 6). As a purely hypothesis generating study, we investigated the interaction
between multiple repeatedly measured biomarkers and the response to the four most im-
portant classes of HF medication regarding the risk of HF hospitalization or death in
patients with reduced ejection fraction. For these analyses, we employed logistic Gener-
alized Estimating Equations (logistic-GEE) model [73, 147].
The four HF medications in this study were β-blockers, Renin-Angiotensin System
(RAS) blockers, Spironolactone and Loop diuretics. The study also included the fol-
lowing briomarkers: Soluble FMS-Like Tyrosine kinase-1 (SFLT), Growth Differenti-
ation Factor 15, Cystatin-C (CysC), Ferritin, Interleukin-6 (IL6), Placental Like Growth
Factor, Sex Hormone-Binding Globulin, Soluble TransFerrin Receptor, High Sensitiv-
ity Troponin T, Type-1 Procollagen N-terminal Peptide, Uric acid, Blood Urea Nitro-
gen (BUN), Soluble ST2 (SST2), NT-proBNP, Creatinine, High Sensitivity C-Reactive
Protein (HSCRP), Prealbumin (PREA), Osteopontin, Mimican, and Insulin-like Growth
Factor-Binding Protein 7.
The results showed that loop diuretics up-titration has a beneficial effect for patients
with high IL6 or high HSCRP, whereas the opposite was true with low IL6 or low HSCRP.
Higher dosage of loop diuretics was associated with poor outcome in patients with high
BUN or PREA, but not in those with low levels of these biomarkers. Spironolactone up-
titration was associated with lower risk of HF hospitalization or death in patients with
high CysC. Patients with a high SFLT concentration may have a worse outcome with
higher doses of β-blockers as compared to those on lower doses. Patients with low SFLT
levels had a more favourable outcome overall, largely irrespective of β-blockers dose in
our population. No treatment biomarker interactions were found for RAS blockers. Such
interactions between biomarkers and treatment might help to personalize treatment in
HFrEF patients, but prospective validation is required before this approach can be applied
to clinical practice. In order to support and assess the accuracy of these results, in Chapter
5, we proposed a new performance measure for logistic-GEE models, which we called
Generalized Ranking Accuracy (GRA).
GRA is defined as the probability that a randomly selected instance with positive out-
come is ranked higher than a randomly selected instance with negative outcome from
another cluster, with logistic-GEE model. There are several advantages with GRA com-
pared with other standard goodness-of-fit criteria for logistic-GEE models: (a) there is no
restriction in computation of GRA regarding the number and types of covariates in the
model; (b) GRA as a probability is easy to interpret; (c) GRA has an absolute range and
can be used for comparing the goodness-of-fit of different logistic-GEE models for differ-
ent data sets; and (d) by using cross-validation, GRA-CV can be used as a predictive per-
formance criterion for logistic-GEE models. In addition we showed experimentally that
GRA is not biased in the presence of two-class imbalanced data. Moreover, we showed
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that GRA-CV performs well as a model selection criterion for logistic-GEE models. We
note that GRA is also applicable to any model for bipartite ranking trained on clustered
data.
Dichotomizing the biomarkers (or any continuous covariates) may make it easier to
interpret the obtained statistical results and may help to have a more precise treatment de-
cision. Therefore, we introduced a Bayesian approach (Chapter 4) to estimate cutpoints
for continuous covariates. The proposed approach is based on the assumption that the
dichotomized covariates are related to an outcome variable through linear regression. In
the multivariate setting, this approach can be used to dichotomize all or a subset of the co-
variates. To the best of our knowledge the proposed Bayesian approach is the first method
that can deal with multivariate dichotomization with respect to modeling a continuous
outcome variable. We applied the Bayesian approach to estimate the cutpoints for three
markers in the TIME-CHF study, the BMI (Body Mass Index) and two biomarkers: SST2
and Mimecan, with respect to NT-proBNP. We observed that the estimated cutpoints and
associations of the dichotomized markers with NT-proBNP were in the same line with the
recommended cutpoints and previously observed associations in the other studies.
Valorization
Heart Failure (HF) is recognized as an escalating public health problem in Western soci-
eties with ageing populations [51, 83]. In addition, HF is the most common reason for
hospitalization in patients aged 65 years and over which imposes enormous health care
costs related to relatively long hospital stays [81, 127]. Thus, HF accounts for almost 2%
of health care budget in western countries and its total economic burden is increasing,
the greatest portions attributable to HF related hospitalizations. These health care costs
can be decreased by having a more precise diagnosis of disease in HF patients and imple-
menting more effective therapy. Diagnosing HF and treating patients on clinical signs and
symptoms can be challenging, as signs and symptoms of HF are not specific. Therefore,
biomarkers might be helpful in this regard. The obtained results in this thesis improve
implementation of biomarkers in diagnosis of HF and guiding individualized medical HF
therapy. In addition, we developed new methods with the aim to facilitate investigation
of biomarkers. In this thesis the analysis were based on the Trial of Intensified versus
standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)
study [19, 102]. In this chapter we provide valorization opportunities result from this
thesis, which may be of interest for medical researchers, patients, clinicians and pharma-
ceutical companies.
Although HF patients are known to experience repeated hospitalizations, most studies
only evaluated the time-to-first event and do not consider the impact of therapy after
the initial event. The results in this thesis demonstrated that guiding the therapy based
on N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) versus standard symptoms
reduces the risk of recurrent hospitalization in HF patients (Chapter 3). This leads to the
decrease in hospitalization costs for the health system. Even more importantly, medical
intervention studies usually use time-to-first event methods only. Our result show that
these methods may result in the wrong conclusions.
The results in Chapter 6 suggest that repeated measurements of biomarkers might be
helpful to individually tailor HF treatment to optimize the balance between beneficial and
adverse effects of HF drugs in a particular patient. This might also be economically be-
neficial, since patients would have better outcome (less hospitalizations, less side effects)
with less medication, thereby reducing costs. However, this novel predictive, preventive
and personalized medicine approach clearly needs confirmation in other studies.
Dichotomizing continuous covariates is widespread in medical prognostic variable
studies. In Chapter 4, we proposed a Bayesian approach to dichotomize continuous cov-
ariates. This might help clinicians to have a more precise interpretation of the covariate’s
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effect on the outcome variable and guides them in their choice of therapy. In addition,
it can establish eligibility criteria for prospective studies. Moreover, some researchers
prefer using dichotomized covariates since they are more straightforward to analyze and
the interpretation of the results may be easier.
In Chapter 5, we proposed Generalized Ranking Accuracy (GRA) as a measure for
assessing the goodness-of-fit as well as the predictive performance of the models trained
on clustered data. Clustered data are very common in biomedical and clinical researches
when the observations for each subject are repeated over time. Using GRA for models
trained on the clinical cluster data may help the researchers in their result interpretations
and help clinicians in making an appropriate treatment decision.
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